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Zusammenfassung
Posttranslationale Proteinmodifikationen (PTMs) sind wichtig, um verschiedene Proteinfunktio-
nen, wie z. B. Lokalisation, Aktivität, Stabilität und Protein-Protein Interaktionen zu regulieren.
In Proteinen können viele Aminosäuren methyliert werden, darunter auch Lysin, Arginin und
Glutamin. Methylierungen sind auf vielen verschieden Protein zu finden, jedoch sind Histonpro-
teine die bedeutendsten. Die Histonmethylierung beeinflusst die Chromatinstrukur und spielt
eine große Rolle in der Regulation der Transkription. Die Enzyme, die für den Transfer von
Methylgruppen auf die Proteine zuständig sind, werden Protein Methyltransferasen (PMTs)
genannt. Sie sind sehr spezifisch und methylieren immer nur eine Art von Aminosäuren. Dabei
zeigt die schnell steigende Anzahl an Berichten über die Methylierung von Proteinen, dass die
Methylierung als posttranslationale Modifikation in den letzten Jahren immer mehr an Bedeu-
tung gewinnt.
In dieser Doktorarbeit wurde die Substratspezifität dreier unterschiedlicher Protein Methyltrans-
ferasen untersucht, und zwar von HEMK2, einer Glutamin Methyltransferase, sowie von NSD2
und Clr4, zwei Protein Lysin Methyltransferasen (PKMTs).
Die Glutamin Methyltransferase HEMK2 methyliert Q185 des Terminationsfaktors eRF1 (eu-
karyotic translation release factor 1), der für die Termination der Peptidsynthese und für die
Hydrolyse der Polypeptidkette von der tRNA am Ribosom verantwortlich ist. Zur Bestimmung
der Substratspezifität von HEMK2 wurde die Aminosäuresequenz von eRF1 als Vorlage verwen-
det und die erhaltenen Daten zeigen, dass das Substrat für eine Methylierung ein G-Q-X3-K
Sequenzmotiv besitzen muss. Eine Suche nach dieser Sequenz in einer Proteindatenbank ergab,
dass mehrere humane Proteine dieses Sequenzmotiv besitzen. Von diesen identifizierten Sub-
stratkandidaten wurden 125 von HEMK2 auf Peptidebene methyliert. Außerdem konnte gezeigt
werden, dass von diesen 125 Kandidaten 16 auf Proteinebene methyliert werden. Zuletzt wurde
eine Methylierung der „Chromodomain helicase DNA binding protein 5“ (CHD5) und „Nuclear
protein in Testis“ (NUT) Proteine mit Hilfe eines glutaminspezifischen Antikörpers in men-
schlichen HEK293 Zellen nachgewiesen.
NSD2 ist ein Mitglied der „nuclear receptor SET domain-containing“ Enzymfamilie und di-
methyliert Lysin K36 von Histon H3 und Lysin K44 von Histon H4. Es wurde gezeigt, dass eine
abnormale Expression von NSD2 zu verschiedenen Arten von Krebs und dem Wolf-Hirschhorn
Syndrom führen kann. Die Analyse der Substratspezifität von NSD2 zeigte, dass dieses Enzym
die Aminosäuren G33 bis P38 von H3 erkennt. Dabei werden hydrophobe Aminosäuren an
den Positionen -1 und +2 (das Ziellysin wird hierbei als Position 0 definiert) bevorzugt. Mit
Hilfe des Spezifitätsprofils von NSD2 wurden mehrere humane Proteine identifiziert, die dieses
Sequenzmotiv enthalten. Von diesen identifizierten Substratkandidaten wurden 45 durch NSD2
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auf Peptidebene methyliert. Des Weiteren wurde gezeigt, dass 3 Kandidaten (ATRX, FANCM
und SET8) auf Proteinebene methyliert wurden und zusätzlich konnte die Methylierung von
ATRX und FANCM durch NSD2 in HEK293 Zellen nachgewiesen werden. Da die Methylierun-
gen einen erheblichen Einfluss auf die Eigenschaften und Funktionen von Proteinen besitzen,
müssen weitere Experimente an den neuen Substraten von HEMK2 (CHD5 und NUT) und
NSD2 (ATRX und FANCM) durchgeführt werden, um die Auswirkungen auf die biologischen
Funktionen der Methylierung herauszufinden.
Abgesehen von den menschlichen Enzymen, wurden ähnliche Untersuchungen auch an der His-
ton Lysin Methyltransferase Clr4, einem SUV39H1-Homolog aus S. pombe, durchgeführt. Clr4
trimethyliert Lysin K9 des Histonproteins H3. Zur Bestimmung des Spezifitätsprofils von Clr4
wurde die Aminosäuresequenz von H3 (1 - 18) verwendet. Die Ergebnisse zeigten, dass Clr4
spezifisch die Aminosäuren der Positionen -1 bis +3 der Zielsequenz erkennt. Zusätzlich wurden
6 neue Peptidsubstrate aus S. pombe identifizieren, die durch Clr4 methyliert wurden.
Um die Detektion von Proteinmethylierungen weiter zu verbessern, wurde eine neue radioak-
tivitätsfreie, Mikrotiter-Untersuchungsmethode entwickelt, die natürlich vorkommende Lese-
Domänen anstelle von methylspezifischen Antikörpern zur Erkennung von Methylierungen auf
Histonpeptiden verwendet. Es wurde gezeigt, dass diese Methode erfolgreich die Methyltrans-
feraseaktivität bestimmen und für die Suche nach PKMT Inhibitoren verwendet werden kann.
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Abstract
Posttranslational modifications (PTMs) are crucial for the regulation of protein properties, such
as localization, activity, stability and protein-protein interactions. One important PTM is pro-
tein methylation. This occurs on various amino acids, most frequently at lysine and arginine but
also glutamine. Methylation was found on many proteins, though the most prominent group is
constituted out of histone proteins. Histone methylation influences the chromatin structure and
plays an important role in transcriptional regulation. The enzymes responsible for the transfer
of methyl groups are called protein methyltransferases (PMTs) and they are very specific toward
the methylated substrate. The rapidly increasing number of reports about protein methylation
illustrates that this modification is very frequent and has important roles in various cellular
signaling pathways.
In this doctoral thesis, the substrate specificity of three different protein methyltransferases,
namely the glutamine methyltransferase HEMK2 and the two protein lysine methyltransferases
(PKMTs), NSD2 and Clr4 were investigated. The glutamine methyltransferase HEMK2 has been
shown to methylate Q185 of the eukaryotic translation release factor eRF1, which is responsible
for termination of peptide synthesis and hydrolysis of the nascent polypeptide from the tRNA
at the ribosome. The substrate specificity profile of HEMK2 was determined using the eRF1
sequence as template, the data showed that HEMK2 requires a G-Q-X3-K motif for methylation
activity. Based on the obtained substrate specificity profile, several human proteins containing
the corresponding sequence motif were identified and methylation at the peptide level was shown
for 125 substrates. Furthermore, the in vitro methylation of 16 substrates at the protein level was
confirmed. Finally, the cellular methylation could be demonstrated for Chromodomain helicase
DNA binding protein 5 (CHD5) and Nuclear protein in Testis (NUT), by using a Qme-specific
antibody.
NSD2, a member of the nuclear receptor SET domain-containing enzyme family, was shown
to dimethylate K36 of histone H3 and K44 of histone H4. The aberrant expression of NSD2
was reported to be associated with several cancers and the Wolf-Hirschhorn syndrome (WHS).
The substrate specificity analysis of NSD2, revealed that the enzyme recognizes the residues
between G33 and P38, on the H3 tail. NSD2 prefers hydrophobic residues at the positions
-1 and +2, considering the target lysine as position 0. Several human proteins containing
the sequence motif of NSD2 were identified and methylation on 45 novel non-histone peptide
substrates was observed. For 3 of the substrates (ATRX, FANCM and SET8) methylation could
be confirmed at protein level. In addition, the methylation of ATRX and FANCM could be shown
in HEK293 cells, upon ectopic expression of NSD2. Since methylation can strongly influence
protein properties, further experiments have to be carried out to uncover the biological effects
of the novel substrates of HEMK2 (CHD5 and NUT protein) and NSD2 (ATRX and FANCM).
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Abstract
Apart from the human enzymes, similar studies were performed for the histone lysine methyl-
transferase Clr4, the yeast homolog of the human SUV39H1, which trimethylates K9 of histone
H3. The specificity profile of Clr4 was investigated using the H3 (1 - 18) sequence as template.
The analysis revealed that the enzyme specifically recognizes the residues from -1 to +3 of the
H3 tail. Additionally, it was shown that Clr4 is able to methylate 6 novel S. pombe substrate
candidates at peptide level.
To facilitate the detection of protein methylation, a new radioactivity free, microplate assay was
developed, which employs a natural reading domain instead of methyl specific antibodies for the
recognition of methylation on histone peptides. It was demonstrated that this approach can be
successfully used to determine the activity of PKMTs as well as screen for PKMT inhibitors in
medium or high throughput scale.
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1 Introduction
1.1 Posttranslational Modification of Proteins
Proteins harbor several posttranslational modifications (PTMs) that can be categorized into
two major classes: enzyme-catalyzed modification and hydrolytic cleavage of proteins. The
enzymatic-catalyzed modification reactions need cosubstrates, which provide the activated mol-
ecule that is added to the substrate. The second class is the hydrolytic cleavage, where one
or more polypeptides are cleaved from proteins by enzymes called proteases. Additionally, the
generation of disulfide bonds between two cysteine residues is also considered to be a posttrans-
lational modification. Disulfide bonds are important for the proper folding and stability of many
proteins [1].
Most of the covalently added PTMs occur on the side chains of amino acids, where functional
groups of the amino acids serve as nucleophiles. These are hydroxyl groups (serine, threonine and
tyrosine), carboxylates (aspartate and glutamate), thiolates (cysteine) or the functional groups
of lysine, arginine and histidine. Even weaker amide nucleophiles of asparagine and glutamine
can be modified in various ways [1]. These modifications regulate many protein properties and
functions, such as stability, localization, interaction with other proteins or ligands, or alter the
enzymatic activity. PTMs may also act in combination. Different modifications can influence
each other, and preventing a certain event by blocking an adjacent residue [2], influence the
catalytic activity [3] or change the substrate recognition efficiency [4] of the enzyme that is setting
new modifications.
1.1.1 Protein Phosphorylation
The most common and well studied posttranslational modification is phosphorylation. Kinases,
are the enzymes responsible for the addition of a phosphoryl group to the side chain of serine,
threonine and tyrosine residues [5]. More than 500 enzymes are encoded in the human genome.
Kinases use adenosine triphosphate (ATP) or more rarely guanosine triphosphate (GTP) as
cosubstrates for the transfer of a phosphoryl group to their target substrates [1]. The phospho-
rylation of amino acid side chains can be reverted by dephosphorylation, which is catalyzed by
phosphatases. Phosphorylation and dephosphorylation are important regulators of cellular pro-
cesses. The introduction of the bulky and negatively charged phosphoryl group to one or more
amino acids of a protein has drastic effects on protein function, conformation and interactions
with other proteins [6].
For example, protein kinase A (PKA) is one of the best studied kinases and it serves as a
good model enzyme. PKA is activated by increased levels of cyclic adenosine monophosphate
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(cAMP), a second messenger, which is produced in the cAMP-dependent pathway by an initial
signal transduced through a receptor at the plasma membrane [7]. Glycogen synthase [8] and
phosphoryl kinase [9] are two of the many substrates, regulated by PKA. In addition, PKA
regulates several other pathways by phosphorylating serine or threonine residues of enzymes,
thereby modulating their activities.
1.1.2 Protein Acetylation
Another important posttranslational modification is the acetylation of proteins. Similar to phos-
phorylation, acetylation is also a very frequent occurring PTM on proteins. Acetyltransferases
utilize acetyl-coenzyme A as a cofactor to transfer the acetyl group to the target residue of
the protein. Two possible positions can be acetylated, the ε-amino group of a lysine residue
or the Nα-terminus of a protein. Nα-terminal acetylation occurs during protein biosynthesis
and it is therefore called co-translational modification. The enzyme complexes responsible for
these modifications are called N-terminal acetyltransferases (NATs) [10]. The effects of N-terminal
acetylation are extensive. This modification can influence protein stability [11], localization [12,13],
protein synthesis [14] and is connected to metabolic regulation and apoptosis [15,16]. The second
important position for acetylation is the ε-amino group of lysines. Although it is not as frequent
as Nα-terminal acetylation, it contributes to many cellular functions [17]. By contrast to Nα-
terminal acetylation, the transfer of the acetyl group onto the ε-amino side chain can be removed
by deacetylases. Acetylation on a lysine residue neutralizes its positive charge and thereby alters
the biochemical properties of the protein. In addition, it can also block other modifications on
this lysine residue. This modification regulates transcriptional activity by changing the strength
of the interaction between histones and deoxyribonucleic acid (DNA) on chromatin [18], affects
protein-protein interactions [19] or influences protein stability by preventing lysine ubiquitination,
which could lead to protein degradation [20].
The enzymes responsible for the acetylation of lysine residues on histones are called histone
acetyltransferases (HATs) and the removal of this modification is catalyzed by histone deacety-
lases (HDACs). The ability to set and remove such a functional group on lysine can change
the charge on histones and thus, alter the accessibility of the DNA in chromatin. Therefore it
has a high impact on the regulation of transcriptional activity. Besides histones some HATs can
also acetylate non-histone proteins, like α-tubulin [21] or the transcriptional regulator p53 [22].
The effect of acetylation on non-histone proteins often depends on the position of the lysine
that is acetylated. For instance, in the transcription factor p53, lysine acetylation next to
the sequence-specific DNA binding domain increases the DNA binding [22]. By contrast, lysine
(K65) acetylation within the DNA binding domain decrease sequence-specific DNA binding and
disrupts enhanceosome [23].
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1.1.3 Protein Methylation
Protein methylation has gained more and more interest in the last decades. Although the
first methylated protein was already discovered 1959 by Ambler et al. [24], the understanding
of this modification has begun only in recent years. Protein methylation can occur on several
amino acids. Among the best studied are lysine and arginine methylation. Methylation of
other residues, such as histidine, cysteine, asparagine or glutamine was also documented [25,26].
Methylation of amino acids has many functions. It can affect protein stability, protein-protein
interactions, protein localization and have indirect effects on other posttranslational modifi-
cations. Protein methylation can also regulate gene transcription or DNA repair. The most
well-studied protein methylation is lysine and arginine methylation on histone proteins. These
residues are reported to be modified at numerous sites on N- and C-terminal histone tails. The
side chain amino group of lysine can harbor up to three methyl groups and the guanidino group
of the arginine side chain can accommodate up to two methyl groups. This makes a determi-
nation of the effect more complex. In contrast to phosphorylation and acetylation, the methyl
group is relatively small and except for methylation of aspartate and glutamate [27] it does not
change the charge of the modified residue. Therefore it is more likely that other effects of this
modification control chromatin processes. One way is through recognition and binding of the
methylated amino acid residues by other proteins, which further can lead to an activation or
repression of gene transcription or initiation of DNA repair [28].
1.1.3.1 Lysine Methylation
Lysine methylation is an ubiquitous modification that occurs on numerous proteins and reg-
ulates various important cellular functions. The ε-amino group of the lysine side chain can
accommodate up to three methyl groups, resulting in either un-, mono-, di- or trimethylated
lysine, as depicted in Figure 1.
Figure 1: Methylation states of lysine. Protein lysine methyltransferases (PKMTs) catalyzing the methyla-
tion of the ε-N atom of lysine. The removal of the methyl groups is catalyzed by lysine demethylases
(KDMs). The four different methylation states are: unmethylated, monomethylated, dimethylated
and trimethylated lysine.
The most well characterized lysine methylation occurs on the histone tails of H3 and H4 proteins.
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On histone H3, lysine residues at positions, such as 4, 9, 27 or 36 can be methylated, whereas on
histone H4 the residues K20 and K44 are methylated. Lysine methylation can lead to different
biological effects, based on the position and degree of methylated residues. Trimethylation of
H3K4 is associated with active gene transcription [29], whereas methylation on H3K9, H3K27
or H4K20 is connected to heterochromatin formation, and subsequent gene repression [30–32].
Furthermore, different methylation stages lead to different signaling functions. Trimethylation
of H4K20 is found at pericentric heterochromatin and is connected to gene repression [32], whereas
H4K20 dimethylation is involved in DNA repair [33] and monomethylation of H4K20 oscillates
during cell cycle [34].
Lysine methylation marks serve as binding sites for different proteins, which are capable to
recognize with conserved functional domains called “reading” domains the methylated residues
based on the degree of methylation and the surrounding sequence [35]. One of these binding
domains is the chromodomain, which is present in many chromatin proteins binding to different
methylated lysines: H3K4, H3K9me2/3, H3K27me2/3, H3K36me3 and H4K20me1 [36]. Due to
the different specificity of this domain one cannot generalize its effect on transcriptional regula-
tion. The chromodomain of heterochromatin protein 1 (HP1) can bind to di- and trimethylated
H3K9 [37,38] and mediate transcriptional repression of genes [39], whereas the chromodomain heli-
case DNA-binding protein 1 (CHD1) from Saccharomyces cerevisiae binds trimethylated H3K4,
a methylation mark associated with transcriptionally active chromatin [40,41]. In addition to the
chromodomain there are several other domains, which can recognize methylated lysines on hi-
stones in a degree-specific manner: PHD (plant homeodomain) fingers, MBT (malignant brain
tumor) repeats, Tudor and ADD (ATRX-DNMT-DNMT3L) domains [35].
Lysine methylation is not only present on histones, but also on non-histone proteins. Apart
from the histone proteins, the effect of lysine methylation are thoroughly investigated in the
tumor suppressor protein p53. This protein plays an important role in DNA repair, cell cycle
regulation and apoptosis based on various stimuli. p53 is methylated at several lysine residues,
such as K370, K372, K382 and K386 by different protein lysine methyltransferases (PKMTs) [42].
For example, SET7/9 and SMYD2 monomethylate p53 at K372 and K370, respectively. Methy-
lation influences the activity of p53 depending on the lysine that is modified and the number
of methyl groups added to the corresponding lysine. Methylation of K372 by SET7/9 increases
transcription of p21, which further controls cell cycle arrest [43]. However, monomethylation by
SMYD2 at K370 suppresses the binding of p53 to the p21 promotor and restrain the transcrip-
tion. Interestingly, SET7/9 mediated K372 methylation inhibits K370 methylation by SMYD2,
suggesting a regulatory crosstalk [44].
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1.1.3.2 Arginine Methylation
Similar to lysine methylation, arginine methylation is present in both nuclear and cytoplasmic
proteins. Methylation on arginine residues was identified 1967 by Paik and Kim [45]. With the
discovery of arginine methylation on histone proteins and its role in various cellular functions,
the importance of this PTM has gained significant attention.
Figure 2: Methylation states of arginine. The protein methyltransferases (PRTMs) catalyzing the
monomethylation of arginine (MMA) on one of the guanidino ω-N atoms. The further methyla-
tion to asymmetrical dimethylarginine (ADMA) is catalyzed by type II enzymes and the generation of
symmetrical dimethylarginine (SDMA) is catalyzed by type II enzymes.
Arginine can have two different methylation states at the guanidino group of its side chain, which
can be either mono- or dimethylated. The dimethylated guanidino group can be further differen-
tiated based on the position of the methyl groups. It is referred to as symmetrical methylation,
when the methyl groups are on different ω-NG atoms, and as asymmetrical methylation, when
both methyl groups are on the same ω-NG atom (Figure 2). Arginine methylation influences
many cellular processes, such as protein sorting [46], protein-protein interaction [47], transcrip-
tional regulation [48,49], RNA processing [50,51], signal transduction [52–54] and DNA repair [55].
Enzymes catalyzing arginine ω-NG-methylation are called protein arginine methyltransferases
(PRMTs) and they can be divided into two types. Type I consists of the enzymes PRMT1,
PRMT3, PRMT4 (CARM1) and PRMT6, which generate monomethylarginine and asymmetric
dimethylarginine. Type II PRMTs are PRMT5 and PRMT7, which catalyze the formation of
monomethylarginine and symmetric dimethylarginine [56]. So far only the Tudor domain, has
been reported to interact specifically with methylarginine residues. The survival motor neuron
(SMN) protein was one of the first proteins identified to bind to methylarginines via its tudor
domain [57].
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1.1.3.3 Glutamine Methylation
Glutamine methylation is a very rare modification unlike the lysine and arginine methylations
described above. Only a handful of proteins were reported to possess a methylglutamine mod-
ification, although the first protein containing a methylated glutamine (the ribosomal protein
L3 from Escherichia coli), was already found 1977 by Lhoest and Colson [58]. A recent study
identified the only known glutamine methylation on histone H2A in yeast and human [59]. This
glutamine methylation occurs at position Q105 in yeast and Q104 in human and are catalyzed
by the glutamine methyltransferase Nop1 and the human ortholog Fibrillarin. Another impor-
tant glutamine methylation was discovered at ribosomal polypeptide release factors (RFs) [60].
RFs are important for the termination of the synthesis of polypeptides at the ribosome. They
recognize the stop codons within mRNA at the A-site of ribosomes and hydrolyze the ester bond
between the nascent polypeptide chain and the peptidyl-tRNA at the P-site [61]. In bacteria two
different release factors are necessary to recognize all three stop codons. RF1 recognize the UAA
and UAG codons, while RF2 recognize the UAA and UGA codons [62]. In contrast, eukaryotes
possess only one release factor, eRF1, which is able to recognize all three stop codons [63]. Though
bacterial RFs and eukaryotic eRF1 does not share sequence or structural homology, they have a
small universally conserved motif [64]. This motif comprises a glycine-glycine-glutamine (GGQ)
tripeptide and it was shown to be involved in the hydrolysis of tRNA bound peptides [65]. In-
terestingly, the glutamine of the universal conserved GGQ motif is methylated, suggesting that
it could affect the hydrolysis of nascent polypeptides. Later Dinçbas-Renqvis et al. confirmed
that the glutamine methylation at the GGQ motif stimulates the translation termination in
E. coli [60].
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1.2 Protein Methyltransferases
In general, methyltransferases (MTases) catalyzes the transfer of a methyl group from a methyl
donor to a substrate. The most commonly used methyl donor is S-Adenosyl-L-methionine (SAM)
and the enzymes, utilizing this cosubstrate, are called SAM-dependent methyltransferases [66,67].
MTases catalyze a bimolecular nucleophilic substitution (SN2) reaction, where the lone pair
electrons of a nucleophile (substrate) attack the carbon atom of the methyl group of SAM.
This results in the generation of a methylated “nucleophile” and S-Adenosyl-L-homocysteine
(SAH)(Figure 3) [68].
Figure 3: General scheme of the methyl transfer reaction from methyl donor S-adenosyl-L-methionine to a
nucleophile (Nu) catalyzed by methyltransferases (MTases), resulting in the formation of S-adenosyl-
L-homocysteine and the methylated nucleophile (Nu-CH3)
MTases methylate a great variety of substrates. These can be DNA, RNA, proteins and small
molecules. The enzymes are classified into different types depending on the substrates they
methylate, like DNA methyltransferase (DNMTs) or protein methyltransferases (PMTs). These
MTases are very specific with respect to the substrate, i.e. to a specific nucleobase or to a
specific amino acid. DNA methylation can occur at the C5 and N4 position of cytosine and
the N6 position of adenine [69–71]. Protein methyltransferases show a much higher level of diver-
sity and complexity than DNA methyltransferases. They can methylate a broad spectrum of
amino acids. Several protein methyltransferases have been identified that are specific for lysine,
arginine, glutamine, histidine or cysteine residues [26].
SAM-dependent MTases were initially categorized into five classes (I-V) depending on their
structures [72]:
• Class I contains the MTases that harbor a Rossmann-like fold. It includes all DNMTs and
several PMTs. It is the biggest group of MTases and has a large diversity of substrates.
Class I MTases show high structural similarity, even when only little sequence similarity
is notable. They are composed of a seven-stranded β-sheet flanked by α-helices. A con-
served GxGxG sequence motif at the end of the first β-sheet is responsible for binding to
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the nucleotide of SAM. Examples for this class of enzymes are the protein arginine methyl-
transferases [73] and the members of the HemK group of glutamine methyltransferase [74,75].
• Class II MTases have a distinct protein structure with eight long antiparallel β-strands
forming the core flanked by several α-helices on each side. SAM is bound by a conserved
RxxxGY motif in a shallow groove formed by the β-strands. The methionine synthase,
MetH, is the only known member of this class of MTases [76].
• The third class of MTases has a homodimeric structure. Similar to class I MTases, these
proteins possess a GxGxG motif, but this is not involved in binding SAM. The SAM
binding site of class III MTases is located between two βαβ-domains, each consisting of
five-stranded β-sheets flanked by four α-helices. CbiF, a cobalt-precorrin-4 MTase is a
member of this class [77].
• The class IV consist of the SPOUT family of RNA MTases. Their structure is made of
a six-stranded parallel β-sheet flanked by seven α-helices. The first three strands form a
half of a Rossmann-fold and part of the C-terminus forms a knot, which creates a binding
cleft for the cofactor [78,79].
• Class V MTases are SET domain containing proteins. This includes a large number of
enzymes with various substrates. The most prominent members of this class are protein
lysine methyltransferases. The SET domain was named after the three proteins, which
share this common motif, Su(var)3-9, Enhancer of Zeste and Trithorax. It consists of
twelve β-strands forming up to five interwoven sheets flanked by regions called pre- and
post-SET domains. These are important for methyltransferase activity and play a role in
substrate recognition and specificity [80].
In the following sections of this doctoral thesis, the structural aspects and the known target
substrates of three different protein methyltransferases will be described in more detail.
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1.2.1 HEMK2
The bacterial N5-glutamine methyltransferase HemK was first discovered in E. coli during a
genetic screen for new heme biosynthesis mutants [81]. It was assumed that HemK plays a role
in the oxidation of protoporphyrinogen to protoporphyrin IX. However, following knock-out
experiments and phenotype analysis did not support this hypothesis [82].
Figure 4: Schematic representation of functional motifs of the HemK family. E. coli HemK, human
HEMK2, mouse N6AMT1 and yeast Mtq2; GxGxG motif responsible for binding of the cofactor
SAM, NPPY motif necessary for binding of the glutamine side chain, N-terminal domain, which
is missing in eukaryotic family members (purple).
Sequence alignment studies revealed that besides bacteria, several lower and higher eukaryotes
also possess HemK homologs (Figure 4). An analysis of all HemK homolog sequences showed
a shared NPPY motif [74]. It was thought that these conserved (D/N/S)PP(Y/F/W) motifs are
limited to N6-adenine and N4-cytosine DNA MTases [83] and, therefore, HemK enzymes were
classified as members of the SAM-dependent DNA MTase group [84]. Based on this finding,
HemK was renamed to N6-adenine-specific DNA methyltransferase (N6AMT). However, subse-
quent experiments could not show methyltransferase activity toward DNA [85]. Later, the seminal
discovery that HemK methylates the glutamine residue in the universal conserved GGQ motif
of the ribosomal release factors RF1 and RF2 was reported [86,87]. This finding confirmed the
classification of HemK as a SAM-dependent MTase, however the substrate is a protein instead of
DNA, as initially predicted. This led to renaming HemK as PrmC (Protein methyltransferase
C). The eukaryotic homologs of the bacterial HemK enzyme are called HEMK2 in human,
N6AMT1 or PRED28 in mice and Mtq2p or YDR140w in S. cerevisiae. They all methylate the
conserved glutamine residue of the corresponding eukaryotic release factor 1 (eRF1) [88–90].
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1.2.1.1 Structure and Catalytic Mechanism of HemK
The first crystal structures of bacterial HemK were derived from Thermotoga maritima [91] and
E. coli [74]. Although the sequences of these two enzymes share only 31% identity and 51%
similarity, the overall structure is very similar. The enzymes consist of two structural domains:
a small N-terminal domain with a bundle of α-helices connected via a β-hairpin linker to the
larger catalytic C-terminal domain. The C-terminal domain consists of a seven-stranded mixed
β-sheet flanked by several α-helices, which is characteristic for class I MTases (Figure 5).
Figure 5: Ribbon representation of the structure of E. coli HemK-SAM. The N-terminal domain is
painted in green, the catalytically active C-terminal domain is painted yellow and a linker connecting
these two domain is represented in red. SAM is depicted as a stick model. The picture was adopted
from Yang et al. [74].
In both enzymes, the cofactor SAM is bound by the nucleotide-binding sequence motif GxGxG,
placed at the C-terminal end of β-strand 1 [74]. Additionally to the GxGxG motif, another
conserved motif can be found in all HemK homologs, the NPPY tetrapeptide. This is positioned
at the end of β-strand 4 and forms the bottom of the active site pocket of HemK. The NPPY
motif is necessary for binding the glutamine side chain [91]. Recently, the crystal structure of
E. coli HemK in complex with its substrate RF1 and the cofactor S-Adenosyl-L-homocysteine
(SAH, methyl donor reaction product) was solved. RF1 is composed of four domains, a compact
structurally rigid center formed by the domains 2 and 4, which are flanked by two more flexible
domains 1 and 3. In both release factors (RF1 and RF2) the universally conserved GGQ motif
is positioned on a flexible loop protruding from domain 3 [92]. This explains its ability to enter
the peptidyl transferase center (PTC) of the ribosome and promote the hydrolysis of a nascent
polypeptide from the tRNA [62]. Apart from this, RFs have an anticodon segment, which is
an important part to recognize the stop codons at the A-site of a ribosome. Although both
release factors contain a tripeptide as an anticodon segment, the residues of these tripeptides
are different. RF1 possess a proline-valine-threonine (PVT) motif, whereas the tripeptide of RF2
consists of serine-proline-phenylalanine (SPF). This explains the different specificity of RF1 and
RF2 toward the stop codons [93].
In contrast to the bacterial HemK, the eukaryotic glutamine MTases need a binding partner
to methylate the glutamine residue of eRF1. The glutamine MTase interacts with the small
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zinc-binding protein called TRM112 (Ynr046w in yeast). TRM112 consist of two domains: a
zinc-binding domain composed of N- and C-terminal residues and a central domain (Figure 6A).
The zinc atom is coordinated by four cysteine residues, two from the N-terminal part (Cys11
and Cys16) and two from the C-terminal section (Cys112 and Cys115)(Figure 6B) [94].
Figure 6: Ribbon diagrams of the structure of the yeast Mtq2 and TRM112. (A) Representation of the
structure of the Mtq2-TRM112 complex. Mtq2 is painted in blue, the TRM112 zinc-binding domain
is shown in pink and its central domain is painted green. The zinc atom is represented as a purple
sphere. The picture was adopted from Liger et al. [75]. (B) Structure of the yeast TRM112 protein.
The TRM112 zinc-binding domain is shown in green and part of the central domain is painted yel-
low. The zinc atom is represented as a black sphere and the Cys side chains coordinating the zinc
atom are shown as sticks. The picture was adopted from Heurgué-Hamard et al. [94].
The yeast glutamine MTase Mtq2 together with TRM112 forms a heterodimeric complex, which
stimulates the activity of Mtq2 and prevents its aggregation. TRM112 masks hydrophobic
regions of Mtq2 upon interaction. This enhances the solubility of Mtq2. In addition, TRM112
increases the SAM binding of Mtq2, because the loop connecting the β-strands 3 and 4, which
is involved in SAM binding, is stabilized by the TRM112 interaction. Structural comparison
of the bacterial and yeast glutamine MTase, showed that the yeast homolog Mtq2 possess only
the class I SAM-dependent MTase domain, but not the additional N-terminal domain present in
HemK from E. coli. However, the superposition of the HemK-RF1 and Mtq2-TRM112 structures
clearly revealed that TRM112 is not a substitute for the N-terminal domain [75].
During methylation of the glutamine residue, RF1 fits perfectly onto the concave surface, formed
by the two domains of HemK and the GGQ motif is inserted into the active site pocket. The
N-terminal domain of HemK contacts the domains 2 and 3 of RF1, whereas the C-terminal part
of HemK only binds domain 3 of RF1. Here, the glutamine side chain forms hydrogen bonds
with the NPPY motif of HemK, which facilitate the methyl transfer [92]. The hydrogen bonds
are formed between the two hydrogens of the N5-amide of glutamine and the main chain oxygen
of proline 198 and the side chain oxygen of asparagine 197 of the NPPY motif. Furthermore, the
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side chain oxygen of glutamine interacts with the tyrosine 200 main chain amide via a hydrogen
bond. These hydrogen bonds induce a change in hybridization of the amide nitrogen from sp2
to sp3, which allows a nucleophilic attack of the lone-pair electrons toward the methyl group of
SAM [91]. The (D/N/S)PP(Y/F/W), which is generally referred as DPPY motif is mainly found
in N6-adenine and N4-cytosine DNA MTases, however it does not exclusively bind nucleotides.
It interacts rather with nitrogens associated with a planar system, like the amide in glutamine
or nucleotide bases in adenine or cytosine. The hydrogen bond formation between DPPY and
substrate is common for MTases with such a motif and was observed in DNMTs, like TaqI or
PMTs, such as HEMK2 [72].
Not much is known about the mechanism of substrate recognition and the interaction between
HEMK2 and its substrate in mammals. A detailed crystal structure of HEMK2 in complex
with eRF1 could provide more information and reveal the residues involved in the interaction
between enzyme and its substrate. However, such a crystal structure is not available yet, and
the existing crystal structures of bacterial HemK in complex with its cognate release factor are
not helpful, since the E. coli and mammalian release factor amino acid sequences differ outside
of the conserved GGQ motif.
1.2.1.2 Effects of Glutamine Methylation
After the identification of HemK as the responsible enzyme methylating the bacterial and eu-
karyotic release factors, many groups determined the outcome of glutamine MTase depletion
in different species. In E. coli, knock-out of HemK reduced the termination activity of un-
methylated RF1 and RF2 by approximately 3- to 4-fold. While this had no major effect on
cell growth in rich media, growth was reduced on poor carbon sources [95]. Deletion strains of
the yeast homolog Mtq2p showed stronger growth defects and several phenotypes in rich me-
dia. However, the deletion strain did not show a significant decrease of translation termination
efficiency. The cells displayed cold-sensitivity and they were also sensitive to paromomycin or
geneticin, two aminoglycosides affecting protein synthesis by binding to ribosomes. They also
revealed increased resistance to the fungicides thiabendazole and benomyl [96]. Compared to
bacteria or lower eukaryotes, depletion of the glutamine methyltransferase N6AMT1 in mice
has drastic consequences. The knock-out leads to reduced cell proliferation, heavily impaired
post-implantation development of mutant embryos and early embryonic lethality [89].
Apart from methylation of the eRF1 protein, not much is known about the cellular functions of
HEMK2. The drastic effects of HEMK2 knock-out in mice suggest that it may have a broader
role in cellular processes and development. In the recent years several studies showed that
many PMTs possess additional unknown substrates [97,98]. Their identification may contribute
to a better understanding of the role of the enzyme and its methylated substrates in cells. To
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gain deeper insights into the cellular role of HEMK2, it would be helpful to understand the
mechanism of how HEMK2 recognize its substrate, eRF1, and find out whether HEMK2 may
have additional unknown substrates with other biological functions. In this study, the substrate
specificity profile of HEMK2 was determined and used to identify novel HEMK2 substrates
in vivo and in vitro.
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1.2.2 The NSD Family
The nuclear receptor SET domain-containing (NSD) enzyme family belongs to the SET-domain
containing class V of PMTs. The family consists of NSD1, NSD2 (also MMSET or WHSC1), and
NSD3 (WHSC1L1), which all share the same functional domains: PWWP (proline-tryptophan-
tryptophan-proline motif) domains, PHD (plant homeodomain) domains and the catalytically
active SET domain with an AWS- (associated with SET) and Post-SET domain. The members
differ in the overall protein sizes and exact arrangement of the domains [99].
Figure 7: Schematic representation of functional domains of NSD1, NSD2 and NSD3. PWWP do-
main; PHD zinc-finger domain; SET lysine methyltransferase (KMT); AWS domain (associated with
SET domain); Post-SET domain, HMG box.
While the precise biological function of the three NSD family members is still not completely
understood, several studies showed that NSD1, NSD2 and NSD3 mainly catalyze mono- and
dimethylation of H3K36 [100]. In addition, multiple other histone lysine residues were also re-
ported to be methylated by these enzymes: H4K20 [101], H4K44 [102] and H1.5K168 [102] for NSD1,
H3K4 [103], H3K27 [104], H4K20 [105,106] and H4K44 [107] for NSD2, and H3K4 and H3K27 for
NSD3 [108]. However, some doubts were raised with respect to the methylation activities toward
H3K4, H3K27 and H4K20, due to disagreements among published reports [107]. The biological
functions of all three NSD family members seems to be very important, since a dysregulation of
protein level is involved in many different cancer types and genetic disorders.
The NSD1 gene is located on chromosome 5q35 and encodes a 2696 aa long protein. Haploinsuf-
ficiency caused by either microdeletions or intragenic mutations of the NSD1 gene leads to the
Sotos syndrome [109,110]. This is characterized by prenatal and postnatal overgrowth, character-
istic facial appearance, advanced bone age, developmental delay [111] and malignancies [112,113].
A second genetic disorder is the Beckwith-Wiedemann syndrome. This is more rare, and is as-
sociated with heterozygous loss-of-function or truncating mutations of NSD1 [114]. Besides these
two genetic disorders, NSD1 is connected to several cancer types, like breast cancer [115], neurob-
lastomas and glioblastomas [116], multiple myeloma [117] and acute myeloid leukemia (AML) [118].
14
Approximately 5% of all AML patients are diagnosed to contain a t(5;11)(q35;p15.5) translo-
cation, which encodes for a NUP98-NSD1 fusion protein. This fusion protein interacts with
CBP/p300 in a complex and exhibits acetyltransferase activity along with the H3K36 methyla-
tion activity, which leads to the aberrant expression of HOX genes [119]. Lu et al. showed that
NSD1 is also able to methylate the non-histone protein NF-κB, which plays a crucial role in
innate and adaptive immune responses. Mono- and dimethylation of lysine 218 (K218me1) and
lysine 221 (K221me2) activates the protein, while demethylation of the same residues by the pro-
tein lysine demethylase FBXL11 inactivates NF-κB. Methylation of K218 and K221 of NF-κB
favors cell proliferation, colony formation and gene expression in HT29 cancer cells [120]. While
recent studies showed that NF-κB was not methylated by NSD1 [102], the regulation of NF-κB
in cells through methylation and demethylation at K218 and K221 by other PKMTs cannot be
denied. Although many studies suggested that NSD1 is an important oncogene other reports
showed that NSD1 can act as a tumor suppressor [121,122]. Taken together, it is possible that
NSD1 acts as tumor suppressor or an oncogene depending on the cellular context and already
existing variations of other chromatin modifiers.
NSD2, which was investigated in this study, will be described in more detail in section 1.2.2.1.
NSD3 is the third member of the NSD family and consist of 1437 aa. It harbors four zinc-
finger PHD domains, two PWWP domains and the catalytically active SET-domain. It is
also referred as Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1), although in con-
trast to the other two NSD family members, no relevant overgrowth syndromes were connected
to defects in the NSD3 gene. Similar to NSD1, the NSD3 gene undergoes a chromosomal
translocation, t(8;11)(p11.2;p15) in AML, which leads to the generation of NUP98-NSD3 fusion
protein [123]. Besides AML, NSD3 was also frequently found upregulated in human breast cancer
cell lines [124,125], bladder cancer, lung cancer, liver cancer and chronic myelogenous leukemia
(CML) [126]. Yang et al. demonstrated the differential expression of two transcription factors
IRX3 and TBL1X, in cancer cells that overexpress NSD3 and also in cells ectopically expressing
NSD3. IRX3 and TBLIX are known to positively regulate WNT-signaling pathway. At the
same time SFRP1, a negative regulator of the WNT-signaling pathway, is downregulated by
NSD3 [127]. This suggests that NSD3 may be a driver of oncogenesis.
1.2.2.1 NSD2
The NSD2 enzyme, also known as Wolf-Hirschhorn syndrome candidate 1 (WHSC1) or multiple
myeloma SET domain (MMSET), is the smallest member of the NSD family, with a length of
1365 aa. NSD2 consists of the catalytically active SET domain with its AWS and Post-SET
domains, two PWWP domains, four PHD zinc-finger domains and one HMG (high mobility
group) box. Several studies reported different substrate lysines on histones H3 and H4 for NSD2.
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As such, the dimethylation of K4 and K9 of histone H3 [103], trimethylation of H3K27 [104], di-
and trimethylation of H4K20 [105,106], monomethylation of H4K44 [107] and di- and trimethylation
of H3K36 [107,128] were documented.
1.2.2.2 Aberrant NSD2 Expression is Involved in the Wolf-Hirschhorn Syndrome
and Various Cancers
Dysregulation of NSD2 causes the Wolf-Hirschhorn syndrome (WHS). This is characterized by
developmental defects, like a prominent forehead with widely spaced eyes, divergent strabism,
heart and several midline fusion defects, growth retardation and brain anomalies, which lead to
mental retardation [129,130]. WHS patients either show a partial or complete deletion of the NSD2
gene, leading to a haploinsufficiency of NSD2. This suggests that NSD2 is essential in causing
this syndrome [131]. Nimura et al. showed NSD2-deficient mice exhibit phenotypes similar to the
human WHS, such as growth defects, deficiencies in midline fusion and congenital heart defects.
Mice with heterozygous NSD2+/- mutation exhibit lower level of the protein than the WT mice,
show symptoms as described above, but are viable and fertile. In contrast, homozygous NSD2 -/-
mice show more severe growth defects and die 10 days after birth [128].
Besides the significant role of NSD2 in WHS, many reports also connect NSD2 to different can-
cer types. Expression profile analysis showed elevated levels of NSD2 mRNA in bladder, lung,
breast, prostate, renal and pancreas cancer lines [132]. An upregulation in protein levels was
documented in ganglioneuromas, ganglioneuroblastomas and neuroblastomas [133]. While NSD2
seems not to affect survival, several studies showed a correlation between elevated NSD2 pro-
tein levels and progression of cancer, in oligodendroglioma, breast, prostate and head and neck
cancers [134]. In endometrial cancer and hepatocellular carcinoma it was reported that increased
levels of NSD2 were associated with tumor development, shorter overall survival and disease-free
survival [135,136]. NSD2 was mentioned for the first time at the t(4;14)(p16.3;q32.3) translocation
in multiple myeloma (MM). This is the second most common translocation occurring in about
20% of all multiple myeloma patients [137]. Upon translocation, the immunoglobulin heavy chain
(IgH) promotor (14q32.3) is connected to the NSD2 gene (4p16). This results in a chimeric fu-
sion transcript of IgH-NSD2 and leads to aberrant overexpression of two proteins: the fibroblast
growth factor receptor 3 (FGFR3) and NSD2. Initially FGFR3 was assumed to be the driving
oncogene in MM, later it was shown that about 30% of MM patients lack overexpressed FGFR3,
but still have an increased NSD2 gene product. This suggests a crucial role of NSD2 in multiple
myeloma [138–140]. Kuo et al. found that the dimethylation of H3K36 is the critical chromatin
mark affected in multiple myeloma with t(4;14) chromosomal translocation [141]. They demon-
strated that the catalytic activity of NSD2 is responsible for the H3K36 dimethylation and
subsequent gene activation in these cell lines. Altering the genome-wide profile of H3K36me2
in MM cell lines leads to upregulation of silenced cancer-associated genes or genes linked to cell
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proliferation or survival. In addition to the globally increased level of H3K36 dimethylation,
the level of methylated H3K27, a modification associated with gene repression, was significantly
reduced. This alteration of histone modifications changed the chromatin structure to a more
open state. The genes affected by NSD2 are involved in the regulation of cell death, DNA repair,
cell cycle, p53 pathway and integrin-mediated signaling. A depletion of NSD2 in MM cells lead
to decreased growth, increased cell adhesion and apoptosis [142].
1.2.2.3 Somatic Cancer Mutations of NSD2
The catalogue of somatic mutations in cancer (COSMIC) database contains approximately 300
varying mutations in NSD2. These were identified by sequencing analysis of numerous different
cancer cell lines and patient specimens. Interestingly, among these, some mutation appeared to
be more frequent than others. One of these is the exchange of a glutamic acid to lysine at the
position 1099 (E1099K). This mutation resides in the catalytic SET domain located in a loop
adjacent to the substrate binding pocket, and it was hypothesized that it may alter the methyl-
transferase activity or the substrate specificity of NSD2 [143]. Another cancer database (CCLE
= Cancer Cell Line Encyclopedia) shows that the E1099K mutation of NSD2 mostly appears in
pediatric lymphoid malignancies, such as hypodiploid acute lymphoid leukemia (ALL), chronic
lymphocytic leukemia (CLL), multiple myeloma, lung adenocarcinoma and adenocarcinoma of
the stomach [144]. Jaffe et al. also observed the recurrent occurrence of NSD2 E1099K mutation
in 14% of pediatric B-cell ALL, but not in adult ALL patients [143]. In both studies the authors
could show a higher methyltransferase activity of the NSD2 E1099K mutant. This led to an
increased level of H3K36 dimethylation and decreased level of H3K27 trimethylation comparable
to the effect in cells with the t(4;14)(p16.3;q32.3) translocation [143,144].
1.2.2.4 Effects of the Aberrant Expressed NSD2 and its Recurrent Somatic
Cancer Mutant
NSD2 affects numerous of genes connected with different cancer types. Although often the exact
role and mechanism of NSD2 is not enlightened, recent reports provided new insights into the
function of this enzyme in various diseases. Ezponda et al. revealed the binding of NSD2 to the
TWIST1 gene (twist family bHLH transcription factor 1), which is associated with epithelial-
mesenchymal transition (EMT) and invasion in different cancers, such as prostate cancer. The
upregulation of TWIST1 is induced by NSD2 mediated H3K36 dimethylation of the TWIST1
locus [145]. The same effect on TWIST1 was observed by Oyer et al. with the hyperactive NSD2
E1099K mutant, leading to an upregulation of about 21-fold compared to wild-type NSD2 [144].
The NSD2 protein has also been reported to be overexpressed in 40% of the primary prostate
cancer tumors and its overexpression correlated with the activation of NF-κB in the tumors [146].
NSD2 acts as a coactivator to regulate the NF-κB signaling in castration therapy resistant
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prostate cancer. NSD2 interacts with NF-κB and elevates the expression of NF-κB target genes,
by di- and trimethylaton of H3K36 in the promotor regions. Interestingly, the NF-κB target
genes, inflammatory cytokines IL-6 and TNF-α, are in turn able to stimulate NSD2 expression
thereby creating a positive-feedback loop, which plays an important role in tumor growth [146].
Despite the described roles of NSD2 or its hyperactive mutant (E1099K) in the promotion
of proliferation, survival and tumorigenicity of multiple myeloma and other cancer types, the
cellular function in normal cells was hardly investigated. Considering, the numerous reported
target sites of NSD2 on the histone proteins H3 and H4 [103,107,128], and the rising number of
identified non-histone substrates for various PKMTs in the last years [97,98,102,147] a closer look
should be taken, at whether NSD2 can affect cellular processes by methylation of non-histone
proteins as well. Without a crystal structure of NSD2 together with its cognate substrate,
important information on how NSD2 interacts with its substrates and how the recognition and
selection may work are missing.
For this reason, the substrate specificity profile of NSD2 was characterized. Based on this, several
substrates candidates were identified, which are methylated by NSD2 at peptide level. Addition-
ally, methylation on three novel substrate was shown at protein level and cellular methylation
for two of them was confirmed in HEK293 cells. These information may help to understand
more about the cellular functions of NSD2 and could be useful for the treatment of the various
cancers in which NSD2 is involved.
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1.2.3 The Suv39 Family
The Suv39 protein family, was named after the first member Su(var)3-9, identified in a genetic
screening for position effect variegation (PEV) mutations in Drosophila melanogaster. It was
shown that Su(var)3-9 is a suppressor protein, which is associated with heterochromatin conden-
sation [148]. Su(var)3-9 possesses several eukaryotic homologs, like Clr4 in Schizosaccharomyces
pombe, Suv39h1 in mice and SUV39H1 in humans. In higher eukaryotes, like mouse and human,
an additional homolog, SUV39H2, is present along with the SUV39H1 [149].
1.2.3.1 SUV39H1
SUV39H1 consists of 412 amino acids and contains two conserved chromatin-associated domains,
which are characteristic of the Suv39 family. These are the C-terminal SET domain, which is
the catalytic center, and the N-terminal chromodomain that recognizes and binds methylated
lysine residues. In addition, the catalytically active SET domain is flanked by a Pre-SET and
Post-SET domain (Figure 8).
Figure 8: Schematic representation of functional domains of the Suv39 family. Human SUV39H1,
D.melanogaster Su(var)3-9 and S. pombe Clr4; N-terminal Chromo domain; C-terminal Pre-SET,
SET lysine methyltransferase and Post-SET domains.
SUV39H1 was the first identified histone lysine methyltransferase in humans and it was shown
to trimethylate lysine 9 on histone H3 [150]. The trimethylated H3K9 deposited by SUV39H1 and
other enzymes, provides binding sites for HP1 proteins, which are associated with heterochro-
matin formation, spreading and gene silencing [37]. The process of spreading this mark along
chromatin by SUV39H1-dependent methylation utilizes the recognition and binding of a chro-
modomain at H3K9me3 sites. Besides the ability to bind H3K9me3 marks, the chromodomain
of SUV39H1 is important for the catalytic activity as well. Deletion of the N-terminal part
(including the chromodomain) or just deletion of the chromodomain, led to a radically reduced
methylation activity [151]. The same effect was observed after truncation of the N-terminus of
Su(var)3-9 in D. melanogaster [152]. Based on structural modeling studies with the HP1 chro-
modomain, Chin et al. could show that the amino acid residues located in the SUV39H1 chro-
modomain i.e., tryptophan 64 and tyrosine 67 that are part of the aromatic binding pocket, are
also necessary for its enzymatic activity. Mutation of one of these amino acids leads to similarly
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decreased catalytic activity as the deletion of the entire chromodomain [151]. A dysregulation
of SUV39H1 could have an effect on the regulation of its target genes and genomic stability.
Peters et al. showed that a deletion of Suv39h1 and Suv39h2 in mice led to reduced H3K9
methyl levels in pericentric heterochromatin, followed by growth defects, reduced viability, ge-
nomic instability and increased tumorigenesis [153]. An increased expression level of SUV39H1 is
observed in basal-like breast cancer (BLBC). This leads to increased H3K9me3 levels and DNA
methylation at the promoter of the E-cadherin gene [154]. It was also reported that SUV39H1
interacts with several transcriptional factors, which are thought to be oncogenic proteins. This
causes transcriptional repression, aberration in bone marrow immortalization and hematopoietic
differentiation, and involvement in acute myeloid leukemia [155,156].
1.2.3.2 Clr4
The histone lysine methyltransferase Clr4 is the yeast homolog of Su(var)3-9. Clr4 is a 490
amino acid long protein, with an N-terminal chromodomain and a catalytically active SET
domain. In fission yeast the Clr4 multiprotein complex (ClrC), which consists of Clr4, Cul4,
Rik1, Raf1 and Raf2, is necessary for heterochromatin formation. Clr4 functions as a reader
and writer of H3K9 methylation. It is recruited to chromatin via the RNAi machinery. The
chromodomain of Clr4 can bind to H3K9me sites and the SET domain can modify adjacent
nucleosomes, thereby providing new binding sites for ClrC. This allows the maintenance and
spreading of heterochromatin structures [157]. Additionally, it was shown that Swi6 (the HP1
homolog in S. pombe) co-localizes at H3K9me3 sites via its chromodomain. It further interacts
with Clr4 and strengthens the binding of Clr4 at heterochromatin [158,159]. Though several studies
reported a role for Clr4 in the maintenance and spreading of heterochromatin, there are still
discrepancies regarding how specific the enzyme is recruited to the methylation sites. An exact
answer is not known yet, but it seems that a difference in the selectivity of the chromodomains
of Clr4 and Swi6 avoids competition in binding of methylated H3K9. The chromodomain of
Clr4 showed a higher preference for H3K9me3 over H3K9me2 (5- to 6-fold), compared to the
Swi6 chromodomain, which displayed only a 1.5- to 2-fold discrimination for H3K9me3 over
H3K9me2 [160].
The expansion of substrates to non-histone proteins was consistently shown for a lot of protein
histone methyltransferases during the last years [26]. The yeast homolog Clr4 revealed methyl-
transferase activity on the non-histone protein Mlo3 in vitro and in vivo. Mlo3 is required for
nuclear export of RNA and is associated with mRNA quality control. It was found to interact
with Clr4 and Rik1, a subunit of ClrC complex. The methylation at lysine 167 of Mlo3 is
necessary for the production of centromeric siRNA and suppression of antisense RNA [161]. In
this doctoral thesis, the substrate specificity profile of Clr4 was determined. Additionally, it was
shown that Clr4 methylates six novel substrate candidates at peptide level.
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2 Aims of the Study
In the recent years, the identification of novel substrates for PKMTs gained more and more
attention, as it was shown that many enzymes of this type are able to methylate non-histone
proteins in addition to their known histone substrates. Methylation of non-histone proteins has
several important regulatory roles in cellular processes and may also influence the functions and
properties of the methylated protein. It is believed that there are still numerous of non-histone
substrates, which remain to be identified.
The primary aim of this doctoral thesis was to characterize the substrate recognition of three
different protein methyltransferases and to discover novel protein substrates. HEMK2 is a glu-
tamine methyltransferase, which had been reported to methylate the glutamine residue of the
universally conserved GGQ motif of the eukaryotic release factor eRF1. Methylation of eRF1 is
crucial for normal translation termination and the hydrolysis of nascent polypeptides from the
ribosome. Therefore, it was planned to characterize the substrate specificity profile of HEMK2
and based on this recognition motif to find novel protein substrates, which are methylated at
peptide and at protein level. To show the cellular methylation of in vitro methylated sub-
strates, it was intended to develop a Qme-specific antibody, able to detect HEMK2-dependent
methylation in vivo. Furthermore, the biological effects of the methylation of some of the novel
substrates were addressed.
The second enzyme studied in this thesis was the NSD2 histone lysine methyltransferase. This
was known to dimethylate K36 of histone H3 and play pivotal role in various diseases and cancers.
The objective of this part of the present work was to determine the specificity profile of NSD2
and to screen for novel non-histone substrates candidates, which are methylated at peptide and
at protein level and in mammalian cells. Additionally, the effects of the NSD2 cancer mutations,
occurring within the catalytically active SET domain on the substrate specificity should be
analyzed.
Clr4, the histone lysine methyltransferase in Schizosaccharomyces pombe was the third enzyme
studied in this thesis. Clr4 trimethylates K9 of histone H3, a mark associated with heterochro-
matin formation, spreading and gene silencing. It was already reported that Clr4 methylates
Mlo3, a non-histone protein as well. The goal of this project was to characterize the substrate
recognition profile of Clr4 and to investigate whether it may methylate additional reported
interaction partners at the peptide level.
The aim of the final part of this thesis was to develop a novel assay, which is able to detect
the methyltransferase activity of PKMTs with the help of natural reading domains. Reading
domains are natural protein domains able to detect methylation on a specific lysine residue and
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the degree of methylation. A reading domain based assay may overcome known disadvantages
of conventional PKMT assays, such as the use of radioactively labeled SAM, high costs and
batch-to-batch variability associated with the application of methyl-specific antibodies. It was
planned to develop a microplate based assay suitable for PKMT inhibitor screening.
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3 Results
3.1 Characterization of the Substrate Specificity of the
Glutamine Methyltransferase, HEMK2
The glutamine methyltransferase HEMK2 was the second reported MTase, and has glutamine
as target. HEMK2 catalyzes the transfer of a methyl group form the cofactor SAM to the
glutamine side chain of the eukaryotic release factor eRF1. The target glutamine, which is
part of an universal conserved GGQ motif, plays an important role in the hydrolysis of nascent
polypeptides from tRNA at the ribosome [65]. Methylation at this residue increases the transla-
tional termination efficiency and prevents aberrant read-through. Importantly, deletion of the
glutamine methyltransferase in higher eukaryotes, such as mice, led to diminished cell prolifera-
tion, strongly impaired embryonic development and early embryonic lethality [89]. Currently, no
crystal structures of higher eukaryotic HemK homologs are available, so a more detailed insight
into the interaction between mammalian HEMK2 and its eRF1 substrate is not possible. The
exact process of substrate recognition and differentiation is still not fully understood. Since
the amino acid sequences of the bacterial and mammalian enzymes and their substrates are too
different outside of the conserved motifs, the crystal structure of E. coli HemK with its release
factors is not helpful in addressing these issues.
3.1.1 Purification and Assessment of Methyltransferase Activity
The His6-tagged mouse HEMK2 enzyme and the mouse complex partner TRM112 were co-
expressed in E. coli BL21-CodonPlus (DE3) cells and purified by affinity chromatography with
good yield and purity (Figure 9). To determine the methyltransferase activity of the recombinant
Figure 9: Quality of the purified His6-fused HEMK2 enzyme. (A) Coomassie stained SDS-PAGE gel
of the co-purification of His6-tagged HEMK2 and TRM112. (B) Confirmation of the identity of the
purified His6-tagged HEMK2 enzyme by probing with anti-His antibody.
HEMK2, peptide arrays were synthesized on a cellulose membrane using the peptide SPOT
synthesizer. Due to the fact the eukaryotic release factor 1 is the only known substrate of
HEMK2, peptides were synthesized with the sequence of eRF1 (178 - 192) harboring the target
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glutamine methylation site Q185. Peptides containing the target glutamine Q185 exchanged
to alanine were included as negative control. Peptide arrays were incubated with the HEMK2-
TRM112 complex and radioactively labeled [methyl-3H]-SAM. The transfer of the methyl groups
was detected by autoradiography. A clear methylation signal was observed for the wild-type, but
not for the peptides containing the mutations (Figure 10A). Heurgué-Hamard et al. reported
that GTP is required for the methylation of eRF1 by HEMK2 [90], so the activity of HEMK2
was tested by incubation of the above described peptide arrays in methylation buffer with or
without GTP.
Figure 10: Determination of the methyltransferase activity of HEMK2-TRM112 complex. The mem-
brane contained eRF1 178 - 192 (KKHGRGGQSALRFAR) and Q185A (KKHGRGGASALRFAR)
peptides. Peptide arrays were incubated without (A) or with (B) GTP in methylation buffer. The
images were taken from the same autoradiography film. (C) Bar diagram presenting the quantita-
tive analysis of the autoradiography images shown in (A) and (B), activities were normalized to the
GGQ peptide of (A).
Similar results were obtained when GTP was added to the methylation buffer (Figure 10B) and
quantification of the methylation reactions demonstrated that the addition of GTP had no sig-
nificant effect on the methyltransferase activity of the HEMK2-TRM112 complex (Figure 10C).
After demonstrating the activity of the HEMK2-TRM112 complex on the peptide substrate, the
efficiency of the HEMK2-TRM112 activity on the protein substrates was assessed. For this, the
His6-tagged eRF1 protein was expressed in E. coli and purified by affinity chromatography with
a good yield and purity (Figure 11A). The identity of the purified His6-tagged eRF1 protein
was confirmed by western blot with an anti-His antibody (Figure 11B). Methylation reactions
were performed by incubation of the purified eRF1 protein with the HEMK2-TRM112 complex
in the presence of radioactively labeled [methyl-3H]-SAM. The reaction mixture was separated
by SDS-PAGE and the transfer of the radioactive methyl groups to the substrate was detected
by autoradiography. Figure 11C clearly shows a methylation signal corresponding to the eRF1
protein size.
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Figure 11: Methyltransferase activity of HEMK2 on purified His6-eRF1 protein. (A) Coomassie
stained SDS-PAGE gel of the purified eRF1 protein. (B) Confirmation of the identity of the pu-
rified eRF1 protein by probing with anti-His antibody. (C) Autoradiography of methylated eRF1 by
the HEMK2-TRM112 complex. Bands corresponding to the eRF1 size are marked with an arrow.
3.1.2 Determination of the Specificity Profile of HEMK2
To investigate the substrate recognition of HEMK2, variable scanning peptide SPOT arrays
were synthesized using the eRF1 sequence (179 - 192) as template. These arrays contained
peptides in which one amino acid of the original sequence was exchanged by one of the other 19
proteinogenic amino acids, such that all possible single mutant variants of the original sequence
are examined. 300 peptides were synthesized in total, including one wild-type peptide at the
beginning of each row. The peptide arrays were incubated in methylation buffer containing the
HEMK2-TRM112 complex and radioactively labeled [methyl-3H]-SAM. The methylation of the
peptides was detected by autoradiography (Figure 12A). The experiment was performed three
times and the results of each experiment were quantitatively analyzed using the PhoretixTM
Array software. First, the intensity of each spot was normalized as described in section 6.1.2.
The normalized spot intensities of each experiment were then averaged and color-coded using
Conditional Formatting with dual color (black to light gray) scale in Microsoft Office Excel
(Figure 12B). Thereby, the black squares represent a strong methylation of the corresponding
peptides and the light gray boxes represent low activity. To evaluate the quality of the results
obtained from the specificity array experiments, the standard deviations of the spot methylation
intensities (SD) were calculated. For about 70% of the peptides a SD of less than 10% and
for about 95% of all peptides a SD of less than 20% was obtained. This indicates a very good
quality of the data (Figure 13A). Subsequently, the discrimination factor for the recognition
of each amino acid at each single position was calculated. This factor reveals if the HEMK2-
TRM112 complex favors a specific amino acid, over all other amino acids at the particular site
for methylation (Figure 13B). The recognition motif of HEMK2 comprises the amino acids from
R182 (-3) to R192 (+7) of the eRF1 sequence, the position of the target Q185 is defined as 0. As
expected, exchange of the target glutamine Q185 to any other amino acid prevented methylation.
In addition to this, HEMK2 showed a strict specificity toward the residues G184 (-1) and R189
(+4). Mutating these amino acids to any other residue, eliminated the methylation activity.
Some preferences were observed at residues S186 (+1) for S, R and G, and R192 (+7) for R and
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Figure 12: Substrate specificity profile of HEMK2. (A) Autoradiography image of the specificity profile
array based on eRF1 sequence (179 - 192) methylated by HEMK2-TRM112. The horizontal axis
represents the original eRF1 sequence and the target glutamine Q185 is highlighted red. The verti-
cal axis shows the residues exchanged at the corresponding position in the original sequence, which
provides an array with all possible single amino acid mutations of the eRF1 sequence. The first
column contains the wild-type sequence of eRF1 as a control (labeled with WT). (B) Averaged spot
intensities of each peptide array experiment of the HEMK2-TRM112 complex. The individual re-
sults were normalized and color-coded depending on their methylation activity. Black to light gray
represents a strong to weak methylation.
slightly less strong for F, C and K. Furthermore, some weaker preferences were detected at the
amino acids R182 (-3), G183 (-2), A187 (+2) and L188 (+3). Interestingly, HEMK2 did not
tolerate an amino acid exchange to proline, glutamic acid, aspartic acid or valine at the positions
184 - 192. Based on these findings, a minimal recognition motif of HEMK2 can be proposed as:
G-Q-X3-R.
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Figure 13: Evaluation of the specificity profile results. (A) Quality control of the peptide intensities de-
rived from the specificity profile arrays of HEMK2, which is shown in Figure 12B. Standard devi-
ation of the averaged HEMK2 activity on all peptide substrates was calculated. (B) The discrimi-
nation factors for the recognition of each amino acid at the corresponding position by HEMK2 is
represented in a bar diagram.
3.1.3 Identification of Putative HEMK2 Peptide Substrates
The substrate specificity profile analysis revealed that HEMK2 prefers or tolerates several other
residues apart from the amino acids naturally present in eRF1 at many positions. This suggests
that HEMK2 might methylate additional substrates. Therefore, Scansite [162] searches were
performed with the substrate specificity profiles shown in Table 1, to retrieve putative novel
protein substrates in the human proteome.
Table 1: Substrate specificity profiles utilized to identify putative novel HEMK2 substrate
Cognate residue G184 Q185 S186 A187 L188 R189
Position -1 0 +1 +2 +3 +4
Search profile 1
(stringent) G Q SRYKLG
ARFGL
WYCS
LARQ
CFYT R
Search profile 1
(relaxed) G Q
SRYKL
GAMTC
ARFGLW
YCSQKH
LARQC
FYTI R
The first search was performed with a relatively stringent substrate specificity motif (Table 1;
Search profile 1), which retrieved 138 putative novel candidates. A second search with a more re-
laxed specificity profile (Table 1; Search profile 2), discovered 164 additional potential substrates.
15 amino acid long peptides harboring the predicted target glutamine of the 302 identified pu-
tative candidates were synthesized on 2 peptide arrays. The protein names and the peptide
27
3 Results
sequences of the synthesized substrates are listed in Table 10 and 11 in section 6.1.3. The pep-
tide arrays were methylated with the HEMK2-TRM112 complex as described before, and the
transfer of the radioactive methyl groups was detected by autoradiography (Figure 14A and
B). eRF1 wild-type and the corresponding Q185A mutant peptides were included as controls
(marked by black and grey arrow heads).
Figure 14: Methylation of novel peptide substrates by HEMK2. Peptide arrays containing putative novel
peptide substrates were methylated by the HEMK2-TRM112 complex. Protein names and peptide
sequences are listed in Table 10 and 11 in section 6.1.3. (A) Peptide array containing the putative
substrates identified using search profile 1. (B) Peptide array containing the putative candidates
identified using search profile 2 (Table 1). Wild-type and Q185A peptides of eRF1 were included as
control and are marked by black and grey arrow heads.
A quantitative analysis of the peptide arrays showed that 49 of the potential substrates were
methylated with an equal or slightly weaker preference compared to the eRF1 control peptide.
76 putative candidates showed a reduced, but still detectable methylation signal. The high
amount of methylated peptide substrates in these experiments confirms the reliability of the
search profiles. Interestingly, 17 of the 42 strongly methylated peptides contain a preferred R at
the +7 position (which correspond to the R189 residue in the original sequence) although this
was not specified in the search profile. Similarly, S, R or G residues at the +1 position (S186)
were observed in 26 of the 42 strongly methylated peptides, although seven other amino acids
were allowed in the search at this site. Taking together, it was shown that HEMK2 methylated
around 40% of the 302 putative novel peptide substrates with good activity in vitro and the
derived substrate specificity profile is in agreement with the sequences of the strong methylated
peptides.
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3.1.4 In vitro Methylation of the Putative Novel Protein Substrates
As described above, HEMK2 catalyzes the methylation of several novel peptide substrates
in vitro. However, peptide methylation can not be directly correlated to the protein level,
as sometimes the target glutamine may not be accessible for the methyltransferase in the 3D
context of the folded protein.
Therefore, the methylation of the most promising peptide substrates was investigated also at
protein level. 58 strongly methylated peptide substrates were chosen and cloned as protein
domains, harboring the target glutamine (Table 7 in section 6.1.1). Putative protein substrates
were overexpressed as GST fusion proteins and purified by affinity chromatography. From the
58 selected substrates, 35 were purified with sufficient yield to proceed with further experiments
(Figure 15).
Figure 15: Quality of the purified GST-fused substrate candidates. Coomassie stained SDS-PAGE gels
of the 35 successfully purified GST-fused protein domains. The corresponding bands of the expected
size are marked with a red asterisk.
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The other 23 candidates failed during different steps from cloning to the purification stage. Com-
parable amounts of the 35 proteins were separated by SDS-PAGE and stained with Coomassie to
provide an input control of the proteins used for the methylation reactions (Figure 16A). Methy-
lation assays were performed with the substrate candidates by incubation of the target proteins
with the HEMK2-TRM112 complex and radioactively labeled [methyl-3H]-SAM in methylation
buffer. The samples were separated by SDS-PAGE and the transfer of the radioactive methyl
groups to the target proteins was detected by autoradiography. As shown in Figure 16B, suc-
Figure 16: Example of two methylation assays of the purified putative protein substrates. (A)
Coomassie stained SDS-PAGE gels of the protein substrates (left top and bottom pictures). (B) Au-
toradiography images of the protein substrates methylated by HEMK2-TRM112 complex (right top
and bottom pictures). The corresponding bands of the expected size are marked with a red asterisk.
cessful methylation of 16 protein substrates by HEMK2 was observed. Out of these 5 proteins
showed strong methylation (CHD5, AMPD2, NUT, ANKRD34A and ABCA2), 8 substrates
exhibited weaker signals (GHDC, RRP1, TGFB3, ZSCAN10, ASH1l, PLEK, ARHGEF10 and
SAMD7) and very weak methylation was observed on BEND7, POLG and GNA12 (detailed
information about the substrate proteins are listed in Table 2). An expected strong methylation
signal was observed for eRF1, which was included as positive control. The other 19 purified
proteins did not show any methylation signal in the autoradiography images (data not shown).
To confirm that the substrate methylations occurred at the predicted target glutamine residues,
site-directed mutagenesis was performed for 11 proteins and the target glutamine was exchanged
to an arginine (Table 9 in section 6.1.1). The mutant proteins were overexpressed and purified
by affinity chromatography. Comparable amounts of purified wild-type and mutant proteins
were used in in vitro methylation reactions (Figure 17 upper panels). Methylation assays were
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Figure 17: Confirmation of the target glutamine methylation. Purified wild-type (WT) and mutant (Q
to R) protein substrates were methylated by the HEMK2-TRM112 complex in presence of radioac-
tively labeled [methyl-3H]-SAM and separated by SDS-PAGE. The amounts of wild-type and mutant
substrates used in the assay were verified by Coomassie staining of the SDS-PAGE gels (upper pan-
els). Detection of the radioactive methyl groups is shown by the autoradiography images on the
lower panels. The corresponding bands of the expected size are marked with a red asterisk.
performed by incubating the wild-type (WT) or mutant (Q to R) protein domains with HEMK2
in the reaction buffer containing radioactively labeled [methyl-3H]-SAM (Figure 17 lower panels).
The results revealed that the HEMK2-TRM112 complex methylates the wild-type substrate
proteins, but not the corresponding Q to R mutants (Figure 17 lower panels). This confirms
that the methylation observed on the substrate proteins takes place at the predicted target
glutamine residues and mutation at this position to arginine prevents the methylation of the
protein domains by HEMK2.
31
3 Results
Table 2: In vitro methylated protein substrates of HEMK2. Names, abbreviations, boundaries of the protein
domains and the position of the predicted target glutamine are provided.
Name Abbre-viation
Swiss Prot
no.
Domain
boundaries
(aa)
Target Q
Position
AMP deaminase 2 AMPD2 Q01433 2 – 135 6
Ankyrin repeat domain-containing
protein 34A ANKRD34A Q69YU3 5 – 235 15
ATP-binding cassette sub-family A
member 2 ABCA2 Q9BZC7 168 – 403 302
BEN domain-containing protein 7 BEND7 Q8N7W2 9 – 282 78
Chromodomain-helicase-DNA-
binding protein 5 CHD5 Q8TDI0 1234 – 1530 1390
DNA polymerase subunit gamma-1 POLG P54098 154 – 387 330
GH3 domain-containing protein GHDC Q8N2G8 325 – 529 489
Guanine nucleotide-binding protein
subunit alpha-12 GNA12 Q03113 183 – 320 231
Histone-lysine N-methyltransferase
ASH1L ASH1L Q9NR48 1119 – 1333 1220
Pleckstrin PLEK P08567 2 – 350 107
Protein NUT NUT Q86Y26 867 – 1132 1046
Rho guanine nucleotide exchange factor
10 ARHGEF10 O15013 1107 – 1343 1313
Ribosomal RNA processing protein 1
homolog A RRP1 P56182 219 – 461 427
Sterile alpha motif domain-containing
protein 7 SAMD7 Q7Z3H4 71 – 416 179
Transforming growth factor beta-3 TGFB3 P10600 159 – 405 293
Zinc finger and SCAN domain-containing
protein 10 ZSCAN10 Q96SZ4 364 – 521 428
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3.1.5 Cellular Methylation of the Novel Target Substrates
In vitro protein methylation assays confirmed the methylation of the predicted target glutamine
residues on 11 substrates, at protein level. To determine if HEMK2 is able to methylate the
substrate proteins in cells, 7 of the strongly methylated targets were selected (CHD5, NUT,
AMPD2, TGFB3, GHDC, RRP1 and ZSCAN10) to investigating cellular methylation.
The chosen protein domains were subcloned into mammalian expression vectors. To detect
their cellular methylation, a methyl-glutamine antibody was generated (Biotem, France). The
antibody was raised against a GQ(me)G tripeptide and was validated by probing against in vitro
methylated and unmethylated protein domains. GST-fused protein domains were incubated in
methylation buffer containing the HEMK2-TRM112 complex and unlabeled SAM. As a negative
control, comparable amounts of unmethylated targets were used. The protein samples were
separated by SDS-PAGE, transferred onto nitrocellulose membranes and then probed with the
methyl-glutamine-specific antibody (Figure 18).
Figure 18: Validation of methyl-glutamine specific antibody on methylated and unmethylated sub-
strates. Unmethylated and methylated protein substrates were separated by SDS-PAGE, transferred
onto nitrocellulose membranes and probed with methyl-glutamine specific antibody. The correspond-
ing bands of the expected size are marked with a red asterisk. The bands marked with a + in the
GHDC and TGFB3 samples are not the protein substrates, they represent unspecific binding of the
antibody.
The methyl-glutamine antibody showed a good discrimination between methylated and un-
methylated substrates for CHD5 and NUT (Figure 18). For other substrates, the antibody
either showed no differences in signal between the methylated and unmethylated proteins (ZS-
CAN10, AMPD2 or RRP1) or no signal at all (GHDC and TGFB3). In the case of GHDC and
TGFB3, the antibody signal was observed at much higher size than the corresponding substrate
protein sizes, which might be due to cross reactivity. Since, CHD5 and NUT were the only
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substrates that showed a methylation-specific antibody signal and these two substrates exhib-
ited the strongest methylation level in vitro, they were chosen for further cellular methylation
studies.
For this purpose, expression of the YFP-fused substrates (CHD5, NUT and eRF1), and of the
glutamine methyltransferase HEMK2-HA and its complex partner TRM112-myc was tested.
HEK293 cells were transfected with one of the mentioned plasmids and harvested three days
after transfection. The cells were lysed, and the extracted proteins were separated by SDS-PAGE
and transferred onto nitrocellulose membranes. These were probed with the corresponding
antibodies to determine the expression levels of the desired proteins (Figure 19).
Figure 19: Detection of protein expression in HEK293 cells. Cells were transfected with the YFP-fused
CHD5, NUT or eRF1 proteins (A), HA-tagged HEMK2 (B), and HA-tagged HEMK2 together with
its myc-tagged complex partner TRM112 (C). Cells were lysed and the protein samples were sepa-
rated by SDS-PAGE and transferred onto nitrocellulose membranes. Proteins were detected with the
corresponding antibodies. Untransfected cells were used as control. The corresponding bands of the
expected size are marked with a red asterisk.
The results revealed the successful overexpression of the 2 novel HEMK2 substrates (CHD5 and
NUT) and of eRF1. Ectopic expression of HA-fused glutamine methyltransferase (HEMK2-HA)
and its myc-tagged complex partner TRM112 was also confirmed in HEK293 cells (Figure 19C
and B). To examine the cellular methylation of the newly identified substrates by HEMK2 in
human cells, the YFP-fused protein domains (CHD5 and NUT) were transiently expressed either
with or without the HEMK2-TRM112 complex. Three days after transfection, the YFP-fused
protein substrates were purified using GFP-Trap® A beads. Approximately 10% of the immuno-
precipitated protein samples were separated by SDS-PAGE, transferred onto a nitrocellulose
membrane and probed with an anti-GFP antibody to provide a loading control (Figure 20).
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Figure 20: Immunoblot detection of protein expression in HEK293 cells. The cells were transfected
with the YFP-fused protein substrates CHD5 or NUT either with or without the glutamine methyl-
transferase HEMK2 and the complex partner TRM112. The cells were harvested, lysed and the
substrate proteins were purified by GFP-Trap®. Approximately 10% of the purified target proteins
were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The expression of the
target protein was analyzed by probing with anti-GFP antibody to adjust the amounts for further
experiments. The corresponding bands of the expected size are marked with a red asterisk.
To assess the methylation, the purified protein substrates were used for the western blot as de-
scribed above and probed with the methyl-glutamine antibody. To rule out non-specific binding
of the antibody to unmethylated proteins, increasing amounts of the recombinant unmethylated
protein substrate were included as negative controls (Figure 21).
Figure 21: Detection of glutamine methylation performed by HEMK2 in HEK293 cells. (A) The
YFP-fused substrate CHD5 was ectopically expressed with (T) or without (S) HEMK2 and
TRM112. CHD5 was purified by GFP-Trap® A shown in Figure 20A, recombinant unmethylated
GST-fused CHD5 substrate was utilized as negative control for specificity of the antibody (lower
panel). Cellular glutamine methylation was determined by Western blot with the methyl-glutamine
specific antibody (upper panel). The Ponceau S staining revealed the loading of proteins. (B) Cellu-
lar glutamine methylation of YFP-fused NUT substrate expressed in HEK293 cells. The experiment
was conducted as described in A. As a negative control recombinant unmethylated NUT protein do-
main was used. The corresponding protein bands are marked with a red asterisk.
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The methyl-glutamine antibody bound specifically to substrate proteins purified from HEK293
cells that were coexpressed with HEMK2-TRM112, but not to the corresponding recombinant
unmethylated protein domains (Figure 21). No signal was detected with the recombinant un-
methylated proteins even with higher concentrations. For the CHD5 substrate a methylation
signal was only detected after coexpression with HEMK2 and TRM112, but not when CHD5
was expressed alone, indicating CHD5 is methylated by HEMK2 in human cells (Figure 21A). A
similar result was observed for NUT. Although in this case, a weak signal was detected for the
NUT substrate expressed in HEK293 cells without coexpression of HEMK2 and TRM112. How-
ever, a significantly increased methylation signal was observed when NUT was coexpressed with
HEMK2 and TRM112, indicating a HEMK2-dependent methylation in vivo (Figure 21B). The
weaker methylation signal for NUT in the absence of HEMK2 and TRM112 in HEK293 cells,
could be attributed to endogenous HEMK2. Taken together, the HEMK2-dependent methyla-
tion of two novel substrate proteins (CHD5 and NUT) in human cells was shown. Additionally,
HEMK2 methylated at least 11 new substrates at protein level and approximately 120 further
peptides substrates in vitro.
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3.2 Characterization of the Substrate Specificity of the Histone
Lysine Methyltransferase, NSD2
The nuclear receptor SET domain-containing protein 2 (NSD2) is a member of the NSD family
of PKMTs. NSD2 is a histone lysine methyltransferase that has been reported to methylate
H3K36 as well as other residues, such as K4 and K27 of histone H3 or K20 and K44 of histone
H4. Although the methylation of most targets is still debated, the dimethylation of H3K36 has
been repeatedly described [107,128].
3.2.1 Purification and Assessment of Methyltransferase Activity
Similar to HEMK2, no crystal structure of the NSD2 SET domain is currently available, which
could provide more detailed knowledge about the recognition, discrimination and interaction
between the enzyme and its peptide substrates.
Since previous attempts to purify the catalytically active SET domain (without the post-SET
domain) of NSD2 (residues 1074 - 1182) failed, three different constructs containing the SET
domain flanked by the AWS and post-SET domain with variable domain boundaries were cloned
in this study (Figure 22).
Figure 22: Schematic representation of the three cloned NSD2 SET domain constructs. Short (amino
acids 991 - 1212), medium (amino acids 991 - 1240) and long (amino acids 941 - 1240) constructs
containing functional domains: PWWP domain; PHD zinc-finger domain; SET lysine methyltrans-
ferase (KMT); AWS domain (associated with SET domain); post-SET domain, HMG box.
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GST-fused NSD2 SET domains were expressed in E. coli cells and purified by affinity chromatog-
raphy with good yield and purity (Figure 23).
Figure 23: Quality of the GST-fused NSD2 SET domain constructs. Coomassie stained SDS-PAGE gel
of the three purified NSD2 constructs.
The methyltransferase activity of the three recombinant NSD2 enzymes was tested on peptide
SPOT arrays. H3 (29 - 43) peptides, containing the K36 site, were synthesized on a cellulose
membrane using the peptide SPOT synthesizer. Additionally, peptides with a target lysine to
alanine mutation were included as negative controls. Methylation reactions were performed
by incubating the peptide arrays in methylation buffer containing the purified NSD2 enzymes
and radioactively labeled [methyl-3H]-SAM. The transfer of methyl groups was detected by
autoradiography (Figure 24).
Figure 24: Determination of methyltransferase activity of the three NSD2 enzyme constructs. The
membrane contained histone H3 (APATGGVKKPHRYRP) and K36A (APATGGVAKPHRYRP)
peptides methylated by the short NSD2 construct (A), medium NSD2 construct (B) or the long
NSD2 construct (C). The images were taken from the same autoradiography film. (D) Bar diagram
represents the quantitative analysis of the methylation images shown in (A), (B) and (C).
As shown in Figure 24 all three purified NSD2 constructs exhibited methyltransferase activity
on the H3 wild-type peptides. This was lost in peptides containing the target K to A mutations.
Additionally, the short NSD2 construct seems to be the most active, followed by the medium and
long NSD2 construct (Figure 24A, B and C). Though the activity of the medium NSD2 construct
was slightly weaker than that of the short one, it could be purified with better yield, so all further
experiments were performed with the medium NSD2 construct and from now it is referred as
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„NSD2“ enzyme. Next, the methyltransferase activity of NSD2 on peptides containing H4K44
(37 - 51) and H1.5K168 (161 - 175) was determined. It was previously shown that these lysine
residues are methylated by NSD2 [107] (methylation of H1.5K168 peptide by NSD2 was shown in
the doctoral thesis of Dr. Qazi M. Raafiq [163]). As before, the peptide array contained H3K36
peptides as positive control and all corresponding target lysine to alanine mutant peptides as
negative controls (Figure 25A).
Figure 25: Methyltransferase activity of NSD2 on peptide array. (A) Autoradiography of pep-
tide array methylation by the medium NSD2 construct. The membrane contained his-
tone H3K36 (APATGGVKKPHRYRP), K36A (APATGGVAKPHRYRP), H4K44 (LAR-
RGGVKRISGLIY), K44A (LARRGGVARISGLIY), H1.5K168 (KPAAAGVKKVAKSPK) and
K168A (KPAAAGVAKVAKSPK) peptides. (B) Bar diagram represents the quantitative analysis
of the autoradiography shown in (A).
The results revealed methyltransferase activity of NSD2 toward the wild-type peptides of H3K36,
H4K44 and H1.5K168 (Figure 25A). No activity was observed on the corresponding lysine to ala-
nine mutant peptides. Interestingly, quantitative analysis showed a 2.7 and 1.7 times higher ac-
tivity of NSD2 on the H1.5K168 and H4K44 peptides than on the H3K36 peptides (Figure 25B).
To confirm the methyltransferase activity of
NSD2 on histone proteins as well, methyla-
tion assays with recombinant histone proteins
H3.1 and H4 (NEB) were performed. After
methylation the samples were separated by
SDS-PAGE and subjected to autoradiography.
Similar to the peptide array methylation re-
sult, the methylation signal of the recombi-
nant H4 protein was stronger than that of H3.1
(Figure 26).
Figure 26: Methyltransferase activity of NSD2 on
histone proteins. Autoradiography of the
methylated recombinant histone proteins
H3.1 and H4 by NSD2. Bands marked with
an arrow show automethylation of NSD2.
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3.2.2 Determination of the Specificity Profile of NSD2
To determine the substrate recognition specificity of histone lysine methyltransferase NSD2,
specificity profile arrays were synthesized based on the H3K36 substrate sequence (residues
29 - 43) by the peptide SPOT synthesizer. Synthesized peptides contained one single amino
acid mutation, where one residue of the original sequence was exchanged by another amino
acid. This allows to investigate methylation of all possible single amino acid mutant peptides.
In total, 288 peptides were synthesized that probed 18 proteinogenic amino acids (cysteine and
tryptophan were not included) at each site. Methylation reactions were performed by incubating
the peptide arrays with NSD2 in methylation buffer containing radioactively labeled [methyl-3H]-
SAM (Figure 27A). Three independent methylation experiments were performed and the results
of each methylation assay were analyzed by the PhoretixTM Array software. Normalization and
the color-coding (Figure 27B) was conducted as described in section 3.1.2.
Figure 27: Substrate specificity profile of NSD2. (A) Autoradiography of a specificity profile array based
on H3K36 sequence (29 - 43) methylated by NSD2. The horizontal axis represents the original
H3 sequence and the target lysine K36 is highlighted red. The vertical axis shows the residues ex-
changed in the corresponding row. The first column contains the wild-type sequence of H3 used as
a control labeled with WT. (B) Data from three experiments were normalized, averaged and the
results were color-coded depending on their methylation activity. Black to light gray represents a
strong to weak methylation.
To determine the quality of the results, standard deviations of the averaged spot methylation
signals (SD) were calculated. Approximately 60% of the peptides showed an SD smaller than
10% and about 90% of the peptides had an SD less than 20%, which reveals a good quality of
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the data (Figure 28A). In addition, the discrimination factor for the recognition of each amino
acid at each single position was calculated (Figure 28B).
Figure 28: Evaluation of the specificity profile results. (A) Quality control of the peptide intensities de-
rived from the specificity profile arrays of NSD2 shown in Figure 27B. Standard deviation of the
averaged NSD2 activity on all peptide substrates was calculated. (B) The discrimination factors
for the recognition of each amino acid at the corresponding position of the H3 substrate by NSD2
represented in a bar diagram.
The specificity analysis shows that NSD2 has a rather narrow recognition range, which spans
the H3 residues from 33 to 38 (Figure 27 and 28). The results reveal a preference for aromatic
but also for small amino acids at the -2 position (F>G>Y>I, L, P, H). At the -1 position only
large aliphatic amino acids (I>L>V) are allowed, whereas at the +1 site many residues are
tolerated. At the +2 position exclusively hydrophobic residues are preferred (V>I>L>P>T).
Further to the N-terminus, the glycine at -3 is favored and bulky and acidic amino acids are
avoided. Based on this, two substrate recognition motifs of NSD2 were proposed in Table 3.
Table 3: NSD2 substrate specificity profiles utilized to search for putative novel NSD2 substrates.
Cognate residue V35 K36 K37 P38 H39 R40 Y41
Position -1 0 +1 +2 +3 +4 +5
Search profile 1
(stringent) ILV K KR VILP
NGLSFTM
IHQAEK
LNQG
HIKMF QEGHI
Search profile 1
(relaxed) ILV K
KR
VQN VILP
NGLSFTM
IHQAEK
LNQG
HIKMF QEGHI
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3.2.3 Identification of Putative NSD2 Peptide Substrates
The specificity profiles of NSD2, which are described in Table 3, were used to search in the
Scansite [162] website for putative novel protein substrates of NSD2 in the human proteome. The
search profile 1, which is more stringent at the +1 position, identified 114 potential target lysine
sites in 110 proteins. With the more relaxed search profile 2 additional 112 potential target
lysine sites in 107 proteins were identified. Since NSD2 is present in the nucleus, the search was
restricted to nuclear proteins [164]. A peptide array was synthesized containing 15 amino acid long
peptides of the 226 identified putative substrate candidates using the peptide SPOT synthesizer.
A detailed list of the protein names and peptide sequences of the putative novel substrates is
provided in Table 15 in section 6.2.2. The membrane was incubated with NSD2 to investigate
the transfer of radioactively labeled methyl groups by autoradiography. Quantitative analysis
Figure 29: Methylation of novel peptide substrates by NSD2. The image shows an autoradiography of
the methylated novel peptide substrates. 15 amino acid long peptides identified by the search profiles
1 and 2 (Table 3) containing the predicted target lysine in the middle were synthesized on a peptide
array. Protein names and peptide sequences are listed in Table 15 in section 6.2.2. H3K36 wild-
type and H3K36A mutant peptides as well as H4K44 wild-type and H4K44A mutant peptides were
included as controls.
of the methylated peptide array revealed 45 methylated peptides (in addition to the H3K36
and H4K44 controls), 19 of them were strongly methylated, 15 had approximately the same
intensity as the H3K36 control and 13 peptides showed weaker methylation signals (Figure 29).
Therefore, NSD2 methylated ~20% of the identified putative novel peptide substrates with a
good activity, which verifies the specificity profile.
3.2.4 In vitro Methylation of the Putative Protein Substrates
It was demonstrated in the last section that NSD2 is able to methylate at least 45 novel peptide
substrates. Since the 15 amino acid long peptides possess no tertiary structure, a similar methy-
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lation of the target lysine cannot be automatically expected to occur in proteins as well. This
is because in proteins, the hydrophobic residues of the recognition sequence might be shielded
inside the folded structure and not accessible for the enzyme.
To investigate if NSD2 is able to methylate the previously identified peptide substrates also at
protein level, 27 of the most strongly methylated peptide substrates were selected and cloned
as proteins domains containing the target lysine (Table 15 in section 6.2.2). The domains
were overexpressed as GST fusion proteins and purified by affinity chromatography. Out of
the 27 chosen putative substrates, 22 could be purified in a sufficient yield (Figure 30A). The
identity of the substrate protein candidates was confirmed by immunoblotting with an anti-GST
antibody (Figure 30B). The remaining 5 substrates failed during different steps from the cloning
to purification stage.
Figure 30: Purification and confirmation of putative NSD2 substrates. (A) Coomassie stained SDS-
PAGE gels of the 22 purified GST-fused substrate candidates. (B) Confirmation of the identity of
the purified substrate proteins by western blot with anti-GST antibody. The corresponding bands
with the expected size are marked with a red asterisk.
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For the following methylation experiments, the concentration of the 22 purified putative sub-
strate proteins was determined by Coomassie staining of SDS-PAGE gels and equal amounts
of proteins were used for methylation reactions (Figure 31A). The methylation assays with the
22 purified putative protein substrates were performed by incubating the proteins with NSD2.
GST-fused H3 substrate protein was included as positive control. Additionally, a sample con-
taining only NSD2 was prepared without additional substrate protein. The methylation samples
were separated by SDS-PAGE and subjected to autoradiography. The autoradiography images
Figure 31: Methylation assays of the purified putative protein substrates. (A) Coomassie stained SDS-
PAGE gels of the substrate candidates (left panels). The same amounts were used for the methy-
lation reactions. (B) Autoradiography images of the potential protein substrates methylated by the
NSD2 medium construct (right panels). The corresponding bands with the expected size are marked
with a red asterisk. Automethylation of NSD2 is indicated by an arrow.
showed a clearly visible methylation signal for ATRX and weaker signals for FANCM and SET8
(very weak) (Figure 31B). As expected, the GST-fused H3 protein revealed a strong methyla-
tion signal. Interestingly, much stronger bands appear in all methylation assays at the same
height. Even the methylated sample containing only NSD2 enzyme revealed a strong methyla-
tion activity, suggesting the signal represents an automethylation of NSD2 (marked by arrows).
Unfortunately most of the putative protein substrates have a similar size as the NSD2 medium
construct, therefore the automethylation bands of NSD2 might cover signals from the methylated
protein substrates.
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To discriminate the potential methylation signal of substrate proteins from the automethylation
of NSD2, the methylation assays were repeated with same substrate candidates and the short
NSD2 construct, as described above. A weak but clear methylation signal corresponding to the
Figure 32: Methylation assays of the selected putative protein substrates for methylation by the
short NSD2 enzyme construct. (A) Coomassie stained SDS-PAGE gel of the normalized sub-
strate candidates same as the gel in Figure 31A top. Similar amounts were used for the methyla-
tion reactions. (B) Autoradiography of the selected substrate candidates methylated by the short
NSD2 construct. The corresponding bands with the expected size are marked with a red asterisk.
Automethylation of NSD2 is indicated by an arrow.
size of the FANCM protein was observed, which is not caused by the automethylation of NSD2
(Figure 32B). However, FANCM was the only band observed in this methylation assay. But,
based on the protein sizes it cannot be excluded that the automethylation band from NSD2 still
covers potential signals from the methylated target proteins.
To identify the automethylation site of NSD2, a peptide scan array of the NSD2 (941 - 1243)
sequence was synthesized with 15 amino acid long peptides always shifted by 5 amino acids. A list
of the peptide sequences is given in Table 16 in section 6.2.2. The peptide array was methylated
by NSD2 and the transfer of the radioactive methyl groups was detected by autoradiography
(Figure 33).
Figure 33: Methylation of a peptide scan array to identify the NSD2 automethylation site. Au-
toradiography of the peptide scan array methylated by NSD2 containing 15 amino acid long pep-
tides with the sequence of NSD2. The peptide sequences of each spot are listed in Table 16 in sec-
tion 6.2.2. The H3K36 wild-type and K36A mutant peptides were included as controls.
H3K36 control peptides (A1 and D15) showed strong methylation signals. Additionally, a weaker
but still clearly detectable signal at peptide spot A15 was observed (Figure 33). The methylated
NSD2 peptide contained lysine residue K992. Interestingly, the corresponding residue was iden-
tified to be automethylated in NSD1 as well (Doctoral thesis of Dr. Srikanth Kudithipudi [165]).
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In an attempt to remove the
automethylation activity of
NSD2, site-directed mutagenesis
was performed to exchange ly-
sine 992 to arginine or alanine.
The GST-fused NSD2 enzymes
containing either the K992R or
K992A mutation were overex-
pressed and purified by affinity
chromatography (Figure 34).
Figure 34: Quality of the purified NSD2 K992A and
K992R mutants. Coomassie staining of the purified
NSD2 enzyme mutations. The corresponding bands of
the expected size are marked with a red asterisk.
The purified NSD2 mutant enzymes were used for methylation of ATRX or recombinant H3.1
as previously described. Methylated samples were separated by SDS-PAGE and the transfer of
the radioactive labeled methyl groups was detected by autoradiography (Figure 35).
Figure 35: Methyltransferase activity of the NSD2 K992A and K992R mutants. Methylation of
ATRX and H3.1 by NSD2 wild-type, K992A and K992R mutants. The image shows an autora-
diography of methylated ATRX and recombinant H3.1 substrates. The corresponding bands of the
expected size are marked with a red asterisk. Automethylation of NSD2 is indicated by an arrow.
As observed in Figure 35, the two NSD2 mutants were able to methylate ATRX and recombinant
H3.1, but still showed strong automethylation bands. This was comparable to wild-type NSD2
indicating that lysine K992 is not the true or only automethylation site of NSD2. As it seems,
non-specific automethylation on lysine or even other amino acid residues in close proximity to
the SAM binding site is not trivial to prevent.
Therefore, NSD2 was subcloned in the pET-28a(+) and the pMAL-c2x expression vectors, which
produce NSD2 either with the small His6-tag or with the larger MBP-tag (maltose-binding
protein). The His6- and MBP-fused NSD2 enzymes were overexpressed and purified by affinity
chromatography (Figure 36A). The purified NSD2 enzymes were used in in vitro methylation
assays with ATRX and recombinant H3.1. The methylation samples were separated by SDS-
PAGE and subjected to autoradiography. As expected, strong methylation signals were observed
46
Figure 36: Methylation of ATRX and H3.1 protein by NSD2 with different affinity tags. (A)
Coomassie staining of the purified GST-, MBP- and His6-fused NSD2 enzymes. (B) Autoradiog-
raphy image of methylated ATRX and recombinant H3.1 substrates by NSD2 enzymes fused either
to GST-, MBP- or His6-tag. The corresponding bands of the expected size are marked with a red
asterisk. Automethylation of NSD2 is indicated by an arrow.
for ATRX and H3.1 after methylation by the GST-fused NSD2 enzyme (Figure 36B). Although
the MBP- and His6-fused NSD2 variants were purified with a good yield, the enzymes did not
show considerable activity. Additionally, an automethylation signal was detected for the His6-
tagged NSD2. This was much weaker than the automethylation of the GST-tagged enzyme.
Since preventing automethylation of NSD2 is not trivial, in the next steps the potential protein
substrates could be subcloned into the pET-28a(+) vector to obtain the substrate proteins and
GST-fused enzyme with different sizes and avoid the overlapping of NSD2 automethylation
signal with the substrate protein methylation signal.
To confirm the methylation of the three newly methylated substrates on the predicted lysine
residues, site-directed mutagenesis was performed to exchange the predicted target lysine to
arginine (Table 14 in section 6.2.1). The mutant proteins were overexpressed and purified
by affinity chromatography (Figure 37A). The purified wild-type and corresponding mutant
proteins were methylated by NSD2. For the methylation reactions of ATRX and SET8 the
medium NSD2 construct and for the methylation of FANCM the short NSD2 construct was
used. The results showed that the methylation signals on the corresponding mutant proteins
of ATRX and FANCM disappeared, whereas the wild-type proteins revealed clear methylation
signals (Figure 37B). However, the SET8 mutant protein still revealed a methylation signal,
which was even stronger than for the wild-type protein. Since, SET8 is also a PKMT it was
checked if this signal was due to its potential automethylation. In vitro methylation assays for
SET8 were repeated as described above and additionally two control methylation reactions were
included: the SET8 wild-type or mutant protein without NSD2 enzyme (Figure 38).
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Figure 37: Confirmation of methylation on the predicted lysine. Purified wild-type (WT) and mutant (K
to R) protein substrates of ATRX, FANCM and SET8 were methylated by the NSD2 enzymes. (A)
Equal amounts of wild-type and mutant proteins was verified by Coomassie staining of the SDS-
PAGE gels (upper panels). (B) Autoradiography images of the methylated protein substrates (lower
panels). The corresponding bands of the expected size are marked with a red asterisk. Automethyla-
tion of NSD2 is indicated by an arrow.
Figure 38: Methylation of the SET8 wild-type and mu-
tant proteins. Autoradiography image of the
methylation of SET8 wild-type and mutant pro-
teins by NSD2. The wild-type and mutant pro-
teins of SET8 were incubated either with or with-
out NSD2 to test for automethylation of SET8.
The corresponding bands of the expected size are
marked with a red asterisk. Automethylation of
NSD2 is indicated by an arrow.
As previously seen a weaker methylation
signal of SET8 wild-type and a stronger
methylation signal on SET8 K158R mu-
tant protein was observed when the pro-
teins were incubated with NSD2, but no
methylation signal on the SET8 wild-
type and mutant proteins was noticed
in the absence of NSD2 enzyme (Fig-
ure 38). This methylation assay con-
firmed that the observed bands are not
caused by automethylation of SET8,
rather that NSD2 methylates another or
an additional lysine residue within the
SET8 sequence, besides the predicted
target lysine K158.
All in all, it was shown that NSD2 specifically methylates two novel substrate (ATRX and
FANCM) at protein level. NSD2 might methylate even more of the purified substrate candi-
dates, however, due to its strong automethylation it is not trivial to discern the signals, so inves-
tigation of other purified substrate proteins was discontinued in the current study. Additionally,
methylation of SET8 was observed, although the target residue could not been identified.
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3.2.5 Cellular Methylation of the Novel Target Substrates
It was shown that NSD2 methylates two of the predicted protein substrates in vitro (Figure 31).
To check if these methylated substrates are also methylated in HEK293 cells, ATRX and FANCM
were subcloned into the mammalian expression vector pEYFP-C1. The coding sequence of
the full-length (FL) NSD2 enzyme was also subcloned into the mammalian expression vector
pECFP-C1.
To develop an appropriate tool to determine the cellular methylation, the specificity of an anti-
H3K36me2 antibody (Active Motif, USA; Cat. no.: 39255) was investigated. This was selected,
because NSD2 dimethylates H3K36 and the methylated sequences in ATRX and FANCM resem-
ble the H3K36 sequence. To investigate if the anti-H3K36me2 antibody recognizes the in vitro
methylated substrates, GST-fused histone H3 or recombinant H3.1 proteins were methylated
by NSD2 in methylation buffer containing unlabeled SAM. The protein samples were separated
by SDS-PAGE and transferred onto nitrocellulose membrane and then probed with the anti-
H3K36me2 antibody (1 : 1.000). However, no signal was detected (data not shown). Since the
used enzyme construct consists only out of the SET domain and not of the full-length protein,
it might be that NSD2 is just able to monomethylate the protein substrates. Methylation as-
says were repeated as described above and the membrane was probed with an anti-H3K36me1
antibody (1 : 2.000) (Abcam, UK; Cat. no.: ab9048). Figure 39 shows a clear signal for both
the GST-fused histone H3 and the recombinant H3.1 proteins, respectively, but no signal for the
sample without a protein substrate.
Figure 39: Validation of the anti-H3K36me1 antibody with methylated histone H3 substrates. Pon-
ceau S staining of the nitrocellulose membrane (left panel). Western blot of the transferred GST-
fused H3 and the recombinant H3.1 substrates detected by anti-H3K36me1 antibody (right panel).
To investigate if the anti-H3K36me1 antibody is also able to detect the methylation of the novel
NSD2 substrates ATRX and FANCM, similar in vitro methylation reactions were performed by
incubating either ATRX or FANCM with or without NSD2 enzyme in methylation buffer con-
taining unlabeled SAM. The methylation samples were separated by SDS-PAGE and transferred
onto nitrocellulose membranes. The membrane was probed with the anti-H3K36me1 antibody
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(1 : 2.000) (Figure 40).
Figure 40: Validation of the anti-H3K36me1 antibody with methylated and unmethylated ATRX
and FANCM proteins. Ponceau S staining of the methylated and unmethylated protein substrates
(lower panel). Western blot of the transferred methylated and unmethylated protein substrates
probed with the anti-H3K36me1 antibody (upper panel). The corresponding bands of the expected
size are marked with a red asterisk.
A clear signal was observed for the methylated FANCM protein, only when NSD2 was present.
For ATRX the H3K36me1 antibody was not able to discriminate fully between methylated
and unmethylated proteins (Figure 40). However, the signal for methylated ATRX protein
was much stronger than for the unmethylated protein. ATRX and FANCM were selected for
further cellular studies, because the antibody revealed a good discrimination between methylated
and unmethylated proteins. The expression levels of the CFP-fused full-length NSD2 enzyme
(NSD2 FL) and the two YFP-fused substrates ATRX and FANCM was tested. HEK293 cells
were individually transfected with each of the three plasmids and harvested three days after
transfection. The cells were lysed, the proteins separated by SDS-PAGE and transferred onto
nitrocellulose membranes. The membranes were probed with an anti-GFP antibody (Clontech,
USA) to determine the expression of the corresponding proteins (Figure 41).
Figure 41: Immunoblot detection of protein expression in HEK293 cells. The cells were transfected
either with NSD2 FL, ATRX or FANCM. Cells were harvested, lysed, separated by SDS-PAGE and
transferred onto nitrocellulose membranes. The expressed proteins were detected by probing with an
anti-GFP antibody. The corresponding bands of the expected size are marked with a red asterisk.
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Western blot results revealed the appearance of signals for all the three proteins (Figure 41) at
the expected size, indicating a successful expression. To investigate if the two protein substrates
are methylated by NSD2 in vivo, HEK293 cells were transiently transfected with one of the
YFP-fused substrate proteins either with or without the full-length NSD2 enzyme. The cells
were harvested three days after transfection and the YFP-fused substrate proteins were purified
using GFP-Trap® A beads. Approximately 10% of the purified substrate proteins samples
were separated by SDS-PAGE, transferred onto nitrocellulose membranes and probed with an
anti-GFP antibody to provide a loading control (Figure 42).
Figure 42: Immunoblot detection of protein expression in HEK293 cells. The cells were transfected
with YFP-fused ATRX or FANCM either with or without NSD2. Cells were harvested, lysed and
the substrate proteins were purified by GFP-Trap®. Approximately 10% of the purified target pro-
teins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The expression
of the protein substrates was analyzed by probing with an anti-GFP antibody. The corresponding
bands of the expected size are marked with a red asterisk.
The adjusted amounts of the target proteins ATRX or FANCM, were loaded on an SDS gel and
separated by SDS-PAGE, transferred onto nitrocellulose membranes and detected by western
blot with the anti-H3K36me1 antibody (1 : 500). Recombinant GST-fused unmethylated sub-
strate proteins with increased concentration were included to rule out possible unspecific binding
of the antibody to unmethylated protein (Figure 43). The results clearly showed that the anti-
H3K36me1 antibody binds specifically to the substrate proteins that were expressed together
with the lysine methyltransferase NSD2, but not to the recombinant GST-fused unmethylated
protein domains (Figure 43). Even with higher concentrations of recombinant unmethylated
substrate protein no signal was observed. For both protein substrates, ATRX and FANCM, a
strong methylation signal was detected when they were coexpressed with the NSD2 enzyme,
indicating a NSD2-dependent methylation in human cells. However, when the substrates were
expressed in the absence of NSD2, only a very weak signal was observed. The weaker methyla-
tion signal, in absence of ectopically expressed NSD2, could be probably due to the endogenous
enzyme. In total, two novel substrate proteins, ATRX and FANCM, were identified, which
are methylated in human cells by NSD2. Additionally, it was shown that NSD2 methylates 43
further substrate candidates at peptide level and 3 substrates at protein level.
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Figure 43: Immunoblot detection of lysine methylation performed by NSD2 in HEK293 cells. (A)
The YFP-fused substrate ATRX was ectopically expressed with or without NSD2. ATRX was puri-
fied by GFP-Trap® as shown in Figure 42. Cellular lysine methylation was determined by western
blot with the anti-H3K36me1 antibody (upper panel). The Ponceau S staining revealed the loading
of recombinant unmethylated GST-fused ATRX substrate as negative control for the specificity of
the antibody (lower panel). (B) Cellular lysine methylation of YFP-fused FANCM substrate ex-
pressed in HEK293 cells. The experiment was conducted as described in A. As a negative control
recombinant unmethylated FANCM protein domain was used. The corresponding bands of the ex-
pected size are marked with a red asterisk.
3.2.6 Somatic Cancer Mutations of NSD2
Jaffe et al. identified in a global chromatin profiling analysis, a novel NSD2 mutation (E1099K)
that was highly prevalent in ALL cell lines lacking the NSD2 t(4;14) translocation [143]. The
glutamic acid E1099 resides within the catalytically active SET domain of NSD2. It was assumed
that the E1099K mutation could alter the interaction between NSD2 and its substrate as it is
located in a loop close to the substrate binding pocket. It was shown that the recombinant NSD2
E1099K enzyme has higher in vitro methylation activity on nucleosomes, compared to the wild-
type NSD2. Furthermore, an increased level of dimethylated H3K36 was observed in cell lines
containing the E1099K mutant, suggesting a hyperactivity of the corresponding NSD2 mutant in
cells [144]. A similar increased methylation activity was also found for D1125N mutation, which is
located in the SET domain as well [143]. To study the effects of these mutations on the substrate
specificity, they were generated by site-directed mutagenesis (Table 4).
Table 4: Reported somatic cancer mutants of NSD2
Name Abbreviation
Domain
boundaries
(aa)
Amino acid
mutation
Nuclear receptor SET-domain containing
protein 2 E1099K Mutant
NSD2 E1099K Mut 991 – 1240 E1099K
Nuclear receptor SET-domain containing
protein 2 D1125N Mutant
NSD2 D1125N Mut 991 – 1240 D1125N
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The GST-fused NSD2 enzymes containing either the E1099K or D1125N mutation were overex-
pressed and purified by affinity chromatography with good yield and purity (Figure 44A).
However, the protein band of the
NSD2 E1099K mutant ran lower than
the NSD2 D1125N mutant, sequenc-
ing results showed that both plasmids
were correct and did not contain ad-
ditional mutations. The methyltrans-
ferase activity of the two somatic can-
cer mutants was tested with peptide
arrays as described before. The mem-
branes were methylated by one of the
NSD2 mutants and subjected to au-
toradiography. Both enzymes showed
a specific methyltransferase activity
toward the H3K36 wild-type peptide
(Figure 44B).
Figure 44: Methyltransferase activity of the NSD2
somatic cancer mutants on peptides. (A)
Coomassie staining of the purified NSD2 E1099K
and D1125N mutants. (B) Autoradiography
of peptide array methylation by either NSD2
E1099K (upper panel) or D1125N (lower panel)
mutants. The arrays contained histone H3K36
(APATGGVKKPHRYRP) and K36A (AP-
ATGGVAKPHRYRP) peptides.
To confirm the methyltranferase activity at protein level, methylation assays with recombinant
histone proteins H3.1 and H4 were performed as well. Coomassie staining of an SDS-PAGE
gel with the purified enzymes was used as loading control (Figure 45A). Then, equal amounts
of the recombinant histone proteins H3.1 or H4 were incubated with NSD2 wild-type, E1099K
or D1125N mutant in methylation buffer containing radioactively labeled [methyl-3H]-SAM and
the transfer of the radioactive methyl groups was detected by autoradiography. All three NSD2
enzymes had a good methyltransferase activity toward the recombinant histone proteins, however
the H4 proteins showed stronger methylation signals (Figure 45B).
Figure 45: Methyltransferase activity of the NSD2 somatic cancer mutants on proteins. (A)
Coomassie staining of the three enzymes NSD2 WT, E1099K and D1125N mutant. (B) Autora-
diography of recombinant histone protein methylation by either NSD2 WT, E1099K or D1125N
mutant. The histone proteins H3.1 or H4 were either methylated by the NSD2 WT, E1099K or
D1125N mutant enzyme in presence of radioactively labeled [methyl-3H]-SAM.
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3.2.7 Comparison of the Substrate Specificity of the NSD2 Somatic Cancer
Mutants to the Wild-Type Protein
To investigate if the substrate specificity of the two NSD2 mutants differs from the wild-type
enzyme, methylation of specificity profile arrays were performed as described in section 3.2.2.
The membranes were methylated by either the E1099K or D1125N mutant, in presence of
radioactively labeled [methyl-3H]-SAM and subjected to autoradiography (Figure 46).
Figure 46: Substrate specificity profiles of the NSD2 mutants. Autoradiography images of specificity
profile arrays based on H3K36 sequence (29 - 43) methylated by NSD2 E1099K (left) and D1125N
(right) mutant. The horizontal axis represents the original H3 sequence and the target lysine K36 is
highlighted red. The vertical axis shows the residues exchanged in the corresponding row. The first
column contains the wild-type sequence of H3 used as a control labeled with WT.
The signal intensities of the specificity arrays of the two NSD2 mutants were quantified, nor-
malized and the residues from G34 to R40 were compared to the wild-type profile (Figure 47A).
Additionally, the discrimination factors at these residues were calculated and the comparison
of all three enzymes is shown in Figure 47B. The specificity profile arrays of NSD2 wild-type
and the two somatic variants (E1099K and D1125N) showed no large differences in the prefer-
ence of amino acids between positions -2 (G34) and +2 (P38). Nevertheless, at the positions
+3 (H39) and +4 (R40), the E1099K mutant showed a higher specificity than the other two
enzymes (Figure 47A and B). All three enzymes showed a strict preference for the same residues
at the -1 (I, L and V) and +2 (I, L, V and P) positions. The D1125N mutant showed a higher
preference for valine at -1 position than the other two variants. At the -2 and +1 positions the
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three NSD2 variants were less strict and tolerated also other amino acids. Taken these results
Figure 47: Specificity profile analysis of NSD2 wild-type, E1099K and D1125N mutant. Comparison
of the specificity from residues G34 to R40 of NSD2 WT, E1099K and D1125N specificity profile
data. The quantified and normalized results were color-coded depending on their methylation activ-
ity. Black to light gray represents a strong to weak methylation.
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together, the substrate recognition profile of the two NSD2 mutants is very similar to the NSD2
wild-type (Table 3). This suggests that the tested mutations within the SET domain of NSD2 do
not change the specificity of the enzyme. Next, it was investigated whether the NSD2 E1099K
variant methylates additional substrates. A peptide array containing all predicted potential
substrates was methylated by NSD2 E1099K and detection was performed as described above
(Figure 48).
Figure 48: Methylation of novel peptide substrates by NSD2 E1099K mutant. Autoradiography of the
methylated novel peptide substrates by NSD2 E1099K mutant. 15 amino acid long peptides iden-
tified by the search profiles 1 and 2 (Table 3) containing the predicted target lysine in the mid-
dle were synthesized. Protein names and peptide sequences are listed in Table 15 in section 6.2.2.
H3K36 and H3K44 wild-type and the corresponding mutant peptides were included as controls.
For a better comparison, the intensities were quantified, normalized and the relative activities
of the peptide array methylated by NSD2 wild-type were plotted against the activities of the
array methylated by NSD2 E1099K (Figure 49).
Figure 49: Scatter plot of the methylated peptide substrate by NSD2 wild-type and E1099K. The
intensities of the peptide substrates methylated by NSD2 wild-type were plotted against intensities of
the corresponding peptide substrates methylated by NSD2 E1099K. Peptide methylation intensities
< 1% of the H4K44 peptide were excluded from the analysis.
The intensities for most of the methylated peptides were similar for both methylation assays, but
56
the scatter plot shows also discrepancies for several peptide substrates, which are indicated by
data points lying off an imaginary bisecting diagonal (Figure 49). However, the results showed
that the E1099K mutant did not methylate any novel peptides.
It was also tested, if the NSD2 mutants are able to methylate the two novel protein substrates
ATRX and FANCM in vitro. Corresponding amounts of the protein substrates were subjected
to in vitro methylation assays with either NSD2 E1099K or D1125N mutant. Figure 50B clearly
shows that both NSD2 mutants methylate ATRX. Additionally, the E1099K mutant revealed
detectable activity for FANCM. The weak activity of the D1125N mutant on FANCM on the
other hand is almost completely covered by the NSD2 automethylation band.
Figure 50: Methyltransferase activity of NSD2 E0199K and D1125N on protein substrates. (A)
Coomassie staining of the three protein substrates ATRX and FANCM. (B) Autoradiography of
the protein substrates methylated either by NSD2 E1099K or D1125N mutant. The corresponding
bands of the expected size are marked with a red asterisk. Automethylation of the NSD2 mutants is
indicated by an arrow.
To confirm the methyltransferase activity of the two NSD2 cancer mutants in human cells,
HEK293 cells were transiently transfected either with the full-length NSD2 WT, E1099K or
D1125N variants and one of the YFP-fused protein substrates. As control, the cells were trans-
fected only with the YFP-fused substrates. Harvesting of the cells, purification of the substrates
and western blot analysis with H3K36me1 antibody was performed as described above for NSD2
wild-type (Figure 51A and B). The results showed specific binding of the H3K36me1 antibody
to the substrate proteins, which were expressed together with the NSD2 variants (Figure 51B).
However, no signal was detected when the substrates were expresses alone in HEK293 cells.
Even the recombinant GST-fused unmethylated protein domains, which were included as neg-
ative controls, did not show antibody binding. Additionally, it was observed that the ATRX
substrate, when coexpressed with the NSD2 mutants showed higher methylation signals in com-
parison to the cotransfection with wild-type NSD2. This agrees with the reported hyperactivity
of the NSD2 mutants [143,144]. Interestingly, such an increased methylation activity was not ob-
served for the FANCM substrate when coexpressed with one of the NSD2 variants. The NSD2
D1125N mutant showed even weaker methylation activity on the FANCM substrate than the
other two variants, however, the loading control reveals also a weaker Ponceau S staining for
this sample.
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Taken together, this data show that the E0199K and D1125N mutants have a comparable
substrate recognition profile to NSD2 wild-type and that they are able to methylate the substrate
proteins, ATRX and FANCM both in vivo and in vitro.
Figure 51: Detection of cellular methylation of ATRX and FANCM by NSD2 somatic variants.
(A) The YFP-fused substrate ATRX was ectopically expressed with the described NSD2 enzymes or
alone and purified by GFP-Trap® A. Cellular lysine methylation was determined by probing with
anti-H3K36me1 antibody (upper panel). Ponceau S staining represents the loading control (lower
panel). Recombinant unmethylated GST-fused ATRX substrate was utilized as negative control for
the specificity of the antibody. (B) Cellular lysine methylation of YFP-fused FANCM substrate ex-
pressed in HEK293 cells. The experiment was conducted as described in A. As a negative control
recombinant unmethylated FANCM protein domain was used. The corresponding bands of the right
size are marked with a red asterisk.
3.2.8 In vitro Methylation of Histone H3 Somatic Cancer Mutations
In the last years an increasing number of studies showed recurrent somatic mutations within
the histone H3 genes, which were identified in different cancer types. Some of these mutations
encode for lysine to methionine exchanges at position 27 or 36. Other residues surrounding
the characterized lysine methylation sites were altered as well [166–168]. The K27M, G34R or
G34V mutations within the histone H3.3 gene H3F3A were identified in approximately 50%
cases of pediatric high-grade gliomas (pHGGs), a highly malignant type of brain tumor in
children [166]. In about 92% of giant cell tumors of bone, the H3F3A gene encoding the histone
H3.3 contained the recurrent mutations G34W or G34L [168]. The K36M mutation of histone
H3.3, occurring in 95% all chondroblastomas (a rare and aggressive bone tumor mostly affecting
the epiphyses or apophyses of long bones), was found mainly in the H3F3B gene but sometimes
also in H3F3A [168].
Since H3K36 is a known substrate of NSD2, the influence of the H3 somatic cancer mutations on
the NSD2 methyltransferase activity was investigated. Peptides with the H3 sequence (29 - 43)
containing the H3 missense alterations, which are listed in the COSMIC (Catalogue of Somatic
Mutations in Cancer) database were synthesized on membranes. A detailed list of the sequences
and the precise mutations of the histone H3 cancer variants is shown in Table 17 in section 6.2.2.
The H3K36 and the K36A mutant peptides were included as controls at the beginning and the
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end of each peptide array. The peptide arrays were methylated with either NSD1 or NSD2 WT,
E1099K or D1125N mutants in methylation buffer containing radioactively labeled [methyl-
3H]-SAM (Figure 52A). Methylated peptide arrays were quantitatively analyzed by PhoretixTM
Array software and normalized spot intensities were color-coded as described above. The red
represent no detectable methylation signal and yellow a strong methylation (Figure 52B).
Figure 52: Methyltransferase activity of NSD2 wild-type, E1099K, D1125N and NSD1 on H3 mis-
sense mutation peptides. (A) Autoradiography images of peptide arrays containing the histone
missense cancer mutations methylated by NSD2 WT, E1099K, D1125N and NSD1. 15 amino acid
long peptides containing the sequence of several histone missense cancer mutations (residues 29 -
43) received from the COSMIC database were synthesized on peptide arrays. The peptide sequences
with the corresponding cancer mutations are listed in Table 17 in section 6.2.2. Peptides of H3.3
K36 wild-type and H3.3 K36A mutant were included as controls. (B) The quantified signals were
normalized, averaged and color-coded dependent on the methylation intensities. Red to yellow repre-
sents a weak to strong methylation.
Overall, NSD1 and the three NSD2 variants showed a similar methylation pattern of the histone
H3 somatic missense mutations (Figure 52). Mutations of T32 (A3 -A5) have little effect on the
activity of NSD1 and the NSD2 variants, the intensities of these spots were comparable to the
corresponding H3K36 peptides. However, mutations of G34 clearly showed differences of the
methylation intensities at peptides A6 to A11. NSD2 wild-type and D1125N mutant showed
decreased activity on these peptides, whereas NSD2 E1099K and NSD1 revealed no big changes
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at the peptides except at G34D (A10), which reduced the activity as well. Mutation of V35 to
I increased the methylation signal, since isoleucine is more preferred than valine at position -1.
In contrast, mutation of the same valine to glycine (V35G) completely prevents the activity of
all four enzymes. Stronger methylation signals were also observed on the K37N, P38L, P38T,
H39Q and R40H mutant-containing peptides. These were either tolerated or even preferred
over the native H3 peptide. The peptides containing the P38S mutation, showed a decreased
methylation signal, since serine is not preferred at this position. Some differences were also
observed for the peptides mutated at position 40 (R40C and R40P), NSD2 wild-type showed
an increased activity, whereas, the activities of the NSD2 mutants and NSD1 were weaker. The
mutation of Y41 to C abolished or reduced the methyltransferase activity of the NSD2 enzymes
and NSD1, respectively, thus cysteine seems to be not tolerated at position +5. The results
showed that the H3 missense mutations have either an elevating or suppressing effect on the
methyltransferase activity of the four tested NSD enzymes. Additionally, it was observed that
the methylation intensities of the H3 mutations fit to the described specificity profiles of the
NSD2 variants.
3.2.9 The H3K36M Missense Mutation Inhibits the Methyltransferase
Activity of NSD2
Lewis et al. showed that the H3K27M mutation inhibits the methyltransferase activity of the
Polycomb repressive complex 2 (PRC2) [169]. PRC2 di- and trimethylates K27 and maintains
epigenetic gene silencing and X chromosome inactivation. The K27M mutant competes with
wild-type substrates for the active site of PRC2 and prevents global methylation at K27 residues.
This can alter cellular processes and lead to gliomagenesis.
To test whether the K36M mutant inhibits the methyltransferase activity of NSD2, in vitro
methylation assays with K36 wild-type and K36M mutant peptides were performed. First, in-
creasing concentrations of K36 peptide was methylated in methylation buffer containing NSD2
and radioactively labeled [methyl-3H]-SAM. The methylation reactions were separated by SDS-
PAGE and the transfer of the radioactively labeled methyl groups was detected by autoradio-
graphy. The results revealed an increasing methylation activity with increasing concentrations
of K36 peptide (Figure 53A). However, above 100µM of peptide the methyltransferase activity
reached saturation and did not rise further.
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To investigated the effect of K36M peptide on the methylation activity of NSD2, two different
concentrations of the K36 containing peptide were selected and methylation assays were per-
formed in the presence of increasing concentrations of K36M mutant peptides (Figure 53B an
C). With increasing concentrations of the K36M peptide, a stronger inhibition of the methyl-
transferase activity of NSD2 was observed. Quantification of the methylation signals of all three
methylation assays are presented next to the corresponding autoradiography images.
Figure 53: Analysis of NSD2 enzymatic activity on H3K36 peptide. (A) Methylation of varying con-
centrations of K36 wild-type peptide. (B) Methylation of varying concentrations of K36M peptide
in presence of 21.2µM K36 peptide. (C) Methylation of varying concentrations of K36M peptide in
presence of 105.8µM K36 peptide. Quantification of the corresponding autoradiography images is
represented next to the methylation assays.
With the received data a Lineweaver-Burk plot was generated to specify the type of inhibition.
The plot shows four different regression lines corresponding to the used inhibitor concentra-
tions, which have all the same y-intercept, suggesting K36M is a competitive inhibitor with the
substrate peptide (Figure 54).
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Figure 54: Lineweaver-Burk plot of the NSD2 peptide methylation assays. Data obtained from the
methylation assays shown in Figure 53 were used generate a Lineweaver-Burk plot to specify the
type of inhibition of the K36M peptide on the H3K36 peptide methylation by NSD2.
Fitting of the data to the equation describing a substrate competitive inhibition by least-squares
method revealed a KM value of 71µM for the methylation reaction of the K36 peptide by NSD2.
KM represents the Michaelis-Menten constant that shows the substrate concentration at which
the reaction rate is equal to one half of the maximum rate for the reaction. Additionally, the
KI value of the K36M peptide inhibitor was determined and revealed a KI of 47µM for the
performed reactions. In summary, it was shown that the somatic cancer mutations of H3 have
an effect on the methyltransferase activity of NSD2 and that the K36M peptide is a competitive
inhibitor of NSD2 activity on H3K36 peptides.
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3.3 Characterization of the Substrate Specificity of the Yeast
Histone Lysine Methyltransferase, Clr4
Clr4 is the homolog of the Schizosaccharomyces pombe histone lysine methyltransferase (HKMT)
Su(var)3-9. Clr4 catalyzes the trimethylation of lysine K9 of histone H3, which is an impor-
tant mark for the formation of heterochromatin. Trimethylated H3K9 serves as a binding site
for the chromodomain of Clr4 but also for the chromodomain of Swi6, an important protein
associated with heterochromatin formation, maintaining heterochromatin structure and tran-
scriptional regulation. Additionally Zhang et al. reported that Clr4 methylates K167 of Mlo3,
a non-histone protein, which is required for nuclear export of RNA [161].
3.3.1 Purification and Assessment of Methyltransferase Activity
To obtain better insights into the substrate recognition pattern of Clr4 and to identify addi-
tional potential non-histone substrates, the substrate specificity profile of this methyltransferase
was determined. The bacterial expression construct of Clr4 was kindly provided by Prof. Dr.
Danesh Moazed. The His6-tagged Clr4 protein was expressed in bacteria and purified by affinity
chromatography with sufficient yield (Figure 55A).
Figure 55: Methyltransferase activity of Clr4. (A) Coommasie staining of the purified Clr4 enzyme. The
band of the expected size is marked with a red asterisk. (B) Autoradiography of peptide array based
on histone H3 sequence (ARTKQTARKSTGGKAPRKQ) containing H3K9 and corresponding K9A
mutant peptides methylated by Clr4.
To test the methyltransferase activity of Clr4, peptide arrays were methylated by the purified
enzyme. The peptide array contained histone H3 (1 - 15) and the corresponding target lysine to
alanine (K9A) mutant peptides. The results showed that Clr4 exhibited strong methyltransferase
activity toward the H3K9 wild-type, but not against the H3K9A mutant peptide (Figure 55).
3.3.2 Determination of the Specificity Sequence Profile of Clr4
To examine the substrate specificity of the histone lysine methyltransferase Clr4, a mutational
scanning peptide SPOT array was synthesized using the histone H3 sequence (residues 1 - 18) as
template. The membrane was incubated with Clr4 in methylation buffer containing radioactively
labeled [methyl-3H]-SAM and subjected to autoradiography (Figure 56).
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Figure 56: Substrate specificity profile of Clr4. Autoradiography image of the specificity profile array based
on H3K9 sequence (1 - 18) methylated by Clr4. Horizontal axis represents the original H3 sequence
and the target lysine K9 is highlighted red. Vertical axis shows the residues exchanged at the corre-
sponding position in the original sequence, which provides an array with all possible single amino
acid mutations of the histone H3 sequence. The first column contains the wild-type sequence of H3
as a control labeled with WT.
The methylated peptide array revealed a recognition motif covering the residues R8 (-1) to G12
(+3) of the H3 sequence, where the target lysine K9 is defined as position 0. Besides the target
lysine K9, Clr4 showed very strict specificity at the -1 (R8) and +3 (G12) positions. A mutation
of the cognate residues at these positions to any other amino acids abolished the methylation
signal. Strong preferences were also observed at the +1 (S10) and +2 (T11) positions. Besides
S, at the +1 position R, K, and T were tolerated and at the +2 (T11) position, along with the
cognate threonine, cysteine and serine were allowed. Outside of this recognition motif, Clr4 is
very unspecific and tolerates almost all other amino acids. The substrate recognition motif is
summarized in (Table 5).
Table 5: Substrate specificity profiles utilized to identify putative novel NSD2 substrate
Cognate residue R8 K9 S10 T11 G12
Position -1 0 +1 +2 +3
Search profile R K SKRT TCS G
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3.3.3 Identification of Putative Novel Substrates of Clr4
It is known that Clr4 interacts with several non-histone proteins, such as Swi6 and Mlo3 and
it was also reported that Clr4 is able to methylate lysine K167 of Mlo3 [161]. Therefore, the
interactors of Clr4 that contain the substrate sequence motif of Clr4 were further analyzed
(Table 5). An alignment of selected K residues of Clr4 interaction partners with its substrate
sequence motif is shown in Table 6. This indicates that all the listed proteins may be potential
substrates of Clr4. Residues matching with the specificity profile were marked in green, while
those which were not matching were marked in red.
Table 6: Sequence alignment of residues surrounding the target lysine of the proteins interacting with Clr4 and
the substrate specificity profile of Clr4. X in the specificity profile stands for all amino acids are al-
lowed. Amino acids in the green box are tolerated and in the red box are not tolerated by Clr4 at the
corresponding position. The potential target lysines are shown in brackets.
Position -4 -3 -2 -1 0 +1 +2 +3 Position onpeptide array
Specificity
Profile
X X X R K SKRT TCS G
Target
K K to A
H3 (K9) Q T A R K S T G A1 A2
Mlo3 (K167) S S K R K T T R A3 A4
Swi6 (K144) P S K R K R T A A5 A6
Spbc28F2.11
(K250)
K P K R K H T R A7 A8
Spbc28F2.11
(K292)
K K R R K S S M A9 A10
Hrp3 (K89) S K H R K G T R A11 A12
Dbp2 (K165) R A G A K G T A A13 A14
Iec3 (K153) K Q K R K R T S A15 A16
Mcp1 (K132) P P A R K T T G A17 A18
Cbc1 (K11) T R P R K R T R A19 A20
Rik1 (K460) Y D S A K R S R A21 B1
Rik1 (K502) E V A R K V F E B2 B3
To investigate if these proteins are potential substrates for Clr4, peptides of the corresponding
sequences containing the putative target lysine were synthesized on cellulose membrane. Protein
names with the corresponding peptide sequences are listed in Table 18 in section 6.3.2. The
membrane was methylated by Clr4 and the transfer of the radioactive labeled methyl groups
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was detected by autoradiography (Figure 57).
Figure 57: Methylation of putative novel peptide substrates by Clr4. Autoradiography of the peptide ar-
ray with the putative substrate peptides containing the predicted target lysine and the corresponding
K to A mutation methylated by Clr4.
The methylation of the array revealed 3 strongly methylated peptides, which belong to Mlo3,
Spbc28F2.11 (K292) and Hrp3 (Figure 57). Additionally, 4 peptides showed weak methylation
signals: Swi6, Spbc28F2.11 (K250), Mcp1 and Cbc1. However, the highest signals were observed
for the native H3K9 peptides, which served as controls. Loss of methylation signal on the
target lysine to alanine mutation peptides confirmed the methylation of the predicted target
residues. All in all, the substrate specificity profile of the histone lysine methyltransferase Clr4
was determined and it was shown that the enzyme was able to methylate six additional putative
substrates at peptide level. Two of them showed a comparable strong methylation as Mlo3
(Figure 57).
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3.4 Development of an Advanced Non-radioactive,
High-throughput PKMT Activity Assay
Many assays already exist that allow the detection of PKMT activity [170–174]. However, these
procedures exhibit a couple of disadvantages, such as the usage of radioactively labeled SAM.
Moreover, sometimes, the identification of the methylated target site and determination of the
degree of methylation is not possible. Also, the employment of methyl-specific antibodies has
disadvantages, the use in high-throughput systems needs large amounts of antibodies. These
are expensive, require animals for production and may have batch-to-batch variability.
To overcome the disadvantages of current PKMT assays, we developed a novel sensitive mi-
croplate ELISA PKMT assay, which is working with non-labeled SAM and uses methyl-lysine
specific reading domains instead of methyl-specific antibodies. These natural reading domains
can be recombinantly produced in E. coli. They have the important advantages that they are
less expensive and exhibit constant quality. Moreover, like antibodies, reading domains are
highly specific for the methylation site and the degree of methylation [175]. The procedure of
this assay consists of seven main steps, which are schematically illustrated in Figure 58. The
biotinylated peptides are methylated by a PKMT in presence of unlabeled SAM and then bound
to the avidin coated wells of a microplate. The wells are next incubated with 2% BSA blocking
solution, to prevent unspecific binding of the reading domains or antibodies. Subsequently, the
reading domain is added to the plate and incubated to allow binding. Afterwards, the primary
antibody, which is either specific for the reading domain or its affinity tag, is added. Finally,
the detection and quantification of the luminescence signal is performed with an HRP-coupled
secondary antibody.
Figure 58: Schematic illustration of the basic steps of the developed PKMT assay utilizing the
reading-domains.
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First, it was investigated whether the reading domain HP1β interacts with the H3K9 methylated
peptides in the microplate assay. Biotinylated H3 peptides (residues 1 - 19) of all K9 methyla-
tion states, were bound to the avidin coated wells. Unmethylated H3K9 and trimethylated
H3K36 peptides were included as negative controls. The wells containing different peptides
were incubated with GST-fused HP1β and binding of the reading domain was analyzed with a
GST-specific antibody (Figure 59A).
Figure 59: Application of the HP1β protein as methyl lysine reader. (A) Interaction of GST-tagged
HP1β with un-, mono-, di- and trimethylated H3K9 peptides detected with anti-GST antibody.
Trimethylated H3K36 peptide included as control. The signals were normalized to the trimethy-
lated H3K9 peptide. (B) Interaction of GST-tagged HP1β protein with the same peptides used in
A, detected with HP1β-specific antibody. The signals were normalized to the trimethylated H3K9
peptide.
Two independent experiments were performed. Both replicates were consistent. In this assay, the
HP1β reading domain interacted strongly with the trimethylated H3K9 peptides (Figure 59A).
Approximately 1.7-fold weaker binding was observed with the dimethylated and 7.6-fold weaker
with the monomethylated peptides. These results reflect the ratios of the binding constants of
HP1β, shown in previous reports [176,177]. There, the binding constant of HP1β to H3K9me3 was
around 6µM, to dimethylated H3K9 ~1.8-fold weaker and to monomethylated H3K9 ~7.3-fold
weaker. The binding signals to the unmethylated H3K9 and trimethylated H3K36 peptides were
both very weak (<5%). The experiments were repeated under the same conditions as described
above, but a primary antibody directed toward HP1β was used, instead of a GST-specific
antibody. This was because in some experimental setups, the use of a reading domain-specific
antibody might be more advantageous, for example if the PKMT itself is fused to a GST-tag
(Figure 59B). The signals of HP1β binding to the different peptides showed a pattern comparable
to that observed with the GST-specific antibody. Although the signals were slightly increased,
the ratio of monomethylated to unmethylated H3K9 peptides was almost the same as the ratio
observed with the GST antibody. However, the ratios of trimethylated to dimethylated H3K9
peptide binding (~1.3-fold) and trimethylated to monomethylated H3K9 peptide binding (~2.6-
fold) were lower. Even with various concentrations of HP1β, primary and secondary antibody,
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we observed the same relative binding signals, suggesting a different binding specificity of the
two primary antibodies. It seems that the HP1β-specific antibody exhibit a higher detection
sensitivity towards HP1β bound to H3K9me1 compared to the GST-specific antibody, which
is an advantage because it allows the detection of monomethylated H3K9. H3K9me1 is the
methylation product of the first cycle of a PKMT, and this increases the sensitivity of the assay.
These results confirmed the suitability of reading domains to detect peptide methylation in a
microplate assay approach.
To investigate the optimal concentration of the HP1β protein, un- and trimethylated H3K9
peptides were incubated with various concentration of the reading domain (Figure 60). The
Figure 60: Determination of optimal HP1β concentration. Interaction of unmethylated ([) and
trimethylated (v) H3K9 peptides with various concentrations of GST-tagged HP1β protein, detected
with HP1β-specific antibody.
increasing concentration of HP1β led to an increase in the luminescence signal for the trimethy-
lated peptide. However, at higher HP1β concentration, increased background (unmethylated
H3K9 peptide) signal was noticed as well (Figure 60). All the following experiments were there-
fore performed with 40 nM of reading domain.
Next, it was investigated if enzymatically methylated substrates could be detected in this ap-
proach as well. An in vitro methylation of biotinylated H3 (1 - 19) peptide was performed with
the recombinant SET domain of SUV39H1. The methylation reactions were carried out with
200 nM of SET-SUV39H1 to provide sufficient methylated peptide for the experiment. The
unmethylated and trimethylated H3K9 peptides were used as controls and HP1β as reading do-
main. For detecting the reading domain the HP1β-specific antibody was used (Figure 61). The
signal of the SET-SUV39H1 methylated peptide was about 85% of the synthetic trimethylated
H3K9 control peptide and more than 7-fold higher than the signal observed with the unmethy-
lated control peptide (Figure 61). This shows that a high level of methylation was obtained
under these conditions and documents a very good dynamic range for the assay. A remarkable
signal-to-noise (SN) ratio of 9.5 showed a very good reproducibility of the experiments. To fur-
ther assess the quality of the assay, its Z-factor was calculated. This is an established statistical
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Figure 61: Analysis of SUV39H1 enzymatic activity using the HP1β protein as methyl reader. Un-
methylated H3K9 peptide was methylated by SUV39H1. Unmethylated and trimethylated H3K9 pep-
tides were included as controls. The peptides were incubated with the HP1β protein and the inter-
actions were detected with the HP1β-specific antibody. The signals were normalized to the synthetic
H3K9me3 peptide.
parameter to judge the overall quality of a high-throughput screening assay. With the results
observed in the experiments, a Z-factor of 0.65 was received. In larger high-throughput assay
systems, Z-factors >0.7 are considered as very good and factors >0.5 are acceptable [178].
To investigate if this assay can be used to screen for PKMT inhibitors, the fungal toxin chaetocin,
which was reported to inhibit the methyltransferase activity of SUV39H1, was tested [173]. The
SET-SUV39H1 enzyme was pre-incubated with DMSO and different concentrations of chaetocin
for 15min. Afterwards, biotinylated H3 (1 - 19) peptides were methylated with the pre-incubated
enzymes (20 nM final concentration of SET-SUV39H1), in methylation buffer containing unla-
beled SAM. The methylation reactions were transferred to the avidin coated plate and handled
as described above. For detection of the reading domain, the HP1β-specific antibody was used
(Figure 62).
Figure 62: Analysis of SUV39H1 enzymatic activity in presence of various concentrations of
chaetocin using the HP1β protein as methyl reader. The signal of the methylated peptide ob-
served after methylation without inhibitor was set as 100%. The signal obtained with unmethylatd
peptide was considered as background, and the signals of the samples were normalized accordingly.
The IC50 value was determined by least-squares fit of the data to an equation describing the simple
inhibition of an enzyme by binding of an inhibitor.
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With increasing concentration of chaetocin, a stronger inhibition of the methyltransferase ac-
tivity of SUV39H1 was observed (Figure 62). The data were analyzed by least-squares fitting
method to an equation, which described a simple enzyme inhibition reaction. The calculated
IC50 value of the inhibition of SUV39H1 by chaetocin for our data is 480 nM, which matches
with the published IC50 of 600 nM [173].
Afterwards, the methylation of these samples was further verified by mass spectrometric. The
H3 (1 - 19) peptides were methylated by SUV39H1 with various concentration of chaetocin. As
control, we included H3 peptide methylated by SUV39H1 in the absence of inhibitor (Figure 63).
Figure 63: MALDI MS analysis of the H3K9 peptide methylation samples incubated with SUV39H1
in presence of various concentrations of chaetocin as shown in Figure 62. The peptide
sequence is ARTKQTARKSTGGKAPRKQ-K(Biot)-NH2 and its theoretical molecular weight in the
unmethylated state is 2423 kDa. The theoretical masses of the methylated peptides are indicated.
The mass spectrum of the control sample indicated all three methylation levels of H3K9, al-
though the highest peak was observed for the unmethylated state (2423.4 kDa). The signals of
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mono- (2437.4 kDa) and dimethylated (2451.4 kDa) H3K9 were weaker and the trimethyled form
of H3K9 (2465.4 kDa) was very weak, but still detectable (Figure 63). However, with increas-
ing concentrations of chaetocin the MALDI analysis showed strongly decreased levels of H3K9
methylation. This is validating the results of the ELISA assay. In summary, it was shown that
reading domains can be used for high-throughput PKMT inhibitor screens instead of antibodies
and that the results obtained by the novel assay were confirmed by mass spectrometry.
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PTMs, such as protein methylation, are important regulators of cellular processes. Methylation
of histone proteins regulates chromatin structure, thereby affecting functions, such as transcrip-
tional regulation and DNA damage response [30–33]. Additionally, methylation of non-histone
proteins controls many other protein functions and properties, such as protein stability, activ-
ity, protein-protein interactions and cellular localization [43,44,46,47]. The enzymes responsible
for transferring the methyl group to protein substrates play important biological roles. This
is indicated by the finding that abnormal expression or aberrant methyltransferase activity is
often associated with various diseases and cancer types [129,130,141]. In the recent years, numer-
ous reports discovered many novel protein methyltransferase substrates and the number of new
protein methylation sites is growing rapidly [97,102]. The identification of such novel substrates is
important for a complete understanding of the function of the methyltransferase enzymes and
the role of protein methylation in various signaling functions.
In this work, an established method to characterize the substrate specificity profile of three
different protein methyltransferases (PMTs) was used [179,180]. Based on the identified substrate
recognition motif of the enzymes, several novel substrates were discovered and their methylation
was confirmed in vivo and in vitro.
4.1 Specificity Analysis of HEMK2 and Identification of Novel
Target Substrates
The glutamine methyltransferase HEMK2 is one of few enzymes responsible for the methylation
of a glutamine side chain. HEMK2 was reported to modify the eukaryotic release factor (eRF1)
within the universally conserved GGQ motif. eRF1 is responsible for the recognition of stop
codons and induces the hydrolysis of nascent polypeptides from tRNA. These functions are
stimulated by its methylation by HEMK2.
The crystal structure of HEMK2 is not available, thereby the residues involved in the substrate
recognition were difficult to pinpoint. To circumvent this limitation, peptide arrays were em-
ployed to determine the specificity profile of HEMK2. For these, the known substrate sequence of
eRF1 (179 - 192) was used as a template. The experiments revealed a wide substrate recognition
motif comprising the positions from -3 (R182) to +7 (R192), when the target Q185 is defined as
position 0. The results of the in vitro peptide array methylation propound a G-Q-X3-R minimal
recognition motif for HEMK2. With this specificity profile, 302 proteins that contain the se-
quence motif could be identified. Peptide array methylation confirmed the methylation at 125 of
these predicted peptide substrates. The highly methylated peptides were selected to be further
investigated and 35 protein domains were successfully purified. In vitro methylation experi-
73
4 Discussion
ments showed that 16 protein substrates were methylated. 5 of them displayed strong methy-
lation signals (CHD5, AMPD2, NUT, ANKRD34A and ABCA2), 8 proteins domains revealed
weaker methylation signals (GHDC, RRP1, TGFB3, ZSCAN10, ASH1l, PLEK, ARHGEF10
and SAMD7), and very weak methylation could be detected on 3 candidates (BEND7, POLG
and GNA12). Additionally, cellular methylation of the strongest targets, CHD5 and NUT, was
confirmed in HEK293 cells. Based on the large set of novel identified peptide and protein sub-
strates, one may speculate that HEMK2 may have more substrates in human cells apart from
eRF1. These however, could not be elucidated in this study. Overall, these results show that
the impact of glutamine methylation in general is underestimated.
Unlike other posttranslational modification, such as phosphorylation or even methylation at
lysine or arginine residues, the glutamine methylation is a subtle PTM. In case of eRF1, the
glutamine methylation influences a hydrogen bonding network within the peptidyl transferase
center (PTC). The lack of a methyl group at glutamine increases the mobility of the side chain,
leading to an increase in the activation energy for hydrolysis of freshly synthesized polypep-
tides [181]. The glutamine methylation of histone H2A affects protein-protein interactions of the
chaperone FACT (Facilitator of transcription) [59]. The two novel strongly methylated substrates,
CHD5 and NUT, identified in this study, are known to have important cellular functions:
• CHD5 is a member of the chromodomain-helicase-DNA binding protein family containing
several chromodomains and PHD domains. It was reported that decreased levels of CHD5,
caused either by deletion of the gene or hyper-methylation of its promoter, lead to the
formation and progression of multiple cancer types, such as breast or epithelial ovarian
cancer, suggesting a role as tumor suppressor gene [182–184].
• The function of the NUT protein is poorly characterized, however, 75% of all NUT midline
carcinoma (NMC) and other cancers are caused by a genetic translocation of the NUT and
BRD4 genes leading to formation of a BRD4-NUT oncogene [185]. The BRD4-NUT fusion
protein blocks differentiation, and its knock-down in NMC cells results in differentiation
and growth arrest [186]. Moreover, the target glutamine in the NUT protein is located
adjacent to the nuclear localization signal, so the methylation may change the localization
of the protein and its targeting to chromatin.
However, the biological function of the methylation at the glutamine residue of CHD5 and NUT
protein is still not elucidated and has to be investigated thoroughly.
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4.2 Specificity Analysis of NSD2 and Identification of Novel
Protein Substrates
The nuclear receptor SET domain-containing protein 2, NSD2, is a histone lysine methyltrans-
ferase, which was shown to mono- and dimethylate lysine K36 of histone H3. Some studies
reported that NSD2 methylates additional lysine residues of H3 and H4, such as H4K20, H3K27
or H3K4 [107]. These findings could be however not confirmed in follow up biochemical assays.
Though, many reports confirmed the methylation of K36 of histone H3 by NSD2, proposing
H3K36 as the main substrate of NSD2 [107,141,142].
The substrate specificity profile of NSD2 was determined by methylating mutational scanning
peptide SPOT arrays prepared using the sequence of histone H3 (29 - 43) as a template. The ob-
tained data revealed a relatively short recognition motif, starting from residue G33 and reaching
to residue P38. It indicates that NSD2 prefers aromatic and small residues at the -2 position
(F>G>Y), with hydrophobic amino acids being tolerated as well. The positions -1 (I>L>V)
and +2 (V>I>L>P) are more specific and hydrophobic residues are allowed at this sites. The
+1 position is not that specific as the surrounding positions, however, basic and uncharged
amino acids (K>V>R>Q) are preferred.
To show which of the reported substrates may be methylated by NSD2, a comparison of their
sequences with the determined specificity profile could help. Interestingly, the substrate se-
quence motif of NSD2 is not matching with the K20 of H4, instead it is fitting with the residues
surrounding K44. In addition, H1.5K168 matches very good to the specificity motif of NSD2.
At position +2, the H4K44 and H1.5K168 substrates possess a more preferred amino acid (I46
for H4 and V170 for H1.5) compared to P38 of histone H3, which would explain the higher
methyltransferase activity of NSD2 on H4K44 and H1.5K168 at peptide level (Figure 25). Al-
though, the methylation activity of NSD2 was not tested on H3K4, H3K27 and H4K20 peptides
in this study, the alignment of the corresponding sequences to the specificity profile reveals many
mismatching residues, which makes a methylation very unlikely.
With the derived substrate specificity profile of NSD2, 217 proteins with 226 potential target
lysines were identified and methylation on 45 of these substrates was observed at peptide level.
19 peptides showed stronger methylation than H3K36 and 15 had a comparable methylation
intensity to the H3K36 substrate peptide. 13 of the 45 methylated substrate peptides revealed
weaker methylation signals than the control peptide. In addition, 3 of the 22 tested protein
domains (ATRX, FANCM and SET8) were methylated by NSD2, although the signals were
weaker compared to the H3 control protein. Methylation on the target lysine was confirmed
for ATRX and FANCM, whereas the mutation of the predicted target lysine of SET8 did not
abrogate the methylation signal at the SET8 mutant protein. This suggests that SET8 has
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more than one target lysine or even other residues, for example cysteine or arginine, that may
be methylated by NSD2. It was not possible to identify the methylated residue(s) in SET8 in this
study, however, an automethylation of SET8 was excluded. Furthermore, cellular methylation
of the in vitro methylated substrate proteins ATRX and FANCM was determined in human
HEK293 cells using a lysine methylation antibody. Considering that a substrate relatively
weakly methylated in vitro, such as ATRX, shows a strong cellular methylation, it might be
possible that NSD2 possesses additional substrates among the other 42 methylated peptides.
A look onto the already identified methylated non-histone substrates shows the importance of
searching for such substrates and investigating the effect of methylation on protein functions
and properties. ATRX and FANCM are known to have very important cellular functions in
transcriptional regulation and DNA damage response:
• ATRX is named after its ATR-X syndrome (alpha-thalassemia X-linked mental retar-
dation) characterized by mental retardation, developmental delay and distinctive facial
features [187]. ATRX is a ATP-dependent chromatin-remodeling factor and is involved in
transcriptional regulation. It has multiple other roles, including control of histone depo-
sition [188]. It was also shown that ATRX interacts with many different other chromatin
proteins, such as HP1α, EZH2 and MeCP2 [189–191].
• FANCM (Fanconi anemia group M protein) is homologues to the archaeal DNA heli-
case/nuclease protein HEF and possesses a helicase/ATPase domain and an endonuclease
domain. FANCM belongs to the FA (Fanconi anemia) core complex, which is important for
monoubiquitination of FANCD2, a key step in the FA DNA damage response pathway [192].
Fanconi anemia is a rare genetic disease characterized by congenital abnormalities, bone
marrow failure, genomic instability, and increased risk of cancer development. FA can be
caused by mutation in any of the involved genes [193].
It is known that both proteins are posttranslationally phosphorylated, but until now no study
showed methylation of ATRX and FANCM. Therefore it is important to further investigate the
effects of the lysine methylation on the biological functions of the two novel NSD2 substrates.
Additionally, it was observed that NSD2 is subjected to automethylation. This was already
shown for NSD1, where the lysine K1769 was identified as the target residue [165]. A candidate
screening approach to identify the amino acid automethylated in NSD2, revealed lysine K992 as
a possible target site. However, the generated and purified NSD2 mutants (K992A and K992R)
still showed automethylation. This indicates either that lysine 992 was not the methylated
residue or that other lysines or even cysteine might be methylated. Nevertheless, it would be
interesting and important to identify the automethylation site of NSD2. Automethylation might
also occur in cells and may alter some functions or properties of NSD2 or create binding sites
for other proteins.
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In addition, the substrate specificity profiles of two NSD2 somatic cancer mutations were eluci-
dated. Recent studies identified the NSD2 E1099K and D1125N mutations within the catalyt-
ically active SET domain in several tumor samples [143]. The E1099K mutation was found in
several different lymphoid malignancies, such as hypodiploid acute lymphoblastic leukemia and
chronic lymphocytic leukemia. It was reported that these two mutants exhibit an enhanced his-
tone methyltransferase activity, thereby leading to an increase in global H3K36me2 levels [143,144].
Since these mutations are located within the SET domain, it might be that they change the sub-
strate specificity of the enzymes. However, the determination of the substrate specificity profiles
of these two mutants, revealed comparable specificity motifs to the NSD2 wild-type, with only
minor differences. Also methylation of the peptide and protein substrates with the cancer mu-
tants did not show any additional candidates. Although it was reported that the NSD2 cancer
mutants exhibit an increased MTase activity, the results of this study could not support these
findings. Noteworthy, in the performed in vitro methylation assays, only a small part of the
enzyme containing the catalytically active SET domain was used. It was already shown that the
PHD domains of NSD2 are important for its biological function, and truncation of the enzyme
can decrease the methyltransferase activity of NSD2 [194]. Finally, the methylation of ATRX and
FANCM by the NSD2 E1099K and D1125N mutant enzymes could be confirmed in human cells.
An elevated methyltransferase activity for the somatic cancer mutants was observed towards
ATRX in HEK293 cells. By contrast, all three NSD2 variants displayed similar activity on the
FANCM substrate.
Interestingly, during detection of cellular methylation of FANCM with the H3K36me1-specific
antibody, a band with higher molecular mass could be detected in addition. The fact that
this signal was observed after purification of the YFP-tagged FANCM protein, suggests either
this signal comes from a co-purified interaction partner of FANCM or that the used antibody
detected a modified FANCM species with a higher molecular weight. In the first case it would
be interesting to know why this protein got detected by the H3K36me1-specific antibody. The
interaction partner may be methylated by NSD2 and detected by the antibody or it may be
unspecific antibody binding. The second possibility is that FANCM was already modified.
Such a modification might be ubiquitination or sumoylation, which would increase the weight
enough to explain both FANCM species during western blot analysis. Indeed, western blot
with anti-ubiquitin antibody showed an ubiquitination of FANCM, which makes co-purification
and detection of an interaction partner very unlikely. Additionally, the ubiquitinated FANCM
protein must be strongly methylated as well, because the detected anti methyl K antibody signal
is much stronger than the corresponding band on the Ponceau S image. Since the second band
was also observed in samples, where FANCM was expressed without NSD2, this indicates that
endogenous NSD2 enzyme efficiently methylated FANCM in cells.
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Additionally, the effect of somatic missense mutations of histone H3 on the NSD2 methyltrans-
ferase activity was analyzed. In the past years, recurrent mutations at different positions of
the amino-terminal tail of histone H3 were found in pediatric brain and bone malignancies.
Since these positions undergo important posttranslational modifications, abnormalities, such as
alteration of the target residue, may lead to changed histone modifications, protein-protein in-
teractions, chromatin structure and dysregulation of gene transcription. Peptide arrays covering
residues from 32 to 41 of H3 were synthesized. These membranes contain the most prevalent
single missense mutations of histone H3. A comparison of the observed methylation intensities
between the H3K36 control and the somatic missense mutant peptides showed clear discrep-
ancies. However, the different intensities of each mutant peptide were in agreement with the
characterized specificity profile of NSD2. Peptides with a more preferred residue than the na-
tive amino acid, revealed stronger activity and peptides with less preferred amino acids were
weakly methylated. In addition, these arrays were methylated by NSD1 as well, however, the
methylation intensities showed only minor differences compared to the NSD2 variants.
The influence of a K36M mutant peptide on the methyltransferase activity of NSD2 was tested
as well. Different concentrations of H3K36 wild-type peptides were methylated by NSD2 in
presence of various concentrations of K36M-containing peptide. The assay results were analyzed
by the least-squares method. The analysis revealed a competitive inhibition of NSD2 by the
K36M peptide on the K36 substrate. Finally, a KM value of 71µM for methylation of the K36
peptide and a KI value of 47µM for inhibition of the methylation reaction by the K36M peptide
was determined, indicating that the K36M peptide inhibitor binds stronger to NSD2 than to
the K36 peptide substrate. One reason for this is the proper fitting of the M36 side chain in
the hydrophobic pocket, which is probably formed by residues Y1092, M1119, F1177 and Y1179
(corresponding conserved residues were shown to be responsible for interaction to K/M36 in
SETD2 [195]). Additionally, for SETD2 it was shown that the side chain of K36M is further
stabilized by sulfur-aromatic and CH-pi interactions through stacking of the side chain against
the aromatic ring of Y1666. The same might hold true for NSD2, since the enzyme contains a
conserved tyrosine (Y1179) in the catalytic pocket [195].
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4.3 Specificity Analysis of Clr4 and Identification of Novel
Peptide Substrates
In this part of the thesis the substrate specificity profile of Clr4, the Schizosaccharomyces pombe
homolog of the human histone lysine methyltransferase SUV39H1, was characterized. Clr4
catalyzes trimethylation of H3K9, which is important for formation, maintenance and spreading
of heterochromatin. Similar to other H3K9 methyltransferases, such as G9a or SUV39H1, the
specificity profile of Clr4 showed a strong preference for an RK motif (R8 and K9). Furthermore,
Clr4 displayed high specificity at position +3, where it tolerated only glycine (G12).
Next, the interaction partners of Clr4 that contained its substrate sequence motif were se-
lected and tested at the peptide level. The results revealed 3 strongly methylated and 4 weakly
methylated substrate peptides. Since Clr4 and its interaction partners are from S. pombe, a
collaborating laboratory conducted further experiments to investigate the methylation of the
substrate candidates at protein level.
4.4 Development of an Advanced Non-radioactive,
High-throughput PKMT Activity Assay
In this project, a non-radioactive, high-throughput PKMT activity assay was developed by
employing reading domains to recognize methylated lysine residues. This assay overcomes many
disadvantages of other PKMT activity assays, such as the usage of radioactivity or methyl-
specific antibodies. This microplate based assay can be used to screen for novel PKMT inhibitors.
It was investigated if the reading domain, in this case HP1β, is able to detect H3K9 peptides with
different methylation levels. The results showed a good discrimination by the reading domain
between unmethylated and trimethylated H3K9 peptides. In addition, the results demonstrated
that HP1β detected in vitro methylated substrate with a comparable intensity to synthetic
trimethylated H3K9 peptide as well. Finally, the results revealed that this assay can be used to
screen PKMT inhibitors. Using this experimental setting, chaetocin, an inhibitor of SUV39H1,
was tested and an IC50 value of 480 nM of the inhibition of SUV39H1 was calculated. This value
is close to the published IC50 of 600 nM [173]. In conclusion, the newly developed assay is able to
successfully detect peptide and protein methylation with a very good dynamic range and high
sensitivity by employing natural reading domains. In addition, the microplate format allows a
medium- to high-throughput campaign analysis and could therefore be used for PKMT inhibitor
screens.
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5 Conclusions
Protein methyltransferases play an important role in many biological processes. They are also
involved in numerous diseases and cancers. By methylation of target residues the enzymes
are able to influence properties, functions, interactions and localization of their targets. The
characterization of MTases is important to gain deeper insights about these enzymes and their
biological functions. Analysis of the substrate specificity, activity and the identification of novel
substrates, help to provide new detailed information about chemical properties of the substrates
that are recognized by the enzymes. This knowledge could be used to develop inhibitors to
prevent or treat related diseases. Moreover, novel substrates of protein MTases can be identified,
which helps to uncover the regulatory roles of these enzymes in cells. Determination of the
substrate specificity profile and the identification of novel substrates was already successfully
applied for different MTases, such as Dim-5, G9a, SET7/9 and NSD1.
The aim of this study was to characterize the substrate specificity of three important protein
methyltransferases and to identify novel substrates and eventually confirm the methylation and
its consequences in human cells. Specificity analysis of HEMK2, a protein glutamine methyl-
transferase, identified a G-Q-X3-R recognition motif, which is essential for the methylation
activity. Moreover, it was demonstrated that HEMK2 methylates two novel substrates, CHD5
and NUT, in mammalian cells. Both of these targets have important cellular functions. In
addition, several other substrate candidates were methylated at protein and peptide level in
vitro. Furthermore, a Pan-Qme-specific antibody was developed for detecting cellular methyla-
tion. This should be further refined for use in proteomic studies, such as to enrich for proteins
containing methyl glutamine modification.
Similarly, the substrate specificity of NSD2, a protein lysine methyltransferase which methylates
histone H3 at K36, demonstrated that the enzyme recognizes the residues from 33 to 38. Like its
family member NSD1, it also prefers hydrophobic residues surrounding the target lysine. With
the derived motif, numerous potential substrates were identified and methylation of several of
these substrate candidates could be confirmed at peptide level. However, only 3 proteins were
shown to be methylated at protein level in vitro. One potential reason for this discrepancy
in the number of targets between the two assays might be that NSD2 prefers target lysines
surrounded by a hydrophobic motif. This may be not accessible for methylation in a folded
protein. Moreover, methylation of two novel important protein substrates, ATRX and FANCM
were identified in human cells.
Furthermore, the specificity profile analysis of Clr4 identified a crucial „RK“ recognition motif,
as observed for its human homolog SUV39H1 or other H3K9 methyltransferases, such as G9a.
Apart from this RK dipeptide, Clr4 requires a glycine at the position +3 (G12) for proper
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MTase activity. Based on this, the methylation of 6 novel substrates by Clr4 could be shown
at peptide level. In the future, it should be further investigated if Clr4 is able to methylate the
identified peptide substrates at protein level in vitro and in vivo as well, and to study the effects
of methylation on the properties of the putative substrates.
In summary, these novel and important results expand the product portfolio of HEMK2, NSD2
and Clr4. They support the notion that protein methylation is a general PTM both in humans
and lower organisms and hints that many more methylation sites need to be identified by similar
or proteomic approaches. For the future, the biological role of the novel substrates of HEMK2
and NSD2 should be elucidated. The introduced methylation may change the properties, local-
ization or cellular functions of these proteins.
82
6 Materials and Methods
6.1 The Glutamine Methyltransferase HEMK2
6.1.1 Cloning, Site-directed Mutagenesis, Expression and Purification
The bacterial expression pRSF-Duet1 vector containing the full-length murine HEMK2 and
TRM112 genes, the pRSET vector with the human eRF1 gene and the mammalian expression
constructs (pcDNA3-HEMK2 and pcDNA4-TRM112) were kindly provided by Dr. G. L. Xu.
The sequences encoding for the putative human substrate protein domains were amplified from
cDNA of HEK293 cells and cloned into the pGEX-6P-2 vector (GE Healthcare) as GST fusion
proteins (Table 7).
Table 7: List with information of putative novel HEMK2 substrate proteins, which were selected for investiga-
tion of methylation at protein level.
Name Abbreviation
Domain
boundaries
(aa)
NCBI accession
number
5-aminolevulinate synthase,
erythroid-specific, mitochondrial
ALAS2 360 – 533 NP_000023.2
ADP-ribosylation factor-like protein 2 ARL2 2 – 184 NP_001658.2
Histone-lysine N-methyltransferase
ASH1L
ASH1L 1119 – 1333 NP_060959.2
AMP deaminase 2 AMPD2 2 – 135 NP_001244289.1
Ankyrin repeat domain-containing
protein 34A
ANKRD34A 5 – 235 NP_001034977.1
ATP-binding cassette sub-family A
member 2
ABCA2 168 – 403 NP_997698.1
BEN domain-containing protein 7 BEND7 9 – 282 XP_011517694.1
Cadherin-23 CDH23 3001 – 3353 NP_071407.4
CD97 antigen CD97 197 – 529 NP_510966.1
Chromodomain-helicase-DNA-
binding protein 5
CHD5 1234 – 1530 NP_056372.1
Collagen alpha-1(XIX) chain COL19A1 344 – 577 NP_001849.2
Collagen alpha-6(IV) chain COL4A6 1464 – 1690 NP_001838.2
C-X-C chemokine receptor type 3 CXCR3 249 – 343 NP_001136269.1
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Cytochrome P450 4F11 CYP4F11 7 – 140 NP_001122404.1
D(3) dopamine receptor DRD3 11 – 274 NP_000787.2
DNA polymerase subunit gamma-1 POLG 154 – 387 NP_001119603.1
DNA repair protein REV1 REV1 568 – 818 NP_057400.1
E3 ubiquitin-protein ligase HUWE1 HUWE1 3622 – 3945 NP_113584.3
E3 ubiquitin-protein ligase RNF220 RNF220 282 – 440 NP_060620.2
F-box only protein 30 FBXO30 453 – 661 NP_115521.3
F-box/LRR-repeat protein 15 FBXL15 1 – 300 NP_077302.3
Gamma-aminobutyric acid receptor
subunit delta
GABRD 279 – 439 NP_000806.2
Gamma-aminobutyric acid receptor
subunit rho-2
GABRR2 223 – 465 P28476
GH3 domain-containing protein GHDC 325 – 529 NP_115873.1
Glucokinase regulatory protein GCKR 360 – 613 NP_001477.2
Glycogenin-2 GYG2 3 – 239 NP_003909.2
Guanine nucleotide-binding protein
subunit alpha-12
GNA12 42 – 366 NP_031379.2
Endogenous retroviral sequence K 6 ERVK6 1202 – 1419 Q9WJR5
HERV-K_5q33.3 provirus ancestral Pol
protein
HERVK5 252 – 495 NW_007925255.1
Kinesin-like protein KIF23 KIF23 113 – 370 NP_612565.1
Latent-transforming growth factor
beta-binding protein 4
LTBP4 13 – 381 NP_001036009.1
Leucine-rich repeat-containing protein 41 LRRC41 410 – 636 NP_006360.3
Leukotriene-B(4) omega-hydroxylase 1 CYP4F2 121 – 360 NP_001073.3
Leukotriene-B(4) omega-hydroxylase 2 CYP4F3 109 – 343 NP_000887.2
Mediator of RNA polymerase II
transcription subunit 24
MED24 730 – 985 NP_055630.2
Neuropeptide W NPW 17 – 157 NP_001092926.2
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Pleckstrin PLEK 2 – 350 NP_002655.2
PR domain zinc finger protein 8 PRDM8 12 – 195 NP_001092873.1
Probable E3 ubiquitin-protein ligase
HERC3
HERC3 122 – 460 NP_055421.1
Protamine-2 PRM2 1 – 102 P04554
Protein NUT NUT 867 – 1132 NP_786883.1
Protein transport protein Sec24C SEC24C 702 – 970 NP_004913.2
Ras-related protein Rab-12 RAB12 1 – 233 NP_001020471.2
Rho guanine nucleotide exchange factor
10
ARHGEF10 1107 – 1343 NP_055444.2
Ribosomal RNA processing protein 1
homolog A
RRP1 219 – 461 NP_003674.1
Serine/arginine repetitive matrix
protein 4
SRRM4 89 – 334 NP_919262.2
Solute carrier family 25 member 47 Solcar1 2 – 299 NP_997000.2
SPARC-related modular calcium-binding
protein 1
SMOC1 13 – 217 NP_001030024.1
Sterile alpha motif domain-containing
protein 7
SAMD7 71 – 416 Q7Z3H4
Sushi, von Willebrand factor type A,
EGF and pentraxin domain-containing
protein 1
SVEP1 6 – 239 NP_699197.3
Tetratricopeptide repeat protein 9B TTC9B 42 – 229 NP_689692.2
TNFAIP3-interacting protein 2 TNIP2 1 – 417 NP_077285.3
Transforming growth factor beta-3 TGFB3 159 – 405 NP_003230.1
Unconventional myosin-XVIIIa MYO18A 105 – 355 NP_510880.2
WD40 repeat-containing protein SMU1 SMU1 5 – 511 NP_060695.2
Zinc finger and SCAN domain-containing
protein 10
ZSCAN10 364 – 521 Q96SZ4
Zinc finger protein ZFPM1 ZFPM1 1 – 264 NP_722520.2
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For bacterial expression, the plasmids were transformed into E.coli BL21-CodonPlus (DE3)
cells (Novagen, USA). These were grown in LB medium at 37 `C until an OD600 of 0.6 to 0.8
was reached. Protein expression was induced with 1 mM isopropyl-β-D-thiogalactopyranoside
(IPTG). The culture was then either shifted to 30 `C for 4 h or to 20 `C over night (14 to 16 h).
Afterwards, the cells were harvested by centrifugation at 4.500 rpm, washed once with STE
buffer (10mM Tris-HCl pH8.0, 1mM EDTA and 100mM NaCl) and the cell pellet was stored
at 20 `C until purification.
For purification the cell pellet was thawed on ice, resuspended in affinity tag-specific sonication
buffer and lysed by sonication. Next, the lysate was centrifuged at 18.000 rpm for 90min at 4 `C
and depending on the affinity tag, the supernatant was passed through Glutathione Sepharose
4B (GE Healthcare) or Nickel-Nitrilotriacetic acid (Ni-NTA; Genaxxon) resin. Afterwards, the
bound protein was washed with sonication buffer. For GST-tagged proteins, the beads were
additionally washed with washing buffer containing high amounts of salt. The bound protein
was eluted with similar buffers containing excess of either glutathione (for GST purification) or
imidazole (for Ni-NTA purification), and then dialyzed against low glycerol dialysis buffer 1 for
3 h and afterwards overnight against high glycerol dialysis buffer 2. The composition of the used
buffers are shown in Table 8.
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Table 8: Buffers used for GST-fused (left column), His6-fused (middle column) and MBP-fused protein purifi-
cation (right column).
GST-Tag Purification His6-Tag Purification MBP-Tag Purification
Sonication buffer (pH 7.5) Sonication buffer (pH 7.5) Sonication buffer (pH 7.5)
50mM Tris 30mM KPI buffer 30mM KPI buffer
150mM NaCl 500mM KCl 500mM KCl
1mM DTT 0.2mM DTT 0.2mM DTT
— 1mM EDTA 1mM EDTA
5% Glycerol 10% Glycerol 10% Glycerol
Washing buffer (pH 8.0) 0.5M KPI buffer (pH 7.2) 0.5M KPI buffer (pH 7.2)
50mM Tris 358.5mL 1M K2HPO4 358.5mL 1M K2HPO4
500mM NaCl 142.5mL 1M KH2PO4 142.5mL 1M KH2PO4
1mM DTT 500mL H2O 500mL H2O
5% Glycerol — —
Elution buffer (pH 8.0) Elution buffer (pH 7.2) Elution buffer (pH 7.5)
40mM reduced
Glutathione 220mM Imidazole
20mM Maltose
Monohydrate
in Washing buffer in Sonication buffer in Sonication buffer
Dialysis buffer 1 (pH 7.4) Dialysis buffer 1 (pH 7.2) Dialysis buffer 1 (pH 7.5)
20mM Tris 20mM HEPES 20mM HEPES
100mM KCl 200mM KCl 200mM KCl
0.5mM DTT 0.2mM DTT 0.2mM DTT
— 1mM EDTA 1mM EDTA
10% Glycerol 10% Glycerol 10% Glycerol
Dialysis buffer 2 (pH 7.4) Dialysis buffer 2 (pH 7.2) Dialysis buffer 2 (pH 7.5)
20mM Tris 20mM HEPES 20mM HEPES
500mM KCl 200mM KCl 200mM KCl
0.2mM DTT 0.2mM DTT 0.2mM DTT
— 1mM EDTA 1mM EDTA
60% Glycerol 65% Glycerol 65% Glycerol
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The target glutamine mutation of the target substrates was performed by site-directed mutage-
nesis using PCR-megaprimers according to the protocol of Jeltsch & Lanio [196]. In addition to
the glutamine to arginine mutation, silent mutations were introduced to allow the identification
of the plasmids containing the mutated targets by specific restriction sites. The successful mu-
tagenesis of the novel substrates was confirmed by restriction digest and DNA sequencing. In
Table 9 all methylated substrates with the target glutamine to arginine mutations are listed.
Table 9: Target glutamine to arginine mutations of methylated HEMK2 substrates.
Name Abbreviation Target Qmutation
AMP deaminase 2 AMPD2 Mut Q6R
Ankyrin repeat domain-containing protein 34A ANKRD34A Mut Q15R
ATP-binding cassette sub-family A member 2 ABCA2 Mut Q302R
Chromodomain-helicase-DNA-binding protein 5 CHD5 Mut Q1390R
GH3 domain-containing protein GHDC Mut Q489R
Histone-lysine N-methyltransferase ASH1L ASH1L Mut Q1220R
Protein NUT NUT Mut Q1046R
Rho guanine nucleotide exchange factor 10 ARHGEF10 Mut Q1313R
Ribosomal RNA processing protein 1 homolog A RRP1 Mut Q427R
Transforming growth factor beta-3 TGFB3 Mut Q293R
Zinc finger and SCAN domain-containing protein 10 ZSCAN10 Mut Q428R
6.1.2 Synthesis of Peptide SPOT Arrays
Peptide array were synthesized by an Autospot peptide array synthesizer (Intavis AG, Köln)
using the SPOT synthesis method [197]. Each spot had a diameter of 2mm and contained approx-
imately 9 nmol of peptide (Autospot Reference Handbook, Intavis AG). The successful synthesis
of each peptide array was confirmed by bromophenol blue staining of the membranes [179].
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6.1.3 In vitro Methylation of the Peptide SPOT Arrays
All peptide arrays were washed for 10min in methylation buffer containing 10mM Tris (pH 7.6),
50mM KCl, 10mM Mg(OAc)2 and 1mM DTT. Then, the membranes were incubated for 60min
in methylation buffer containing 1.3µM HEMK2 and 0.76µM labeled [methyl-3H]-SAM (Perkin
Elmer) at 25 `C. Afterwards, the arrays were washed five times with 50mM NH4HCO3 and 1%
SDS and then incubated for 5min in Amplify NAMP100V solution (GE Healthcare). The mem-
branes were exposed to HyperfilmTM high performance autoradiography films (GE Healthcare)
in the dark, for several days at 80 `C. Film development was performed on an Optimus TR
developing machine. The developed films were scanned and the intensities were analyzed with
the PhoretixTM Array software. Background substraction was performed by measuring an area
on the array, outside of the spot-containing region. The intensities of the spots were quantified
and the normalization was performed in Microsoft Office Excel by presenting all spot intensities
relative to the minimum and the maximum intensity spot in each array. The used equation for
calculating the normalized intensity of each spot was defined as:
Spot intensity (normalized)  
 Spot intensity (raw) Min intensity (raw)
 Max intensity (raw) Min intensity (raw)
Information of synthesized peptides on array A identified from search profile 1:
Table 10: List of putative novel HEMK2 substrates identified in Scansite searches using the stringent specificity
profile as shown in Table 1. The predicted target glutamine is printed in bold. The position of the
corresponding peptide spots in Figure 14A are indicated.
Name SwissProt no.
Position
on Array
Target Q
Position Sequence
eFR1 WT P62495 A1 185 KKHGRGGQSALRFAR
eRF1 Mutant A2 A185 KKHGRGGASALRFAR
B-cell CLL/lymphoma 9-like
protein
Q86UU0 A3 755 LSPPMGQSGLREVDP
Coiled-coil alpha-helical rod
protein 1
Q8TD31 A4 667 ARKEEGQRLARRLQE
C-C chemokine receptor type 10 P46092 A5 188 DGQREGQRRCRLIFP
B-cell receptor CD22 P20273 A6 116 HLNDSGQLGLRMESK
Uncharacterized protein C7orf63 A5D8W1 A7 255 DPDPSGQLLFRSSEI
Chromodomain-helicase-DNA-
binding protein 5
Q8TDI0 A8 1390 EERPEGQSGRRQSRR
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Chondroitin sulfate
glucuronyltransferase
Q9P2E5 A9 137 LLYFTGQRGARAPAG
UMP-CMP kinase 2, mitochondrial Q5EBM0 A10 171 EADPRGQLWQRLWEV
Collagen alpha-5(VI) chain A8TX70 A11 1559 SRGREGQRGLRGVSG
Collagen alpha-1(XIX) chain Q14993 A12 407 PPGKEGQRGRRGKTG
Cytochrome P450 1B1 Q16678 A13 37 ATVHVGQRLLRQRRR
Carnitine O-palmitoyltransferase 2,
mitochondrial
P23786 A14 33 AGSGPGQYLQRSIVP
C-X-C chemokine receptor type 3 P49682 A15 295 LLVSRGQRRLRAMRL
Disks large homolog 5 Q8TDM6 A16 1108 KVDELGQKRRRPKSA
Eukaryotic peptide chain release
factor subunit 1
P62495 A17 185 KHGRGGQSALRFARL
Protein FAM113B Q96HM7 A18 47 RLLTPGQLRARGELN
Protein FAM123C Q8N944 A19 708 GSGLFGQRWARGPDM
F-box/LRR-repeat protein 2 Q9UKC9 A20 414 TAVAGSGQRLCRCCV
Extracellular matrix protein
FRAS1
Q86XX4 A21 265 LRCGKGQSRARRHGQ
FRAS1-related extracellular matrix
protein 3
P0C091 B1 1991 RLPVGGQLGARFPTT
Glycogenin-2 O15488 B2 57 GALVLGQSLRRHRLT
Probable E3 ubiquitin-protein
ligase HERC6
Q8IVU3 B3 54 GDNSRGQLGRRGAQR
Hermansky-Pudlak syndrome 1
protein
Q92902 B4 686 LVQQAGQLARRLWEA
E3 ubiquitin-protein ligase
HUWE1
Q7Z6Z7 B5 3783 QMVREGQRARRQQQA
Intersectin-1 Q15811 B6 886 TVPSAGQLRQRSAFT
Jerky protein homolog O75564 B7 431 GSSCPGQLRQRQAAS
Uncharacterized protein KIAA1908 Q96PY0 B8 202 GLSHLGQSLCRTVKE
Laminin subunit gamma-3 LAMC3 Q9Y6N6 B9 781 THCPPGQRGRRCEVC
Laminin subunit gamma-3 LAMC3 Q9Y6N6 B10 287 GPDVAGQLACRCQHN
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Mineralocorticoid receptor P08235 B11 916 CPNNSGQSWQRFYQL
Mediator of RNA polymerase II
transcription subunit 12
Q93074 B12 813 LGGEDGQKRRRNRPE
Nucleotide-binding oligomerization
domain-containing protein 1
Q9Y239 B13 669 QSQKVGQLAARGICA
Neuropeptide W Q8N729 B14 137 DFSGAGQRLRRDVSR
Nuclear receptor subfamily 5 group
A member 2
O00482 B15 498 QTEKFGQLLLRLPEI
Pleckstrin homology
domain-containing family G
member 4B
Q96PX9 B16 1002 NLKEQGQLRCRDEFI
PRAME family member 10 O60809 B17 15 LLELAGQSLLRNQFL
PRAME family member 13 Q5VWM6 B18 15 LLELAGQSLLRDQAL
PRAME family member 14 Q5SWL7 B19 15 LLELAGQSLLRDQAL
PRAME family member 16 Q5VWM1 B20 15 LLELAGQSLLRNQFL
PRAME family member 17 Q5VTA0 B21 15 LLELAGQSLLRNQFL
PRAME family member 18 Q5VWM3 C1 15 LLELAGQSLLRDQAL
PRAME family member 1 O95521 C2 15 LLELAGQSLLRDQAL
PRAME family member 2 O60811 C3 15 LLELAGQSLLRDQAL
Patched domain- containing
protein 3
Q3KNS1 C4 314 GSLGMGQLLLRAKAM
Probable peptidyl-tRNA hydrolase Q86Y79 C5 55 GMAVLGQLARRLGVA
E3 ubiquitin-protein ligase RLIM Q9NVW2 C6 208 VPPTRGQRRARSRSP
Ribosomal RNA processing protein
1 homolog A
P56182 C7 427 QPRGRGQRGARQRRR
RuvB-like 2 Q9Y230 C8 49 SQGMVGQLAARRAAG
Sodium-dependent neutral amino
acid transporter B(0)AT1
Q695T7 C9 94 LEFAIGQRLRRGSLG
Protein transport protein Sec24C P53992 C10 819 YTSCAGQRRLRIHNL
Protein transport protein Sec24D O94855 C11 757 YTTISGQRRLRIHNL
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Scavenger receptor class B
member 1
Q8WTV0 C12 472 SQVGAGQRAARADSH
N-lysine methyltransferase SET8 Q9NQR1 C13 28 AAVVAGQRRRRLGRR
Transcription elongation factor
SPT6
Q7KZ85 C14 116 VKVKRGQKYRRVK
Probable leucine-tRNA ligase,
mitochondrial
Q15031 C15 610 FRLPSGQYLQREEVD
TNFAIP3-interacting protein 2 Q8NFZ5 C16 29 LYHEAGQRLRRLQDQ
Thymidine phosphorylase P19971 C17 429 LLVDVGQRLRRGTPW
RanBP-type and C3HC4-type zinc
finger-containing protein 1
Q9BYM8 C18 105 QQWVIGQRLARDQET
Vacuolar protein sorting-associated
protein 72 homolog
Q15906 C19 154 VQERQGQSRRRKGPH
DDB1- and CUL4- associated
factor 11
Q8TEB1 C20 119 VELATGQLGLRRAAQ
Y+L amino acid transporter 1 Q9UM01 C21 400 GLSIVGQLYLRWKEP
Y+L amino acid transporter 2 Q92536 D1 408 GLSVVGQLYLRWKEP
Zinc finger homeobox protein 3 Q15911 D2 2946 SGDRPGQKRFRTQMT
Zinc finger matrin-type protein 3 Q9HA38 D3 193 ESSELGQRRARKEGN
free space D4
free space D5
free space D6
AMP deaminase 2 Q01433 D7 6 RGQGLFRLRSRCFLH
Anthrax toxin receptor 1 Q9H6X2 D8 28 VLICAGQGGRREDGG
Apolipoprotein M O95445 D9 139 MLNETGQGYQRFLLY
ADP-ribosylation factor-like
protein 2
P36404 D10 70 IWDVGGQKSLRSYWR
ADP-ribosylation factor-like
protein 6
Q9H0F7 D11 73 VFDMSGQGRYRNLWE
BEN domain-containing protein 7 Q8N7W2 D12 78 SGQFSGQYGTRSRTF
Biotin-protein ligase P50747 D13 417 GEIKSGQLSLRFVSS
Cadherin-23 Q9H251 D14 3263 GDHSPGQGSLRFRHK
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CD97 antigen P48960 D15 376 KNVTMGQSSARMKLN
Cyclin-dependent kinase 10 Q15131 D16 274 KLPLVGQYSLRKQPY
Protein CIP2A Q8TCG1 D17 39 LEVISGQKLTRLFTS
Uncharacterized protein C12orf56 Q8IXR9 D18 193 KLSLHGQGAFRPLPS
Leukotriene-B(4)
omega-hydroxylase 1
P78329 D19 254 YLTPDGQRFRRACRL
Leukotriene-B(4)
omega-hydroxylase 2
Q08477 D20 254 YLTPDGQRFRRACRL
Cytochrome P450 4F11 Q9HBI6 D21 254 YLTPDGQRFRRACHL
Putative uncharacterized protein
encoded LINC00526
Q96FQ7 E1 29 GGLPPGQYATRMTGQ
Cytoplasmic tRNA 2-thiolation
protein 2
Q2VPK5 E2 446 WAQRCGQGACRREDP
DCC-interacting protein 13-alpha Q9UKG1 E3 474 QAKAFGQGGRRTNPF
DNA polymerase subunit gamma-1 P54098 E4 330 PPTKQGQKSQRKARR
D(3) dopamine receptor P35462 E5 144 YQHGTGQSSCRRVAL
FERM, RhoGEF and pleckstrin
domain-containing protein 1
Q9Y4F1 E6 407 AESPGGQSCRRGKEP
F-box only protein 18 Q8NFZ0 E7 54 KRGSRGQGSQRCIPE
F-box only protein 30 Q8TB52 E8 525 FTFVCGQLFRRKEFS
F-box/LRR-repeat protein 15 Q9H469 E9 126 ALGGCGQLSRRALGA
von Willebrand factor A
domain-containing protein 7
Q9Y334 E10 135 DAERLGQGRARLVGA
GH3 domain-containing protein Q8N2G8 E11 489 RVHLVGQGAFRALRA
Guanine nucleotide-binding protein
subunit alpha-12
Q03113 E12 231 MVDVGGQRSQRQKWF
G-protein coupled receptor 98 Q8WXG9 E13 3490 FIWEMGQSSFRYFQS
Solute carrier family 25 member 47 Q6Q0C1 E14 252 QADGQGQRRYRGLLH
E3 ubiquitin-protein ligase
HECW1
Q76N89 E15 199 DETVQGQGSRRLISF
Probable E3 ubiquitin-protein
ligase HERC3
Q15034 E16 351 WAAHSGQLSARADRF
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Iroquois-class homeodomain protein
IRX-2
Q9BZI1 E17 405 NAALQGQGLLRYNSA
Serine/arginine repetitive matrix
protein 4
A7MD48 E18 215 RSPEEGQKSRRRHSR
Keratin-associated protein 1-1 Q07627 E19 161 RPSYCGQSCCRPVCC
Keratin-associated protein 1-3 Q8IUG1 E20 161 RPSYCGQSCCRPVCC
Keratin-associated protein 1-4 P0C5Y4 E21 105 RPSYCGQSCCRPACC
Keratin-associated protein 1-5 Q9BYS1 F1 161 RPSYCGQSCCRPVCC
Leucine-rich repeat and
immunoglobulin-like
domain-containing nogo
receptor-interacting protein 3
P0C6S8 F2 581 PAAAAGQGGARKFNM
Protein LZIC Q8WZA0 F3 105 AKKQPGQLRTRLAEM
Melanoma-associated antigen 8 P43361 F4 5 GQKSQRYKAEEGLQA
Microtubule-associated
serine/threonine-protein kinase 4
O15021 F5 2449 SPSATGQSSFRSTAL
Melanin-concentrating hormone
receptor 1
Q99705 F6 40 GACAPGQGGRRWRLP
Netrin-4 Q9HB63 F7 369 QHNTEGQYCQRCKPG
Protein NUT Q86Y26 F8 1046 HHASGGQGSQRASHL
Otopetrin-3 Q7RTS5 F9 504 SLLELGQGLQRASLA
Serine/threonine-protein
phosphatase 2A regulatory subunit
B” subunit gamma
Q969Q6 F10 185 LYDVAGQGYLRESDL
Pleckstrin homology-like domain
family B member 1
Q86UU1 F11 828 ERELAGQGLLRSKAE
Pleckstrin P08567 F12 107 KCIEGGQKFARKSTR
PR domain zinc finger protein 8 Q9NQV8 F13 111 AYIKNGQLFYRSLRR
Ras-related protein Rab-12 Q6IQ22 F14 28 PALSGGQGRRRKQPP
E3 ubiquitin-protein ligase RNF25 Q96BH1 F15 439 PRLPRGQGAYRPGTR
Sterile alpha motif
domain-containing protein 7
Q7Z3H4 F16 179 FEESWGQRCRRLRKN
Semaphorin-4G Q9NTN9 F17 607 MGLSDGQGGYRVGVD
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Histone-lysine N-methyltransferase
SETDB1
Q15047 F18 415 LEKKQGQLRTRPNMG
SH2B adapter protein 2 O14492 F19 589 PRPVEGQLSARSRSN
Putative E3 ubiquitin-protein ligase
SH3RF2
Q8TEC5 F20 506 GPGTLGQGSLRKGRS
Somatoliberin P01286 F21 47 YRKVLGQLSARKLLQ
SWI/SNF-related matrix-associated
actin-dependent regulator of
chromatin subfamily D member 1
Q96GM5 G1 46 MGPAPGQGLYRSPMP
Transforming growth factor beta-3 P10600 G2 293/296 RLDNPGQGGQRKKRA
Transforming growth factor beta-3 P10600 G3 296 RLDNPGAGGQRKKRA
Transforming growth factor beta-3 P10600 G4 293 RLDNPGQGGARKKRA
Tetratricopeptide repeat
protein 9B
Q8N6N2 G5 73 AFKAEGQRCYREKKF
E3 ubiquitin-protein ligase UBR5 O95071 G6 1247 KTLIAGQKSARLDLL
Uromodulin P07911 G7 208 WYRFVGQGGARMAET
USP6 N-terminal-like protein Q92738 G8 750 RPETQGQSWTRDASR
Putative zinc finger protein 852 Q6ZMS4 G9 122 EGVLKGQKSYRCDEC
Zinc finger B-box
domain-containing protein 1
A8MT70 G10 628 RITLAGQKSQRPSTA
Probable palmitoyltransferase
ZDHHC1
Q8WTX9 G11 37 SPELQGQRSRRNGWS
Zinc finger homeobox protein 2 Q9C0A1 G12 2065 VPDGMGQRRYRTQMS
Zinc finger protein 142 P52746 G13 143 KAVDKGQGAQRLEGD
Zinc finger protein 167 Q9P0L1 G14 380 EGVLKGQKSYRCDEC
Zinc finger protein 407 Q9C0G0 G15 503 QEAEQGQGSARPPDS
Zinc finger protein 787 Q6DD87 G16 352 VCSSCGQSYYRAGGE
Zinc finger and SCAN
domain-containing protein 10
Q96SZ4 G17 428 LCSHCGQSFQRRSSL
eFR1 WT P62495 G18 185 KKHGRGGQSALRFAR
eRF1 Mutant G19 A185 KKHGRGGASALRFAR
95
6 Materials and Methods
Information of synthesized peptides on array B identified from search profile 2:
Table 11: List of putative novel HEMK2 substrates identified in Scansite searches using the relaxed specificity
profile as shown in Table 1. The predicted target glutamine is printed in bold. The position of the
corresponding peptide spots in Figure 14B are indicated.
Name SwissProt no.
Position
on Array
Target Q
Position Sequence
eRF1 WT P62495 A1 185 KHGRGGQSALRFARL
eRF1 Mutant A2 A185 KHGRGGASALRFARL
Chromodomain-helicase-DNA-
binding protein 5 WT
Q8TDI0 A3 1390 EERPEGQSGRRQSRR
Chromodomain-helicase-DNA-
binding protein 5 Mutant
A4 A1390 EERPEGASGRRQSRR
DNA-3-methyladenine glycosylase P29372 A5 20 FCRRMGQKKQRPARA
ATP-binding cassette sub-family A
member 2
Q9BZC7 A6 302 DAVCSGQAAARARRF
Abhydrolase domain-containing
protein 3
Q8WU67 A7 92 CWEGRGQTLLRPFIT
Acyl-CoA synthetase family
member 3, mitochondrial
Q4G176 A8 465 VVFKDGQYWIRGRTS
Disintegrin and metalloproteinase
domain-containing protein 15
Q13444 A9 199 PEHPLGQRHIRRRRD
Neuroblast
differentiation-associated protein
AHNAK
Q09666 A10 98 RSPEPGQTWTREVFS
Ankyrin repeat domain-containing
protein 34A
Q69YU3 A11 15 LLRAVGQGKLRLARL
Adenomatous polyposis coli
protein 2
O95996 A12 814 SPFLQGQALARTPPT
Rho guanine nucleotide exchange
factor 10
O15013 A13 1313 LVVCGGQGHRRVHRK
ADP-ribosylation factor-like
protein 1
P40616 A14 71 VWDLGGQTSIRPYWR
ADP-ribosylation factor-like
protein 3
P36405 A15 71 VWDIGGQRKIRPYWK
Histone-lysine N-methyltransferase
ASH1L
Q9NR48 A16 1220 AEKFCGQKKRRHSFE
Ancient ubiquitous protein 1 Q9Y679 A17 320 VAKELGQTGTRLTPA
Brain-specific angiogenesis
inhibitor 1
O14514 A18 1002 ALILIGQTQTRNKVV
Protein BTG1 P62324 A19 82 MDPLIGQAAQRIGLS
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Complement C1q tumor necrosis
factor-related protein 2
Q9BXJ5 A20 262 GLVHNGQYRIRTFDA
Uncharacterized protein C1orf170 Q5SV97 A21 426 NKPGSGQASARPSAP
Voltage-dependent T-type calcium
channel subunit alpha-1H
O95180 B1 2253 KGERWGQASCRAEHL
Calcium-binding and coiled-coil
domain-containing protein 1
Q9P1Z2 B2 330 MKDTLGQAQQRVAEL
Cathepsin Z Q9UBR2 B3 31 LYFRRGQTCYRPLRG
Uncharacterized protein C2orf50 Q96LR7 B4 137 LDTPLGQTLIRMDFF
Uncharacterized protein C3orf30 Q96M34 B5 86 GHSTPGQAGRRASNP
Coiled-coil domain-containing
protein 157
Q569K6 B6 494 SEREQGQCQLRAQQE
Glucose-fructose oxidoreductase
domain-containing protein 1
Q9NXC2 B7 92 WGVRKGQRHIRYGMC
Uncharacterized protein C9orf84 Q5VXU9 B8 1399 KVPGRVDGQTRLRFF
UPF0614 protein C14orf102 Q9H7Z3 B9 515 LFDDIGQSLIRLSSH
Cyclic nucleotide-gated cation
channel beta-1
Q14028 B10 878 GAATAGQTYYRSCMD
Collagen alpha-2(I) chain P08123 B11 212 ENGTPGQTGARGLPG
Collagen alpha-6(IV) chain Q14031 B12 1676 ETLKAGQLHTRVSRC
Collagen alpha-1(IX) chain P20849 B13 812 ENGFPGQMGIRGLPG
Collagen alpha-1(XVI) chain Q07092 B14 854 RDGQQGQTGLRGTPG
Collagen alpha-1(XIX) chain Q14993 B15 407 PPGKEGQRGRRGKTG
Copine-1 Q99829 B16 479 LHTRSGQAAARDIVQ
Putative uncharacterized protein
encoded LINC00526
Q96FQ7 B17 29 GGLPPGQYATRMTGQ
Cone-rod homeobox protein O43186 B18 111 QQPPGGQAKARPAKR
Caskin-2 Q8WXE0 B19 1943 GTVGPGQAQQRLEQT
Protein FAM207A Q9NSI2 B20 216 PLVAIGQTLARQMQL
Extracellular matrix protein 1 Q16610 B21 30 GFTATGQRQLRPEHF
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Histone-lysine N-methyltransferase
EHMT2
Q96KQ7 C1 989 SNCLCGQLSIRCWYD
Echinoderm microtubule-associated
protein-like 3
Q32P44 C2 298 GPGGGGQRHYRGHTD
Histone acetyltransferase p300 Q09472 C3 233 SPQMGGQTGLRGPQP
DNA excision repair protein
ERCC-6
Q03468 C4 1444 QAHTDGQASTREILQ
Protein FAM150B Q6UX46 C5 35 REPADGQALLRLVVE
F-box/WD repeat-containing
protein 7
Q969H0 C6 218 LRAANGQGQQRRRIT
Zinc finger protein ZFPM1 Q8IX07 C7 100 PVVQDGQRRIRARLS
Gamma-aminobutyric acid receptor
subunit delta
O14764 C8 412 AARSGGQGGIRARLR
Gamma-aminobutyric acid receptor
subunit rho-2
P28476 C9 454 KGLLKGQTGFRIFQN
Glucokinase regulatory protein Q14397 C10 529 LQRFSGQSKARCIES
Glial cell line-derived neurotrophic
factor
P39905 C11 176 VSDKVGQACCRPIAF
Golgin subfamily A member 2-like
protein 2
Q9H5Y0 C12 85 STSARGQCQRRSTGR
Golgin subfamily A member 2-like
protein 3
Q8NCE8 C13 85 STSARGQCQRRSTGR
Solute carrier family 25 member 47 Q6Q0C1 C14 252 QADGQGQRRYRGLLH
5-aminolevulinate synthase,
erythroid-specific, mitochondrial
P22557 C15 444 LKGEEGQALRRAHQR
Hepatocyte growth factor P14210 C16 32 IPYAEGQRKRRNTIH
Integrator complex subunit 1 Q8N201 C17 1334 PEQPIGQGRIRVGTQ
IQ domain-containing protein C Q4KMZ1 C18 426 EPSHEGQKKQRTIPW
Integrin alpha-5 P08648 C19 257 INLVQGQLQTRQASS
Uncharacterized protein KIAA1908 Q96PY0 C20 202 GLSHLGQSLCRTVKE
Kinesin-like protein KIF23 Q02241 C21 284 EVFWRGQKKRRIANT
Kinesin-like protein KIF7 Q2M1P5 D1 763 AELSEGQRQLRELEG
Kinesin-like protein KIF7 Q2M1P5 D2 837 MRQQQGQLQRRLREE
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Laminin subunit alpha-5 O15230 D3 559 CDPDTGQCRCRVGFE
Laminin subunit alpha-5 O15230 D4 695 CDPRSGQCSCRPRVT
Laminin subunit alpha-5 O15230 D5 1549 CDTDSGQCKCRPNVT
Laminin subunit alpha-5 O15230 D6 2087 CHPQSGQCHCRPGTM
Laminin subunit beta-1 P07942 D7 528 CFAESGQCSCRPHMI
Laminin subunit beta-1 P07942 D8 791 CDPNGGQCQCRPNVV
Laminin subunit beta-2 P55268 D9 540 CDEGTGQCHCRQHMV
Laminin subunit beta-2 P55268 D10 849 CEKTSGQCLCRTGAF
Laminin subunit beta-2 P55268 D11 1113 CNEFTGQCHCRAGFG
La-related protein 4B Q92615 D12 459 QTRQAGQTRTRIQNP
Leucine-rich repeat-containing
protein 41
Q15345 D13 517 LRALSGQAGCRLRAL
Latent-transforming growth factor
beta-binding protein 4
Q8N2S1 D14 59 CRCCPGQTSRRSRCI
Nuclear body protein SP140 Q13342 D15 851 KYKDFGQMGFRLEAE
Membrane-associated guanylate
kinase, WW and PDZ
domain-containing protein 2
Q86UL8 D16 1305 ELSACGQKKQRLGEQ
Mediator of RNA polymerase II
transcription subunit 24
O75448 D17 827 YSSHKGQASTRQKKR
Midnolin Q504T8 D18 367 ASLLQGQSQIRMCKP
Histone-lysine N-methyltransferase
MLL2
O14686 D19 4588 GCPVNGQSQLRGAFG
Putative helicase MOV-10 Q9HCE1 D20 138 HEARDGQLLIRLDLN
M-phase inducer phosphatase 3 P30307 D21 249 KKYFSGQGKLRKGLC
Unconventional myosin-XVIIIa Q92614 E1 248 DRGPEGQACRRVVHF
Myosin light chain kinase 2,
skeletal/cardiac muscle
Q9H1R3 E2 136 KKAAEGQAAARRGSP
Endonuclease 8-like 3 Q8TAT5 E3 256 KRPNCGQCHCRITVC
Ras GTPase-activating protein
nGAP
Q9UJF2 E4 867 RQNSTGQAQIRKVDQ
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C2 calcium-dependent
domain-containing protein 4C
Q8TF44 E5 319 AEYEAGQARLRVHLL
Obscurin-like protein 1 O75147 E6 1327 GCRMCGQRKARTCVS
Occludin/ELL domain-containing
protein 1
Q9H607 E7 23 ELQTLGQAARRPPPP
Olfactory receptor 4K17 Q8NGC6 E8 236 NHSPTGQSKARSTLT
Polyadenylate-binding protein 5 Q96DU9 E9 378 SKPLHVTLGQARRRC
Paralemmin-3 A6NDB9 E10 76 PQSPEGQAQARIRNL
Protocadherin-16 Q96JQ0 E11 1784 DVGANGQLQYRILDG
Protocadherin-17 O14917 E12 386 DSGKNGQLQCRVLGG
Protocadherin gamma-C5 Q9Y5F6 E13 729 GDGGGGQCCRRQDSP
Peroxisomal biogenesis factor 3 P56589 E14 34 ILGKYGQKKIREIQE
Phosphoinositide 3-kinase
regulatory subunit 5
Q8WYR1 E15 419 GHRRPGQKFIRIYKL
Phosphatidylinositol
N-acetylglucosaminyl- transferase
subunit Q
Q9BRB3 E16 558 LEAERGQAGLRELLA
Pleckstrin homology
domain-containing family G
member 5
O94827 E17 725 TFQASGQALCRGWVD
HERV-K_5q33.3 provirus ancestral
Pol protein
P10266 E18 385 IATLIGQTRLRITKL
HERV-K_1q22 provirus ancestral
Pol protein
P63135 E19 385 IATLIGQTRLRIIKL
HERV-K_11q22.1 provirus
ancestral Pol protein
P63136 E20 385 IATLIGQTRLRIIKL
HERV-K_3q27.3 provirus ancestral
Pol protein
Q9UQG0 E21 385 IATLIGQTRLRIIKL
HERV-K_7p22.1 provirus ancestral
Pol protein
Q9BXR3 F1 385 IATLIGQTRLRIIKL
HERV-K_19q12 provirus ancestral
Pol protein
Q9WJR5 F2 1308 IATLIGQTRLRIIKL
HERV-K_19p13.11 provirus
ancestral Pol protein
P63132 F3 385 IATLIGQTRLRIIKL
HERV-K_8p23.1 provirus ancestral
Pol protein
P63133 F4 385 IATLIGQTRLRIIKL
PRAME family member 1 O95521 F5 15 LLELAGQSLLRDQAL
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PRAME family member 2 O60811 F6 15 LLELAGQSLLRDQAL
Protamine-2 P04554 F7 50 YERTHGQSHYRRRHC
PH and SEC7 domain-containing
protein 4
Q8NDX1 F8 223 EPEGEGQAWLREGTP
Adenylosuccinate lyase P30566 F9 241 AFIITGQTYTRKVDI
Glutamine-rich protein 1 Q2TAL8 F10 752 SREQMGQMLTRILVI
DNA repair protein REV1 Q9UBZ9 F11 689 FGPKTGQMLYRFCRG
E3 ubiquitin-protein ligase
RNF133
Q8WVZ7 F12 236 LQNTFGQLQLRVVKE
E3 ubiquitin-protein ligase
RNF220
Q5VTB9 F13 361 EYEWCGQKRIRATTL
Ribosome-recycling factor,
mitochondrial
Q96E11 F14 67 KAKGKGQSQTRVNIN
Solute carrier family 22 member 12 Q96S37 F15 473 TAVGLGQMAARGGAI
Solute carrier family 4 member 8 Q2Y0W8 F16 69 HHRTHGQKHRRRGRG
Protein transport protein Sec23A Q15436 F17 491 YQHSSGQRRIRVTTI
Serine/arginine-rich splicing
factor 9
Q13242 F18 79 NGYDYGQCRLRVEFP
Phosphatidylinositol
3,4,5-trisphosphate 5-phosphatase 1
Q92835 F19 431 WFLSKGQGKTRDDSA
Neutral and basic amino acid
transport protein rBAT
Q07837 F20 79 LFQFSGQARYRIPRE
Mothers against decapentaplegic
homolog 7
O15105 F21 405 FVKGWGQCYTRQFIS
SPARC-related modular
calcium-binding protein 1
Q9H4F8 G1 92 RCKDAGQSKCRLERA
WD40 repeat-containing protein
SMU1
Q2TAY7 G2 297 WKIQSGQCLRRFERA
Suppressor of cytokine signaling 4 Q8WXH5 G3 175 TELRDGQLKRRNMEE
Stabilin-1 Q9NY15 G4 1994 GMSGSGQCLCRSGFA
Sushi domain-containing protein 5 O60279 G5 614 YKLNVGQRQARHYHQ
Sushi, von Willebrand factor type
A, EGF and pentraxin
domain-containing protein 1
Q4LDE5 G6 66 RVERLGQAFRRRVRL
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TP53-target gene 1 protein Q9Y2A0 G7 18 SRRHSGQAALRPRRY
Transcription factor IIIB 90 kDa
subunit
Q92994 G8 298 PSYTAGQRKLRMKQL
Transferrin receptor protein 2 Q9UP52 G9 628 VAQLAGQLLIRLSHD
Transmembrane protein 50A O95807 G10 90 SEGCLGQTGARIWLF
Transmembrane and coiled-coil
domain-containing protein 6
Q96DC7 G11 330 VETVGGQMQLRDERV
Tumor necrosis factor ligand
superfamily member 6
P48023 G12 237 SYCTTGQMWARSSYL
Transformation/ transcription
domain-associated protein
Q9Y4A5 G13 612 QIAGNGQTYIRVANC
Tryptase alpha/beta-1 Q15661 G14 24 AAPAPGQALQRVGIV
Tryptase beta-2 P20231 G15 24 AAPAPGQALQRVGIV
Testis-specific Y-encoded-like
protein 5
Q86VY4 G16 99 AAGDHGQAAARPGPG
Tubulin polyglutamylase TTLL13 A6NNM8 G17 736 RLTSQGQASRRLEAI
Protein shisa-7 A6NL88 G18 16 LASSAGQARARPSNA
Ubiquitin carboxyl-terminal
hydrolase 42
Q9H9J4 G19 1314 RLFEYGQGKRRYLEL
Unhealthy ribosome biogenesis
protein 2 homolog
Q14146 G20 222 TWTQAGQGQLRQVLS
VEGF co-regulated chemokine 1 Q6UXB2 G21 37 GHRDRGQASRRWLQE
Voltage-dependent anion-selective
channel protein 2
P45880 H1 6 MATHGQTCARPMCIP
Vinculin P18206 H2 516 DDRGVGQAAIRGLVA
DDB1- and CUL4-associated
factor 11
Q8TEB1 H3 119 VELATGQLGLRRAAQ
Wee1-like protein kinase P30291 H4 250 LLHSSGQCRRRKRTY
Putative UPF0607 protein
ENSP00000381514
A8MUA0 H5 292 EALLVGQASQREGRL
Nuclease-sensitive element-binding
protein 1
P67809 H6 181 ESAPEGQAQQRRPYR
Nuclear transcriptional regulator
1-like protein
A6NF83 H7 80 QKLLNGQRKRRQRQL
Putative UPF0607 protein
ENSP00000382826
A8MV72 H8 262 EALLVGQASQREGRL
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Putative UPF0607 protein
FLJ37424
Q8N9G6 H9 292 EALLVGQASQREGRL
Putative zinc finger protein 852 Q6ZMS4 H10 122 EGVLKGQKSYRCDEC
Putative UPF0607 protein
ENSP00000383144
A8MX80 H11 292 EALLVGQASQREGHL
Putative UPF0607 protein
ENSP00000381418
A8MU76 H12 292 EALLVGQASQREGRL
Zinc finger BED domain-containing
protein 2
Q9BTP6 H13 117 EKSGHGQAGQRQDPR
Zinc finger protein 256 Q9Y2P7 H14 143 QKQHVGQKHFRSNGG
Zinc finger protein 479 Q96JC4 H15 276 TCEECGQAFRRSSAL
Zinc finger protein 517 Q6ZMY9 H16 324 RCLRCGQRFIRGSSL
Zinc finger protein 648 Q5T619 H17 483 PCTQCGQAFARSSTL
Zinc finger protein 648 H18 539 483 QCEDCGQAFTRSNHL
Putative zinc finger protein 735 P0CB33 H19 276 ACEECGQAFRRSSTL
Zinc finger protein 785 A8K8V0 H20 204 RPFSCGQCQARFSQR
Tight junction protein ZO-3 O95049 H21 528 LHPGPGQSHARGGHW
eRF1 WT P62495 I1 185 KHGRGGQSALRFARL
eRF1 Mutant I2 A185 KHGRGGASALRFARL
Chromodomain-helicase-DNA-
binding protein 5 WT
Q8TDI0 I3 1390 EERPEGQSGRRQSRR
Chromodomain-helicase-DNA-
binding protein 5 Mutant
I4 A1390 EERPEGASGRRQSRR
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6.1.4 In vitro Methylation of the Protein Domains
The methylation of protein domains was performed overnight at 25 `C in 40µL methylation
buffer (10mM Tris pH 7.6, 50mM KCl, 10mM Mg(OAc)2, 1mM DTT) containing 0.76µM
labeled [methyl-3H]-SAM (2.7Tbq/mmol; PerkinElmer) and 4.5µM HEMK2. Equal loading
of target protein amounts were confirmed by Coomassie Brilliant Blue staining. The methy-
lation reaction was stopped by addition of an appropriate volume of 5 x SDS-loading buffer,
subsequently boiled at 95 `C for 5min and separated by loading on a 12% SDS-PAGE gel. Af-
terwards, the gel was dried with vacuum at 65 `C and then incubated with HyperfilmTM high
performance autoradiography films at 80 `C, in the dark for varying time.
6.1.5 Cell culture, Transfection and Immunoprecipitation
For mammalian expression of the full length proteins, the coding sequences of Chromodomain-
helicase-DNA-binding protein 5 (CHD5) (kindly provided by Dr. A. A. Mills), Protein NUT
(kindly provided by Dr. C. A. French) and eRF1 were subcloned into the pEYFP-C1 vector
(Clontech, USA). The corresponding target glutamine to arginine mutants of CHD5 (Q1390R)
and Protein NUT (Q1046) were subcloned into the pECFP-C1 vector (Clontech, USA).
The transfection of the plasmids into eukaryotic cell lines was performed using Polyethylen-
imine (PEI; MAX 40000; Polyscience, USA). The transfection of HEK293 cells was routinely
performed done at a confluency of approximately 80%. 2 h before transfection the DMEM
medium supplemented with 10% Fetal Bovin Serum (Sigma-Aldrich, USA), 100 units Penicillin
and 100µg per mL Streptomycin (Sigma-Aldrich, USA) and 2µM L-Glutamine (Sigma-Aldrich,
USA) was removed and replaced with fresh pre-warmed growth medium. For transfection, a
ratio of DNA:PEI of 1:3 was used. The DNA (0.8µg per mL of total culture volume) was added
to 5% Serum-free media (SFM; of total transfection volume) and mixed by pipetting. In a
separate tube, three times more PEI was added to 5% Serum-free media and mixed as well.
Then the DNA/SFM mixture was added to the PEI/SFM mixture, gently mixed by pipetting
and incubated at room temperature for 20min. Afterwards, the DNA-PEI solution was added
drop-wise to the flask containing the cells and incubated at 37 `C and 5% CO2. 72 h after trans-
fection, the cells were washed with PBS buffer and harvested by centrifugation at 500 g for 5min.
The YFP-fused CHD5 and NUT substrate proteins were immunoprecipitated from cell extract
using GFP-Trap® A (Chromotek). The composition of the buffers used for the GFP-Trap® A
are shown in Table 12.
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The cell pellet was thawed on ice, resuspended with 150µL lysis buffer using a syringe with
a 26 gauge needle and mixed by vortexing. This resuspention was incubated end-over-end for
30min at 8 `C with vortexing every 10min. After that, the cell lysate was centrifuged for 5min
at 13.000 rpm at 4 `C and the supernatant was transferred to a pre-cooled tube. Then, dilution
buffer (4 times the volume of lysis buffer) was added to the supernatant and the diluted lysate
was added to 20µL pre-equilibrated GFP-Trap® A magnetic beads and rolled end-over-end for
2 h at 8 `C. The beads were magnetically separated until the supernatant was clear and the
latter was discarded. The magnetic beads were washed three times with 300µL lysis buffer.
Finally, the beads were resuspended in 30µL lysis buffer and 30µL 2 x SDS-loading buffer was
added to release the bound proteins.
Table 12: Composition of the buffers used for GFP-Trap® A purification.
Lysis buffer (pH 7.5) Dilution buffer (pH 7.5)
10mM Tris-HCl 10mM Tris-HCl
300mM NaCl 300mM NaCl
0.5mM EDTA 0.5mM EDTA
0.5% NP 40 —
1 x mammalian 1mM PMSF
Inhibitor Cocktail
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6.2 The Histone Lysine Methyltransferase NSD2
6.2.1 Cloning, Site-directed Mutagenesis, Expression and Purification
The sequence encoding for the human NSD2 enzyme and the putative human substrate protein
domains were amplified from cDNA of HEK293 cells. NSD2 was amplified in three different
variants, which differed in size, but all possessing the AWS, the catalytic active SET domain
and the Post-SET domain (Figure 22).
The amplified NSD2 inserts were subcloned into pGEX-6P-2 (fused to GST), pET-28a(+) (fused
to His6) and pMAL-c2x (fused to MBP) vectors. The putative substrates were cloned as GST
fusion proteins into the pGEX-6P-2 vector (GE Healthcare)(Table 13).
Table 13: List with information of putative novel NSD2 substrate proteins, which were selected for methylation
at protein level.
Name Abbreviation
Domain
boundaries
(aa)
NCBI accession
number
Abnormal spindle-like
microcephaly-associated protein
ASPM 2112 – 2361 NP_060606.3
Bromodomain adjacent to zinc finger
domain protein 2B
BAZ2B 807 – 1092 NP_038478.2
DNA polymerase alpha catalytic subunit POLA1 803 – 1074 NP_058633.2
ETS domain-containing protein Elk-3 ELK3 1 – 272 NP_005221.2
ETS domain-containing protein Elk-4 ELK4 1 – 275 NP_001964.2
Eukaryotic initiation factor 4A-III EIF4A3 2 – 280 NP_055555.1
Fanconi anemia group M protein FANCM 723 – 933 NP_065988.1
Mediator of RNA polymerase II
transcription subunit 12-like protein
MED12L 1486 – 1749 NP_443728.3
Mismatch repair endonuclease PMS2 PMS2 446 – 750 NP_000526.1
Myoneurin MYNN 372 – 603 NP_001172047.1
N-lysine methyltransferase SET8 SET8 1 – 346 NP_065115.3
Nuclear protein localization protein 4
homolog
NPLOC4 1 – 289 NP_060391.2
Prickle-like protein 2 PRICKLE2 1 – 276 NP_942559.1
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Probable U3 small nucleolar
RNA-associated protein 11
UTP11L 3 – 253 NP_057121.2
Putative homeodomain transcription
factor 2
PHTF2 456 – 719 NP_001120829.1
RNA polymerase II elongation factor
ELL2
ELL2 379 – 640 NP_036213.2
RNA-binding E3 ubiquitin-protein ligase
MEX3C
MEX3C 224 – 478 NP_057710.3
RNA-binding protein MEX3A MEX3A 134 – 371 NP_001087194.1
RNA-binding protein MEX3B MEX3B 29 – 303 NP_115622.2
Sister chromatid cohesion protein DCC1 DSCC1 13 – 278 NP_076999.2
STE20/SPS1-related proline-alanine-rich
protein kinase
STK39 66 – 296 NP_037365.2
Transcription factor RFX4 RFX4 336 – 493 NP_998759.1
Transcription factor SOX-17 SOX17 41 – 287 NP_071899.1
Transcriptional regulator ATRX ATRX 893 – 1188 NP_000480.3
U5 small nuclear ribonucleoprotein
40 kDa protein
SRNP40 4 – 293 NP_004805.2
Zinc finger protein 292 ZNF292 2415 – 2655 NP_055836.1
Zinc finger protein ZFAT ZFAT 232 – 496 NP_065914.2
For bacterial expression, the plasmids were transformed into E. coli BL21-CodonPlus (DE3)
cells (Novagen, USA). These were grown in LB medium at 37 `C until an OD600 of 0.6 to 0.8
was reached. Protein expression was induced with 1mM isopropyl-β-D-thiogalactopyranoside
(IPTG). The culture was then shifted to 20 `C overnight (14 to 16 h). Afterwards the cells were
collected by centrifugation at 4.500 rpm, washed once with STE buffer (10mM Tris-HCl pH8.0,
1mM EDTA and 100mM NaCl) and the cell pellet was stored at 20 `C until purification.
For purification the cell pellet was thawed on ice, resuspended in sonication buffer and lysed by
ultra sound. Then the samples were centrifuged at 18.000 rpm for 90min and the supernatants
were passed through Glutathione Sepharose 4B resin (GE Healthcare). Afterwards, the beads
were washed once with sonication buffer and twice with washing buffer. Subsequently, the bound
proteins were eluted with elution buffer containing excess of glutathione and then dialyzed
against low glycerol dialysis buffer 1 for 3 h and afterwards over night against high glycerol
dialysis buffer 2. The composition of the used buffers is shown in Table 8 in section 6.1.1.
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The mutation of the target lysine of the methylated substrates was performed by site-directed
mutagenesis using PCR-megaprimers according to the protocol of Jeltsch & Lanio [196]. In ad-
dition to the needed lysine to arginine mutations, silent mutations were introduced to allow the
identification of the plasmids containing the mutated targets by specific restriction sites. The
successful mutagenesis of the novel substrates was confirmed by restriction digest and DNA
sequencing (Table 14).
Table 14: Target lysine mutations of methylated substrate proteins of NSD2
Name Abbreviation Target Kmutation
Transcriptional regulator ATRX ATRX Mut K1033R
Fanconi anemia group M protein FANCM Mut K819R
N-lysine methyltransferase SET8 SET8 Mut K158R
6.2.2 In vitro Methylation of the Peptide SPOT Arrays
Synthesis of the peptide arrays was performed according to the description in section 6.1.2. All
peptide arrays were washed for 10min with methylation buffer containing 50mM Tris (pH 8.5),
50mM NaCl and 0.5mM DTT. Then the peptide SPOT membranes were incubated for 60min in
methylation buffer containing 3µMNSD2 and 0.76µM labeled [methyl-3H]-SAM (Perkin Elmer)
at 23 `C. Afterwards, the arrays were washed five times with 50mM NH4HCO3 and 1% SDS
and then incubated for 5min in Amplify NAMP100V solution (GE Healthcare). The membranes
were exposed on HyperfilmTM high performance autoradiography films (GE Healthcare) in the
dark, for several days at 80 `C. Film development was performed on an Optimus TR developing
machine. Quantification and analysis of the developed films were performed as described in
section 6.1.3.
Information of peptide array containing the synthesized peptides harboring the predicted target
lysine residues derived from Scansite searches using the two specificity profiles from NSD2:
Table 15: List of putative novel NSD2 substrates identified in Scansite searches using a stringent and a relaxed
specificity profile as shown in Table 3. The predicted target lysine is printed in bold. The position of
the corresponding peptide spots in Figure 29 are indicated.
Name SwissProt no.
Position
on Array
Target K
Position Sequence
Histone H3 K36 P68431 A1 36 APATGGVKKPHRYRP
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Histone H3 K36A Mut A2 36 APATGGVAKPHRYRP
H4K44 WT P62805 A3 44 LARRGGVKRISGLIY
H4K44 Mut A4 A44 LARRGGVARISGLIY
Apoptotic chromatin condensation inducer
in the nucleus
Q9UKV3 A5 969 PPAEHEVKKVTLGDT
Apoptotic chromatin condensation inducer
in the nucleus
Q9UKV3 A6 548 GITEECLKQPSLEQK
Afadin- and alpha-actinin-binding protein Q9Y2D8 A7 278 LMENAELKKVLQQMK
Adipocyte enhancer-binding protein 1 Q8IUX7 A8 340 DEEKEELKKPKKEDS
Amino-terminal enhancer of split Q08117 A9 83 HKQAEIVKRLNGICA
Protein arginine N-methyltransferase 7 Q9NVM4 A10 117 NGFSDKIKVINKHST
Ankyrin repeat domain-containing
protein 23
Q86SG2 A11 194 GGHLVILKQLLNQGA
Poly(ADP-ribose) glycohydrolase ARH3 Q9NX46 A12 213 SSSEHFLKQLLGHME
AT-rich interactive domain-containing
protein 4A
P29374 A13 39 VKRLVKVKVLLKQDN
Aryl hydrocarbon receptor nuclear
translocator 2
Q9HBZ2 A14 439 ICTNTNVKQLQQQQA
Abnormal spindle-like
microcephaly-associated protein
Q8IZT6 A15 888 ALSKFTLKKLLLLVC
Abnormal spindle-like
microcephaly-associated protein
Q8IZT6 A16 2213 QTYFNKLKKITKTVQ
Transcriptional regulator ATRX P46100 A17 1033 CHFPKGIKQIKNGTT
Ataxin-1 P54253 A18 688 VCISLTLKNLKNGSV
Protein BANP Q8N9N5 A19 165 RQNTIVVKVPGQEDS
Bromodomain adjacent to zinc finger
domain protein 2B
Q9UIF8 A20 948 MKQQEKIKRIQQIRM
BRCA2 and CDKN1A-interacting protein Q9P287 A21 75 DNDYDGIKKLLQQLF
Ribosome biogenesis protein BOP1 Q14137 B1 708 NPLLVPVKVLKGHVL
Bromodomain-containing protein 8 Q9H0E9 B2 109 AERVEELKKVIKETQ
E3 ubiquitin-protein ligase BRE1A Q5VTR2 B3 627 KKEAEIIKQLKIELK
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Transcription factor BTF3 homolog 3 Q13892 B4 79 KKLQFSLKKLQVNNI
Mitotic checkpoint
serine/threonine-protein kinase BUB1
O43683 B5 1055 DLLRQKLKKVFQQHY
Coiled-coil domain-containing protein 110 Q8TBZ0 B6 57 IQPQSALKVLQQQLE
Coiled-coil alpha-helical rod protein 1 Q8TD31 B7 360 LEHSDSVKQLKGQVA
PITSLRE serine/threonine-protein kinase
CDC2L1
P21127 B8 467 TDEIVALKRLKMEKE
PITSLRE serine/threonine-protein kinase
CDC2L2
Q9UQ88 B9 455 TDEIVALKRLKMEKE
Cell division protein kinase 7 P50613 B10 41 TNQIVAIKKIKLGHR
Cell division protein kinase 9 P50750 B11 48 TGQKVALKKVLMENE
Centrosomal protein of 290 kDa O15078 B12 1645 SSLLVKLKKVSQDLE
Centrosomal protein of 290 kDa O15078 B13 1681 ENHEDEVKKVKAEVE
E3 ubiquitin-protein ligase CHFR Q96EP1 B14 88 GTVINKLKVVKKQTC
Cirhin Q969X6 B15 514 GVHVYNVKQLKLHCT
Condensin-2 complex subunit G2 Q86XI2 B16 421 TILIDLLKKVTGELA
Cleavage and polyadenylation specificity
factor subunit 2
Q9P2I0 B17 550 RSDGDSIKKIINQMK
Catenin delta-1 O60716 B18 433 LGACGALKNISFGRD
Dachshund homolog 1 Q9UI36 B19 347 IAEAMKVKKIKLEAM
Sister chromatid cohesion protein DCC1 Q9BVC3 B20 139 RPKLKKLKKLLMENP
Deoxycytidine kinase P27707 B21 22 SSEGTRIKKISIEGN
Probable dimethyladenosine transferase Q9UNQ2 C1 40 GIGQHILKNPLIINS
H/ACA ribonucleoprotein complex
subunit 4
O60832 C2 367 HGIVAKIKRVIMERD
Dentin matrix acidic phosphoprotein 1 Q13316 C3 482 SEEDGQLKNIEIESR
Diphthamide biosynthesis protein 1 Q9BZG8 C4 43 QIPPEILKNPQLQAA
DNA polymerase delta subunit 3 Q15054 C5 292 SKKAEPVKVLQKEKK
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DNA polymerase alpha catalytic subunit P09884 C6 926 VERRKQVKQLMKQQD
Dual specificity tyrosine-
phosphorylation-regulated kinase 2
Q92630 C7 226 AYRYEVLKVIGKGSF
Erythroid differentiation-related factor 1 Q3B7T1 C8 131 VSDSENIKKLLKIPY
EF-hand calcium-binding
domain-containing protein 6
Q5THR3 C9 61 TLSSLDVKRILFQKI
Eukaryotic translation initiation factor 3
subunit E
P60228 C10 279 QVLKDLVKVIQQESY
ETS domain-containing protein Elk-3 P41970 C11 73 YYDKNIIKKVIGQKF
ETS domain-containing protein Elk-4 P28324 C12 73 YYVKNIIKKVNGQKF
RNA polymerase II elongation factor
ELL2
O00472 C13 625 HNKLAHIKRLIGEFD
Alpha-enolase P60228 C14 279 QVLKDLVKVIQQESY
Separin Q14674 C15 515 RLQVESLKKLGKQAQ
Separin Q14674 C16 1075 TQHLDSVKKVHLQKG
Ecotropic virus integration site 1 protein
homolog
Q03112 C17 543 PQSPGEVKKLQKGSS
Exonuclease 1 Q9UQ84 C18 252 ANNPDIVKVIKKIGH
Fanconi anemia group M protein Q8IYD8 C19 819 HKKSSFIKNINQGSS
FK506-binding protein 5 Q13451 C20 38 RGVLKIVKRVGNGEE
FYN-binding protein O15117 C21 683 KTEEKDLKKLKKQEK
Glucocorticoid receptor P04150 D1 770 KYSNGNIKKLLFHQK
Vasculin-like protein 1 Q9HC44 D2 199 PSKMLVIKKVSKEDP
General transcription factor II-I P78347 D3 185 AGISFIIKRPFLEPK
Histone H2B type F-M P0C1H6 D4 69 PYFPRVLKQVHQGLS
Histone H2B type W-T Q7Z2G1 D5 90 TYFRRVLKQVHQGLS
Histone deacetylase 6 Q9UBN7 D6 1199 HQALLDVKNIAHQNK
Homeodomain-interacting protein
kinase 2
Q9H2X6 D7 29 SSAFCSVKKLKIEPS
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Homeobox protein HMX3 A6NHT5 D8 34 KESPFSIKNLLNGDH
Heterochromatin protein 1-binding
protein 3
Q5SSJ5 D9 517 RPSSTVIKKPSGGSS
Eukaryotic initiation factor 4A-III P38919 D10 70 AIQQRAIKQIIKGRD
Zinc finger protein Aiolos Q9UKT9 D11 440 ICPRDSVKVINKEGE
Integrator complex subunit 6 Q9UL03 D12 457 YSVISYLKKLSQQAK
Integrator complex subunit 7 Q9NVH2 D13 269 NDPRKAVKRLAIQDL
Iroquois-class homeodomain protein
IRX-2
Q9BZI1 D14 341 EIATSDLKQPSLGPG
Lysine-specific demethylase 2B Q8NHM5 D15 549 QALLEGVKNVLKEHA
Lysine-specific demethylase 4A O75164 D16 468 EVKFEELKNVKLEEE
Kinesin-like protein KIF20B Q96Q89 D17 1300 TDAKKQIKQVQKEVS
Antigen KI-67 P46013 D18 548 MHTPPVLKKIIKEQP
Chromosome-associated kinesin KIF4B Q2VIQ3 D19 562 FQYQDNIKNLELEVI
Kinetochore-associated protein KNL-2
homolog
Q6P0N0 D20 752 TRLLPKLKKIENQVA
Kinetochore-associated protein 1 P50748 D21 1737 EKAEALLKKLHIQYR
Ribosomal protein S6 kinase alpha-2 Q15349 E1 63 PSQFELLKVLGQGSY
Putative leucine-twenty homeobox A8MZ59 E2 92 LREPSGIKNPGGASA
Protein lin-54 homolog Q6MZP7 E3 184 KLPPQQIKVVTIGGR
Leucine zipper protein 1 Q86V48 E4 766 VIVDKDVKKIMGGSG
Leucine zipper protein 1 Q86V48 E5 265 KGGLDYLKQVENETR
Mitogen-activated protein kinase kinase
kinase 2
Q9Y2U5 E6 411 ECEIQLLKNLLHERI
Metastasis-associated in colon cancer
protein 1
Q6ZN28 E7 615 LVHCKNVKVISKEQV
MAD protein Q05195 E8 207 GYSSTSIKRIKLQDS
Mediator of RNA polymerase II
transcription subunit 12-like protein
Q86YW9 E9 1604 RAYMNLVKKLKKELG
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Midasin Q9NU22 E10 1622 MGEEAALKRPEIIST
Midasin Q9NU22 E11 1670 ECLKFLIKRLAKIVR
Merlin P35240 E12 578 SSKHNTIKKLTLQSA
RNA-binding protein MEX3A A1L020 E13 247 GPKGATIKRIQQQTN
RNA-binding protein MEX3B Q6ZN04 E14 184 GPKGATIKRIQQQTH
RNA-binding protein MEX3C Q5U5Q3 E15 350 GPKGATIKRIQQQTH
MAX gene-associated protein Q8IWI9 E16 29 PTFFVILKQPGNGKT
Methylated-DNA-protein-cysteine
methyltransferase
P16455 E17 104 QVLWKLLKVVKFGEV
Msx2-interacting protein Q96T58 E18 2930 VTQGGTVKVLTQGIN
Histone-lysine N-methyltransferase MLL2 O14686 E19 4553 RASEALLKQLKQELS
Histone-lysine N-methyltransferase MLL2 O14686 E20 5244 GRPEFVIKVIEQGLE
Mitogen-activated protein kinase kinase
kinase MLT
Q9NYL2 E21 45 QDKEVAVKKLLKIEK
Myeloid cell nuclear differentiation
antigen
P41218 F1 102 TQEKAPVKKINQEEV
M-phase phosphoprotein 8 Q99549 F2 228 VKETKELKKVKKGEI
Protein maestro Q9BYG7 F3 47 FQKREPLKNVFFILA
Myb proto-oncogene protein P10242 F4 524 ENGPPLLKKIKQEVE
Myc proto-oncogene protein P01106 F5 126 PDDETFIKNIIIQDC
Myoneurin Q9NPC7 F6 512 GNSYTDIKNLKKHKT
Histone acetyltransferase MYST3 Q92794 F7 18 EWILEAIKKVKKQKQ
Myelin transcription factor 1 Q01538 F8 1040 SSMEKNLKNIEEENK
NGFI-A-binding protein 2 Q15742 F9 376 ELGGPPLKKLKQEVG
NACHT, LRR and PYD
domains-containing protein 1
Q9C000 F10 765 IKFSRHVKKLQLIEG
Nuclear cap-binding protein subunit 2 P52298 F11 67 FSKSGDIKKIIMGLD
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Nipped-B-like protein Q6KC79 F12 1639 GSIERILKQVSGGED
RNA-binding protein NOB1 Q9ULX3 F13 215 WITPSNIKQIQQELE
Nucleolar complex protein 3 homolog Q8WTT2 F14 386 EMCCEAVKKLFKQDK
Nucleolar protein 14 P78316 F15 772 LFTPRLVKVLEFGRK
Nuclear protein localization protein 4
homolog
Q8TAT6 F16 31 ETAATFLKKVAKEFG
Nuclear receptor subfamily 0 group B
member 2
Q15466 F17 119 APVPSILKKILLEEP
Nuclear receptor subfamily 1 group I
member 2
O75469 F18 331 LKFHYMLKKLQLHEE
Nucleolin P19338 F19 513 FEKATFIKVPQNQNG
Origin recognition complex subunit 2 Q13416 F20 288 PSFSAELKQLNQQYE
Serine/threonine-protein kinase PAK 2 Q13177 F21 278 LGQEVAIKQINLQKQ
Poly [ADP-ribose] polymerase 15 Q460N3 G1 444 TPSLKTVKVVIFQPE
Phosphorylated CTD-interacting factor 1 Q9H4Z3 G2 126 QPSGNGVKKPKIEIP
Periplakin O60437 G3 1099 SFLQDKLKRLEKERA
Periplakin O60437 G4 550 AERAKDLKNITNELL
Period circadian protein homolog 3 P56645 G5 470 YASVNKIKNLGQQLY
PHD finger protein 21A Q96BD5 G6 214 ATPPQPIKVPQFIPP
PH domain leucine-rich repeat-containing
protein phosphatase 1
O60346 G7 1317 MSCEEELKRIKQHKA
PH domain leucine-rich repeat-containing
protein phosphatase 1
O60346 G8 246 HKGGGVVKVLGQGPG
Putative homeodomain transcription
factor 1
Q9UMS5 G9 585 EIPHFRLKKVENIKI
Putative homeodomain transcription
factor 1
Q9UMS5 G10 210 TIFGNRIKRVKLISN
Putative homeodomain transcription
factor 2
Q8N3S3 G11 608 EVPHFRLKKVQNIKM
Pinin Q9H307 G12 108 DPEDDDVKKPALQSS
Mismatch repair endonuclease PMS2 P54278 G13 630 SSLAKRIKQLHHEAQ
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POU domain, class 6, transcription
factor 2
Q12972 G14 81 LVYHKHLKRVFLIDL
DNA polymerase kappa Q9UBT6 G15 461 RTVTIKLKNVNFEVK
Protein phosphatase 1 regulatory
subunit 7
Q15435 G16 287 DIASNRIKKIENISH
Nuclear inhibitor of protein phosphatase 1 Q12972 G17 81 LVYHKHLKRVFLIDL
Prickle-like protein 2 Q7Z3G6 G18 74 PGEKLRIKQLLHQLP
Proteasome subunit beta type-4 P28070 G19 109 YADFQYLKQVLGQMV
Proteasome activator complex subunit 3 P61289 G20 237 TLHDMILKNIEKIKR
Protein QN1 homolog Q5TB80 G21 704 PVTGEKLKQIQKEIQ
RB1-inducible coiled-coil protein 1 Q8TDY2 H1 893 EENENKIKKLKGELV
Probable RNA-binding protein 19 Q9Y4C8 H2 792 EQAQKALKQLQGHVV
RNA-binding protein 40 Q96LT9 H3 425 PNCRIYVKNLAKHVQ
E3 SUMO-protein ligase RanBP2 P49792 H4 458 PGIRKWLKQLFHHLP
Regulator of nonsense transcripts 3A Q9H1J1 H5 285 EVRIKLLKKPEKGEE
Regulator of nonsense transcripts 3B Q9BZI7 H6 285 VNQKNLLKKPEKGDE
Transcription factor RFX4 Q33E94 H7 421 AKRQGSLKKVAQQFL
RANBP2-like and GRIP
domain-containing protein 8
O14715 H8 1713 AANLEYLKNVLLQFI
Telomere-associated protein RIF1 Q5UIP0 H9 290 RSGAPMIKKIAFIAW
RecQ-mediated genome instability
protein 1
Q9H9A7 H10 188 LLKPENVKVLGGEVD
Nuclear receptor ROR-beta Q92753 H11 187 GLDMTGIKQIKQEPI
DNA-directed RNA polymerase II subunit
RPB1
P24928 H12 19 ACPLRTIKRVQFGVL
Ribosomal RNA processing protein 1
homolog A
P56182 H13 131 MVLNESLKVLKMQGW
SAM domain and HD domain-containing
protein 1
Q9Y3Z3 H14 148 FQRLRYIKQLGGGYY
Sex comb on midleg-like protein 1 Q9UN30 H15 115 KHSYRLVKKLKLQKM
115
6 Materials and Methods
Serologically defined colon cancer
antigen 1
O60524 H16 578 GATSCVIKNPTGEPI
Septin-10 Q9P0V9 H17 396 QAKFEHLKRLHQEER
Histone-lysine N-methyltransferase SET8 Q9NQR1 H18 199 AIAKQALKKPIKGKQ
Splicing factor 1 Q15637 H19 165 GPRGNTLKNIEKECN
Serine/threonine-protein kinase Sgk1 O00141 H20 102 PSDFHFLKVIGKGSF
Protein SGT1 O95905 H21 96 WFIVYVIKQITKEFP
Paired amphipathic helix protein Sin3a Q96ST3 I1 813 KEDKYKIKQIMHHFI
SWI/SNF-related matrix-associated
actin-dependent regulator of chromatin
subfamily D member 1
Q96GM5 I2 173 LDIQEALKRPIKQKR
SWI/SNF-related matrix-associated
actin-dependent regulator of chromatin
subfamily D member 3
Q6STE5 I3 148 VDIQEALKRPMKQKR
U5 small nuclear ribonucleoprotein 40 kDa
protein
Q96DI7 I4 145 SETGERVKRLKGHTS
SOSS complex subunit B1 Q9BQ15 I5 15 KDIKPGLKNLNLIFI
Transcription factor SOX-17 Q9H6I2 I6 149 RKQVKRLKRVEGGFL
Transcription elongation factor SPT5 O00267 I7 1042 PTKNNKVKVILGEDR
Serine/threonine-protein kinase SRPK1 Q96SB4 I8 190 GLPLPCVKKIIQQVL
STE20/SPS1-related proline-alanine-rich
protein kinase
Q9UEW8 I9 92 RQERVAIKRINLEKC
Serine/threonine-protein kinase 3 Q13188 I10 441 DGDFDFLKNLSLEEL
ATP-dependent RNA helicase SUPV3L1,
mitochondrial
Q8IYB8 I11 749 LLTPDMLKQLEKEWM
Polycomb protein SUZ12 Q15022 I12 72 GAAVLPVKKPKMEHV
Synaptonemal complex protein 2-like Q5T4T6 I13 370 KIFIIYLKKPMIISY
Synaptonemal complex protein 1 Q15431 I14 437 EVELEELKKVLGEKE
Nesprin-1 Q8NF91 I15 4833 QDSGIVLKRVTIHLE
Nesprin-2 Q8WXH0 I16 2601 KLLESQIKQLEHGWE
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Nesprin-2 Q8WXH0 I17 3992 QEQNELLKVVIKQTN
General transcription factor IIF subunit 2 P13984 I18 128 SENYMRLKRLQIEES
TATA box-binding protein-associated
factor RNA polymerase I subunit A
Q15573 I19 357 KYLAKYLKNILMGNH
Transcription initiation factor TFIID
subunit 2
Q6P1X5 I20 142 WKHVDELKVLKIHIN
Transcription initiation factor TFIID
subunit 4B
Q92750 I21 179 KVAVTPVKKLAQIGT
TATA box-binding protein-like protein 2 Q6SJ96 J1 218 LACKLDLKKIALHAK
Transcription elongation regulator 1 O14776 J2 981 TSTWKEVKKIIKEDP
G/T mismatch-specific thymine DNA
glycosylase
Q13569 J3 248 EVFGVKVKNLEFGLQ
Methylcytosine dioxygenase TET1 Q8NFU7 J4 50 TLSPGKLKQLIQERD
General transcription factor 3C
polypeptide 3
Q9Y5Q9 J5 728 FCLRLMLKNPENHAL
Transcription factor AP-4 Q01664 J6 189 HMYPEKLKVIAQQVQ
Transducin-like enhancer protein 2 Q04725 J7 82 HKQAEIVKRLSGICA
Serine/threonine-protein kinase
tousled-like 1
Q9UKI8 J8 436 NLHIRELKRINNEDN
Serine/threonine-protein kinase
tousled-like 2
Q86UE8 J9 442 NLHIRELKRIHNEDN
DNA topoisomerase 2-beta Q02880 J10 1226 KVGKPKVKKLQLEET
Targeting protein for Xklp2 Q9ULW0 J11 585 NLPEKKVKNVTQIEP
tRNA pseudouridine synthase A Q9Y606 J12 184 HIRILGLKRVTGGFN
Transcription termination factor 2 Q9UNY4 J13 1023 SQWTNMLKVVALHLK
U5 small nuclear ribonucleoprotein
200 kDa helicase
O75643 J14 2080 SNSLISIKRLTLQQK
Ubiquitin-conjugating enzyme E2
variant 1
Q13404 J15 118 WQNSYSIKVVLQELR
SUMO-conjugating enzyme UBC9 P63279 J16 110 WRPAITIKQILLGIQ
Ubiquitin carboxyl-terminal hydrolase 21 Q9UK80 J17 64 GLPDERLKKLELGRG
Ubiquitin carboxyl-terminal hydrolase 36 Q9P275 J18 408 LVHSSNVKVVLNQQA
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Uridine-cytidine kinase-like 1 Q9NWZ5 J19 170 DLIISTLKKLKQGKS
Protein unc-84 homolog A O94901 J20 374 KPTTSRLKQPLQGDS
Uracil-DNA glycosylase P13051 J21 147 MCDIKDVKVVILGQD
Probable U3 small nucleolar
RNA-associated protein 11
Q9Y3A2 K1 189 VTNQTGLKRIAKERQ
Small subunit processome component 20
homolog
O75691 K2 1591 HRRARALKKLAKQLM
Small subunit processome component 20
homolog
O75691 K3 2690 SEQDPLLKNLSQEII
Vitamin D3 receptor P11473 K4 321 IKFQVGLKKLNLHEE
Vezatin Q9HBM0 K5 525 HCTVVPLKQPTLHIA
WW domain-binding protein 4 O75554 K6 81 KAYQEDLKRLGLESE
YEATS domain-containing protein 2 Q9ULM3 K7 900 AQGQQTLKVISGQKT
Zinc finger protein 280A P59817 K8 305 FKCLSCVKVLKNIKF
Zinc finger protein 585A Q6P3V2 K9 150 SQLKVHLKVLAGEKL
Zinc finger protein 585B Q52M93 K10 150 SQFKVHLKVPTGEKL
Zinc finger and BTB domain-containing
protein 4
Q9P1Z0 K11 301 GGPEHVVKVVGGHVL
Zinc finger protein ZFAT Q9P243 K12 367 KKKYSDVKNLIKHIR
Zinc finger homeobox protein 4 Q86UP3 K13 1525 VSHLHKLKKVLQEAS
Zinc finger MYM-type protein 5 Q9UJ78 K14 454 GSSNTLLKKIEGIPE
Zinc finger protein 251 Q9BRH9 K15 663 KRYFIHIKKIFQERH
Zinc finger protein 292 O60281 K16 2531 RQKASNLKRVNKEKN
Zinc finger protein 509 Q6ZSB9 K17 70 DVFHLDVKNVSGIGQ
Zinc finger protein 644 Q9H582 K18 809 DHRRVAVKRVIKESK
Zinc finger protein 41 P51814 K19 201 NNLLSHVKVLIKERG
Zinc finger protein 8 P17098 K20 157 LKEQNNLKQLEFGLK
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Information of peptide array containing the synthesized peptides for the search for a potential
automethylation site in NSD2:
Table 16: List of synthesized peptides for the NSD2 automethylation scanning array.
Name Residues Positionon Array Sequence
Histone H3 K36 WT 29 – 43 A1 APATGGVKKPHRYRP
Histone H3 K36A Mut 29 – 43 A2 APATGGVAKPHRYRP
free space A3
Nuclear receptor SET domain-containing protein 2
NSD2
941 – 955 A4 EGDRGSRYQGVRGIG
Nuclear receptor SET domain-containing protein 2
NSD2
945 – 959 A5 GSRYQGVRGIGRVFK
Nuclear receptor SET domain-containing protein 2
NSD2
949 – 963 A6 QGVRGIGRVFKNALQ
Nuclear receptor SET domain-containing protein 2
NSD2
953 – 967 A7 GIGRVFKNALQEAEA
Nuclear receptor SET domain-containing protein 2
NSD2
957 – 971 A8 VFKNALQEAEARFRE
Nuclear receptor SET domain-containing protein 2
NSD2
961 – 975 A9 ALQEAEARFREIKLQ
Nuclear receptor SET domain-containing protein 2
NSD2
965 – 979 A10 AEARFREIKLQREAR
Nuclear receptor SET domain-containing protein 2
NSD2
969 – 983 A11 FREIKLQREARETQE
Nuclear receptor SET domain-containing protein 2
NSD2
973 – 987 A12 KLQREARETQESERK
Nuclear receptor SET domain-containing protein 2
NSD2
977 – 991 A13 EARETQESERKPPPY
Nuclear receptor SET domain-containing protein 2
NSD2
981 – 995 A14 TQESERKPPPYKHIK
Nuclear receptor SET domain-containing protein 2
NSD2
985 – 999 A15 ERKPPPYKHIKVNKP
Nuclear receptor SET domain-containing protein 2
NSD2
989 – 1003 A16 PPYKHIKVNKPYGKV
Nuclear receptor SET domain-containing protein 2
NSD2
993 – 1007 A17 HIKVNKPYGKVQIYT
Nuclear receptor SET domain-containing protein 2
NSD2
997 – 1011 A18 NKPYGKVQIYTADIS
Nuclear receptor SET domain-containing protein 2
NSD2
1001 – 1015 A19 GKVQIYTADISEIPK
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Nuclear receptor SET domain-containing protein 2
NSD2
1005 – 1019 A20 IYTADISEIPKCNCK
Nuclear receptor SET domain-containing protein 2
NSD2
1009 – 1023 A21 DISEIPKCNCKPTDE
Nuclear receptor SET domain-containing protein 2
NSD2
1013 – 1027 B1 IPKCNCKPTDENPCG
Nuclear receptor SET domain-containing protein 2
NSD2
1017 – 1031 B2 NCKPTDENPCGFDSE
Nuclear receptor SET domain-containing protein 2
NSD2
1021 – 1035 B3 TDENPCGFDSECLNR
Nuclear receptor SET domain-containing protein 2
NSD2
1025 – 1039 B4 PCGFDSECLNRMLMF
Nuclear receptor SET domain-containing protein 2
NSD2
1029 – 1043 B5 DSECLNRMLMFECHP
Nuclear receptor SET domain-containing protein 2
NSD2
1033 – 1047 B6 LNRMLMFECHPQVCP
Nuclear receptor SET domain-containing protein 2
NSD2
1037 – 1051 B7 LMFECHPQVCPAGEF
Nuclear receptor SET domain-containing protein 2
NSD2
1041 – 1055 B8 CHPQVCPAGEFCQNQ
Nuclear receptor SET domain-containing protein 2
NSD2
1045 – 1059 B9 VCPAGEFCQNQCFTK
Nuclear receptor SET domain-containing protein 2
NSD2
1049 – 1063 B10 GEFCQNQCFTKRQYP
Nuclear receptor SET domain-containing protein 2
NSD2
1053 – 1067 B11 QNQCFTKRQYPETKI
Nuclear receptor SET domain-containing protein 2
NSD2
1057 – 1071 B12 FTKRQYPETKIIKTD
Nuclear receptor SET domain-containing protein 2
NSD2
1061 – 1075 B13 QYPETKIIKTDGKGW
Nuclear receptor SET domain-containing protein 2
NSD2
1065 – 1079 B14 TKIIKTDGKGWGLVA
Nuclear receptor SET domain-containing protein 2
NSD2
1069 – 1083 B15 KTDGKGWGLVAKRDI
Nuclear receptor SET domain-containing protein 2
NSD2
1073 – 1087 B16 KGWGLVAKRDIRKGE
Nuclear receptor SET domain-containing protein 2
NSD2
1077 – 1091 B17 LVAKRDIRKGEFVNE
Nuclear receptor SET domain-containing protein 2
NSD2
1081 – 1095 B18 RDIRKGEFVNEYVGE
Nuclear receptor SET domain-containing protein 2
NSD2
1085 – 1099 B19 KGEFVNEYVGELIDE
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Nuclear receptor SET domain-containing protein 2
NSD2
1089 – 1103 B20 VNEYVGELIDEEECM
Nuclear receptor SET domain-containing protein 2
NSD2
1093 – 1107 B21 VGELIDEEECMARIK
Nuclear receptor SET domain-containing protein 2
NSD2
1097 – 1111 C1 IDEEECMARIKHAHE
Nuclear receptor SET domain-containing protein 2
NSD2
1101 – 1115 C2 ECMARIKHAHENDIT
Nuclear receptor SET domain-containing protein 2
NSD2
1105 – 1119 C3 RIKHAHENDITHFYM
Nuclear receptor SET domain-containing protein 2
NSD2
1109 – 1123 C4 AHENDITHFYMLTID
Nuclear receptor SET domain-containing protein 2
NSD2
1113 – 1127 C5 DITHFYMLTIDKDRI
Nuclear receptor SET domain-containing protein 2
NSD2
1117 – 1131 C6 FYMLTIDKDRIIDAG
Nuclear receptor SET domain-containing protein 2
NSD2
1121 – 1135 C7 TIDKDRIIDAGPKGN
Nuclear receptor SET domain-containing protein 2
NSD2
1125 – 1139 C8 DRIIDAGPKGNYSRF
Nuclear receptor SET domain-containing protein 2
NSD2
1129 – 1143 C9 DAGPKGNYSRFMNHS
Nuclear receptor SET domain-containing protein 2
NSD2
1133 – 1147 C10 KGNYSRFMNHSCQPN
Nuclear receptor SET domain-containing protein 2
NSD2
1137 – 1151 C11 SRFMNHSCQPNCETL
Nuclear receptor SET domain-containing protein 2
NSD2
1141 – 1155 C12 NHSCQPNCETLKWTV
Nuclear receptor SET domain-containing protein 2
NSD2
1145 – 1159 C13 QPNCETLKWTVNGDT
Nuclear receptor SET domain-containing protein 2
NSD2
1149 – 1163 C14 ETLKWTVNGDTRVGL
Nuclear receptor SET domain-containing protein 2
NSD2
1153 – 1167 C15 WTVNGDTRVGLFAVC
Nuclear receptor SET domain-containing protein 2
NSD2
1157 – 1171 C16 GDTRVGLFAVCDIPA
Nuclear receptor SET domain-containing protein 2
NSD2
1161 – 1175 C17 VGLFAVCDIPAGTEL
Nuclear receptor SET domain-containing protein 2
NSD2
1165 – 1179 C18 AVCDIPAGTELTFNY
Nuclear receptor SET domain-containing protein 2
NSD2
1169 – 1183 C19 IPAGTELTFNYNLDC
121
6 Materials and Methods
Nuclear receptor SET domain-containing protein 2
NSD2
1173 – 1187 C20 TELTFNYNLDCLGNE
Nuclear receptor SET domain-containing protein 2
NSD2
1177 – 1191 C21 FNYNLDCLGNEKTVC
Nuclear receptor SET domain-containing protein 2
NSD2
1181 – 1195 D1 LDCLGNEKTVCRCGA
Nuclear receptor SET domain-containing protein 2
NSD2
1185 – 1199 D2 GNEKTVCRCGASNCS
Nuclear receptor SET domain-containing protein 2
NSD2
1189 – 1203 D3 TVCRCGASNCSGFLG
Nuclear receptor SET domain-containing protein 2
NSD2
1193 – 1207 D4 CGASNCSGFLGDRPK
Nuclear receptor SET domain-containing protein 2
NSD2
1197 – 1211 D5 NCSGFLGDRPKTSTT
Nuclear receptor SET domain-containing protein 2
NSD2
1201 – 1215 D6 FLGDRPKTSTTLSSE
Nuclear receptor SET domain-containing protein 2
NSD2
1205 – 1219 D7 RPKTSTTLSSEEKGK
Nuclear receptor SET domain-containing protein 2
NSD2
1209 – 1223 D8 STTLSSEEKGKKTKK
Nuclear receptor SET domain-containing protein 2
NSD2
1213 – 1227 D9 SSEEKGKKTKKKTRR
Nuclear receptor SET domain-containing protein 2
NSD2
1217 – 1231 D10 KGKKTKKKTRRRRAK
Nuclear receptor SET domain-containing protein 2
NSD2
1221 – 1235 D11 TKKKTRRRRAKGEGK
Nuclear receptor SET domain-containing protein 2
NSD2
1225 – 1239 D12 TRRRRAKGEGKRQSE
Nuclear receptor SET domain-containing protein 2
NSD2
1229 – 1243 D13 RRRRAKGEGKRQSED
free space D14
Histone H3 K36 WT 29 – 43 D15 APATGGVKKPHRYRP
Histone H3 K36A Mut 29 – 43 D16 APATGGVAKPHRYRP
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Information of peptide array containing the synthesized peptides of the somatic missense muta-
tions in histone H3 variants:
Table 17: List of somatic missense mutations in histone H3 variants. The position of the corresponding pep-
tide spots in Figure 52 are indicated. Target lysines (K36) are printed in bold and the corresponding
mutations are highlighted red.
Histone H3 variant CancerMutation
Position on
Array Sequence
Histone H3.3 WT K36 A1 APATGGVKKPHRYRP
Histone H3.3 K36A Mut K36A A2 APATGGVAKPHRYRP
Histone H3.1 T32A A3 APAAGGVKKPHRYRP
Histone H3.1 T32S A4 APASGGVKKPHRYRP
Histone H3.1 T32M A5 APAMGGVKKPHRYRP
Histone H3.1 G34V A6 APATGVVKKPHRYRP
Histone H3.1 G34R A7 APATGRVKKPHRYRP
Histone H3.1 G34W A8 APATGWVKKPHRYRP
Histone H3.1 G34L A9 APATGLVKKPHRYRP
Histone H3.1 G34D A10 APATGDVKKPHRYRP
Histone H3.3 G34S A11 APATGSVKKPHRYRP
Histone H3.1 V35I A12 APATGGIKKPHRYRP
Histone H3.2 V35G A13 APATGGGKKPHRYRP
Histone H3.1 K37N A14 APATGGVKNPHRYRP
Histone H3.1 P38S A15 APATGGVKKSHRYRP
Histone H3.3 P38L A16 APATGGVKKLHRYRP
Histone H3.1 P38T A17 APATGGVKKTHRYRP
Histone H3.2 H39Q A18 APATGGVKKPQRYRP
Histone H3.1 R40H A19 APATGGVKKPHHYRP
Histone H3.1 R40C A20 APATGGVKKPHCYRP
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Histone H3.1 R40P A21 APATGGVKKPHPYRP
Histone H3.1 Y41C B1 APATGGVKKPHRCRP
Histone H3.3 WT K36 B2 APATGGVKKPHRYRP
Histone H3.3 K36A Mut K36A B3 APATGGVAKPHRYRP
6.2.3 In vitro Methylation of the Protein Domains
Protein domain methylation was performed in 40µL methylation buffer containing 50mM Tris
pH 8.5, 50mM NaCl and 0.5mM DTT supplemented with 0.76µM labeled [methyl-3H]-SAM
(2.7Tbq/mmol; PerkinElmer) and 3µM NSD2 at 23 `C for 4 h. Equal loading of target protein
amounts were confirmed by Coomassie Brilliant Blue staining. The methylation was stopped
by adding 5µL of 5 x SDS-loading buffer. The proteins were subsequently boiled at 95 `C for
5min and separated by loading on a 12% SDS-PAGE gel. Afterwards, the gel was dried with
vacuum at 65 `C and then incubated with HyperfilmTM high performance autoradiography films
at 80 `C, in the dark for several days.
6.2.4 In vitro Methylation of the Histone H3 Peptides
Methylation of histone H3K36 and the K36M missense peptides was performed in 20µL methy-
lation buffer containing 50mM Tris pH 8.5, 50mM NaCl and 0.5mM DTT supplemented with
0.76µM labeled [methyl-3H]-SAM (2.7Tbq/mmol; PerkinElmer) and 1.5µM NSD2 at 23 `C
for 4 h. The methylation was stopped by adding 20µL of 2 xTricin-SDS-loading buffer. The
reaction was subsequently boiled at 95 `C for 5min and separated by loading on a 16% Tricine-
SDS-PAGE gel. Afterwards, the gel was dried with vacuum at 55 `C and then incubated with
HyperfilmTM high performance autoradiography films at 80 `C, in the dark for several days.
6.2.5 Cell culture, Transfection and Immunoprecipitation
For mammalian expression, the full-length sequence encoding for the histone lysine methyltrans-
ferase NSD2 was cloned into the pECFP-C1 (Clontech, USA) and the substrate protein domains
of ATRX and FANCM were subcloned into the pEYFP-C1 vector (Clontech, USA). Transfection
and purification of the YFP-fused protein substrates was performed according to the protocol
described in section 6.1.5.
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6.3 The Histone Lysine Methyltransferase Clr4
6.3.1 Protein Expression and Purification
For bacterial expression, the plasmid encoding for Clr4 was transformed into E.coli BL21-
CodonPlus (DE3) cells (Novagen, USA). These were grown in LB medium at 37 `C until an
OD600 of 0.6 to 0.8 was reached. Protein expression was induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and shifted to 30 `C for 4 h. Afterwards, the cells were harvested
by centrifugation at 4.500 rpm, washed once with STE buffer (10mM Tris-HCl pH8.0, 1mM
EDTA and 100mM NaCl) and the cell pellet was stored at 20 `C until purification.
For purification the cell pellet was thawed on ice, resuspended in sonication buffer and lysed by
ultra sound. The lysed cells were centrifuged at 18.000 rpm for 90min at 4 `C and the super-
natant was passed through Nickel-Nitrilotriacetic acid (Ni-NTA; Genaxxon) resin. Afterwards,
the beads were washed twice with sonication buffer. The bound proteins were eluted with elu-
tion buffer containing excess of imidazole and then dialyzed against low glycerol dialysis buffer
1 for 3 h and afterwards over night against high glycerol dialysis buffer 2. The composition of
the used buffers are shown in Table 8 (His6-tag purification).
6.3.2 In vitro Methylation of the Peptide SPOT Arrays
Synthesis of the peptide arrays was performed according to the description in section 6.1.2. All
peptide arrays were washed for 10min with methylation buffer containing 50mM Tris (pH 8.0),
20mMKCl, 500 mMMgCl2 and 1mMDTT. Then the peptide SPOTmembranes were incubated
for 60min in methylation buffer containing 0.5µM Clr4 and 0.76µM labeled [methyl-3H]-SAM
(Perkin Elmer) at 23 `C. Afterwards, the arrays were washed five times with 50mM NH4HCO3
and 1% SDS and then incubated for 5min in Amplify NAMP100V solution (GE Healthcare).
The membranes were exposed on HyperfilmTM high performance autoradiography films (GE
Healthcare) in the dark for several days at 80 `C. Film development was performed on an Op-
timus TR developing machine. Quantification and analysis of the developed films was performed
as described in section 6.1.3.
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Information of peptide array containing the synthesized peptides of the putative non-histone
substrates of Clr4:
Table 18: List of interaction partners of Clr4, which are putative substrate of Clr4. The position of the corre-
sponding peptide spots in Figure 57 are indicated. Target lysine residues or the corresponding lysine
to alanine mutants are printed in bold.
Name TargetLysine
Position on
Array Sequence
Histone H3 WT K9 A1 ARTKQTARKSTGGKAPRK
Histone H3 Mut K9A A2 ARTKQTARASTGGKAPRK
mRNA export protein Mlo3 WT K167 A3 NGAKSSKRKTTRRRRTPN
mRNA export protein Mlo3 Mut K167A A4 NGAKSSKRATTRRRRTPN
Chromatin-associated protein Swi6 WT K144 A5 GRPEPSKRKRTARPKKPE
Chromatin-associated protein Swi6 Mut K144A A6 GRPEPSKRARTARPKKPE
HMG box-containing protein
Spbc28F2.11 WT
K250 A7 QHAKKPKRKHTRSTVPTS
HMG box-containing protein
Spbc28F2.11 Mut
K250A A8 QHAKKPKRAHTRSTVPTS
HMG box-containing protein
Spbc28F2.11 WT
K292 A9 KREKKKRRKSSMSSSITT
HMG box-containing protein
Spbc28F2.11 Mut
K292A A10 KREKKKRRASSMSSSITT
Chromodomain helicase Hrp3 WT K189 A11 DVFPSKHRKGTRNGSSFS
Chromodomain helicase Hrp3 Mut K189A A12 DVFPSKHRAGTRNGSSFS
ATP-dependent RNA helicase Dbp2 WT K165 A13 GRTGRAGAKGTAYTYFTS
ATP-dependent RNA helicase Dbp2 Mut K165A A14 GRTGRAGAAGTAYTYFTS
Iec3 WT K153 A15 SSSRKQKRKRTSEGPSER
Iec3 Mut K153A A16 SSSRKQKRARTSEGPSER
Meiotic coiled-coil protein 1 Mcp1 WT K132 A17 PESSPPARKTTGKIENKK
Meiotic coiled-coil protein 1 Mcp1 Mut K132A A18 PESSPPARATTGKIENKK
Nuclear cap-binding protein subunit 1
Cbc1 WT
K11 A19 YRGSTRPRKRTREGENYG
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Nuclear cap-binding protein subunit 1
Cbc1 Mut
K11A A20 YRGSTRPRARTREGENYG
Chromatin modification-related protein
Rik1 WT
K460 A21 FLCIYDSAKRSRLVYIEK
Chromatin modification-related protein
Rik1 Mut
K460A B1 FLCIYDSAARSRLVYIEK
Chromatin modification-related protein
Rik1 WT
K502 B2 KKDTEVARKVFESEISCL
Chromatin modification-related protein
Rik1 Mut
K502A B3 KKDTEVARAVFESEISCL
Histone H3 WT K9 B4 ARTKQTARKSTGGKAPRK
Histone H3 Mut K9A B5 ARTKQTARASTGGKAPRK
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6.4 Development of an Advanced Non-radioactive,
High-throughput PKMT Activity Assay
6.4.1 Protein Expression and Purification
The DNA sequence encoding the SET domain of human SUV39H1 (residues 81 - 412) and human
HP1β protein (residues 1 - 185) was amplified from cDNA isolated from human HEK293 cells
and cloned as GST fusion protein into pGEX-6P-2 vector. GST-tagged SUV39H1 was cloned
and purified by Dr. S. Kudithipudi and the GST-fused HP1β protein was cloned and purified
by Dr. A. Dhayalan. Purification was conducted as described in section 6.1.1.
6.4.2 Reading Domain PKMT Assay
Each well of a 96-well plate was coated with 100µL avidin solution (1µg avidin in 100µL of
100mM NaHCO3 pH 9.6) overnight at 4 `C. The wells were washed three times for 5 min
with 200µL of PBST buffer (140mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM K2HPO4,
0.05% (v/v) Tween 50, pH 7.2) + 500mM NaCl and subsequently once for 5 min with 200µL
of PBST buffer. The biotinylated peptides (Intavis AG, Germany) (100 nM) were then added
to the avidin-coated wells and incubated for 30 min with continuous shaking. Afterwards, the
unbound peptides were removed by washing the plate three times for 5 min with 200µL of PBST
buffer. The wells with the bound peptides were then blocked with BSA blocking solution (2%
bovine serum albumin in PBST buffer) for 2 h at room temperature. After blocking, the plate
was washed three times for 5 min with 200µL of PBST buffer. In the meantime, HP1β protein
was diluted in interaction buffer (100mM KCl, 20mM HEPES, 1mM EDTA, 0.1mM DTT and
10% glycerol pH 7.5) and 50µL of the solution was added to the wells, followed by incubation for
1 h at room temperature, with continuous shaking. The wells were washed three times for 5 min
with 200µL of PBST buffer and then incubated with 50µL HP1β monoclonal antibody (Active
Motif,#39979; 0.37µg*mL-1) or GST-specific antibody (GE Healthcare, #27-4577; 1:6000 dilu-
tion) for 1 h at room temperature with continuous shaking. Subsequently, the plate was washed
and incubated with 50µL of the respective HRP-conjugated secondary antibody for 1 h at room
temperature, with continuous shaking. Alternatively, the HRP-conjugated anti-GST antibody
(GE Healthcare, RPN1236) was used. Finally, the wells were washed five times for 5 min with
200µL of PBST buffer and 50µL of an enhanced chemiluminescent substrate for detection of
HRP (Thermo Scientific, #32106) was added to the plate, and luminescence signal was detected
with an Enspire microplate reader (PerkinElmer).
The used equation for calculating the signal-to-noise (SN) ratio was defined as:
SN  
µSignal  µControl
SDSignal
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in which µSignal and µControl are the received average values of signal and background control,
and SDSignal is the standard deviation of the signal.
The Z-factor was defined as:
Z   1 
3    SDSignal  SDControl
µSignal  µControl
in which SDSignal and SDControl are the calculated standard deviations of signal and background
controls, respectively, and µSignal and µControl are the means of corresponding signals.
6.4.3 In vitro Methylation of Peptides and MALDI Analysis
In vitro peptide methylation was performed by incubation of 100 nM biotinylated H3 (residues 1 -
19) peptide in methylation buffer (50mM Tris-HCl, 5mM MgCl2, 4mM DTT pH 9.0) containing
200 nM SET-SUV39H1 enzyme and unlabeled SAM for 3 h at 25 `C. 50µL of the methylation
reactions were added to the avidin-coated wells.
For MALDI analysis, 1µL of the methylation reaction was diluted with 9µL of 0.1% TFA. 10%
of this mixture was spotted on a pre-spotted Anchor chip (PAC) HCCA plate (Bruker Daltonics,
#227463), and the methylation of the peptides was assessed by mass spectrometry using Bruker
Autoflex Speed MALDI-TOF system (Brucker Daltonics). The spectra were collected in the
mass-to-charge ratio 500 – 3.500Da range in reflector mode. The system was calibrated with a
peptide calibration standard (Bruker Daltonics), with peptides covering masses of 700 – 3.200Da.
The spectra were collected using flexControl and flexAnalysis software (Bruker Daltonics).
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